<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006247.pub3" GROUP_ID="CHILDCA" ID="149505050512144268" MERGED_FROM="" MODIFIED="2016-04-18 08:37:45 +0100" MODIFIED_BY="Cochrane Childhood Cancer Editorial Base" REVIEW_NO="024" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2016-04-18 08:37:45 +0100" MODIFIED_BY="Cochrane Childhood Cancer Editorial Base">
<TITLE MODIFIED="2011-12-21 20:41:16 +0100" MODIFIED_BY="[Empty name]">Low bacterial diet versus control diet to prevent infection in cancer patients treated with chemotherapy causing episodes of neutropenia</TITLE>
<CONTACT MODIFIED="2016-04-18 08:37:45 +0100" MODIFIED_BY="Cochrane Childhood Cancer Editorial Base"><PERSON ID="13730" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Marianne</FIRST_NAME><MIDDLE_INITIALS>D</MIDDLE_INITIALS><LAST_NAME>van de Wetering</LAST_NAME><POSITION>Paediatric Oncologist</POSITION><EMAIL_1>m.d.vandewetering@amc.uva.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Paediatric Oncology</DEPARTMENT><ORGANISATION>Emma Children's Hospital/Academic Medical Center</ORGANISATION><ADDRESS_1>PO Box 22660</ADDRESS_1><CITY>Amsterdam</CITY><ZIP>1100 DD</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31-20-5669111 ext: 59077</PHONE_1><FAX_1>+31-20-6912231</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2016-04-18 08:37:45 +0100" MODIFIED_BY="Cochrane Childhood Cancer Editorial Base"><PERSON ID="13729" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Elvira</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>van Dalen</LAST_NAME><EMAIL_1>e.c.vandalen@amc.uva.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Paediatric Oncology</DEPARTMENT><ORGANISATION>Emma Children's Hospital/Academic Medical Center</ORGANISATION><ADDRESS_1>PO Box 22660 (room H4-139)</ADDRESS_1><CITY>Amsterdam</CITY><ZIP>1100 DD</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 20 5665697</PHONE_1><FAX_1>+ 31 20 5669021</FAX_1></ADDRESS></PERSON><PERSON ID="DD15A2E782E26AA201E74FE9A702656E" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Arno</FIRST_NAME><LAST_NAME>Mank</LAST_NAME><POSITION>Nurse Researcher</POSITION><EMAIL_1>a.p.mank@amc.uva.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Haematology</DEPARTMENT><ORGANISATION>Academic Medical Center</ORGANISATION><ADDRESS_1>PO Box 22660</ADDRESS_1><CITY>Amsterdam</CITY><ZIP>1100 DD</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>0031 20 5667905</PHONE_1><FAX_1>0031 20 5669060</FAX_1></ADDRESS><FOOTNOTE>Joint first authorship with Elvira C van Dalen</FOOTNOTE></PERSON><PERSON ID="FCC8B8A982E26AA2001B9B030D8F01D8" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Edith</FIRST_NAME><LAST_NAME>Leclercq</LAST_NAME><POSITION>Trials Search Co-ordinator</POSITION><EMAIL_1>E.Leclercq@amc.uva.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Paediatric Oncology</DEPARTMENT><ORGANISATION>Emma Children's Hospital/Academic Medical Center</ORGANISATION><ADDRESS_1>PO Box 22660</ADDRESS_1><CITY>Amsterdam</CITY><ZIP>1100 DD</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>020-5661416</PHONE_1></ADDRESS></PERSON><PERSON ID="D0402DB382E26AA2012E60F38D3AC37D" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Renée</FIRST_NAME><MIDDLE_INITIALS>L</MIDDLE_INITIALS><LAST_NAME>Mulder</LAST_NAME><EMAIL_1>r.l.mulder@amc.uva.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Paediatric Oncology</DEPARTMENT><ORGANISATION>Emma Children's Hospital/Academic Medical Center</ORGANISATION><ADDRESS_1>P.O. Box 22660</ADDRESS_1><CITY>Amsterdam</CITY><ZIP>1100 DD</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+ 31 20 5665419</PHONE_1></ADDRESS></PERSON><PERSON ID="B0587C7E82E26AA200D5E26B3D7CC63D" ROLE="AUTHOR"><PREFIX>Mrs</PREFIX><FIRST_NAME>Michelle</FIRST_NAME><LAST_NAME>Davies</LAST_NAME><POSITION>Haematology Research Nurse</POSITION><EMAIL_1>michelle.davies@christie-tr.nwest.nhs.uk</EMAIL_1><ADDRESS><DEPARTMENT>Haematology and Transplant Unit</DEPARTMENT><ORGANISATION>Christie Hospital NHS Foundation Trust</ORGANISATION><CITY>Manchester</CITY><ZIP>M20 4BX</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 (0)161 446 8093</PHONE_1></ADDRESS></PERSON><PERSON ID="80898431249738019025100128151637" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Marie José</FIRST_NAME><LAST_NAME>Kersten</LAST_NAME><POSITION>Haematologist</POSITION><EMAIL_1>m.j.kersten@amc.uva.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Haematology</DEPARTMENT><ORGANISATION>Academic Medical Center</ORGANISATION><ADDRESS_1>P.O. Box 22660/room F4 224</ADDRESS_1><CITY>Amsterdam</CITY><ZIP>1100 DD</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+ 31 20 5665755</PHONE_1><FAX_1>+ 31 20 6919743</FAX_1></ADDRESS></PERSON><PERSON ID="13730" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Marianne</FIRST_NAME><MIDDLE_INITIALS>D</MIDDLE_INITIALS><LAST_NAME>van de Wetering</LAST_NAME><POSITION>Paediatric Oncologist</POSITION><EMAIL_1>m.d.vandewetering@amc.uva.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Paediatric Oncology</DEPARTMENT><ORGANISATION>Emma Children's Hospital/Academic Medical Center</ORGANISATION><ADDRESS_1>PO Box 22660</ADDRESS_1><CITY>Amsterdam</CITY><ZIP>1100 DD</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31-20-5669111 ext: 59077</PHONE_1><FAX_1>+31-20-6912231</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2016-03-23 13:47:34 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="4" MONTH="5" YEAR="2015"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="4" MONTH="5" YEAR="2015"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="16" MONTH="4" YEAR="2018"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="9" YEAR="2012"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2016"/>
</DATES>
<WHATS_NEW MODIFIED="2016-04-01 09:56:15 +0200" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2016-04-01 09:56:15 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="17" MONTH="12" YEAR="2015"/>
<DESCRIPTION>
<P>No new studies were identified during the update. Thus the conclusions have not changed</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-01-28 12:08:27 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="4" MONTH="5" YEAR="2015"/>
<DESCRIPTION>
<P>The search for eligible studies was updated to May 2015</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2016-04-15 10:12:13 +0200" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2016-04-15 10:12:13 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="29" MONTH="1" YEAR="2015"/>
<DESCRIPTION>
<P>Contact details were updated</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2016-01-19 14:26:15 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2016-01-19 14:26:15 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2016-01-19 14:26:15 +0100" MODIFIED_BY="[Empty name]">
<NAME>Stichting Kinderen Kankervrij (KiKa)</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-04-15 10:12:29 +0200" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2016-04-04 14:43:39 +0200" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2012-02-28 15:59:01 +0100" MODIFIED_BY="[Empty name]">Low bacterial diet versus control diet to prevent infection in cancer patients treated with chemotherapy causing episodes of neutropenia</TITLE>
<SUMMARY_BODY MODIFIED="2016-04-04 14:43:39 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Cancer patients are often at much higher risk of severe or even life threatening infection due to a compromised immune system (known as neutropenia) as a result of chemotherapy or radiotherapy. It has been argued that a diet which is adapted to exclude foods with low or no levels of bacteria might help to reduce the number or severity of infections in cancer patients with compromised immune systems. However, in the literature there is no agreement that the use of a low bacterial diet (LBD) decreases the number of serious infections with bacteria, fungi or virusses.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2016-04-04 14:43:39 +0200" NOTES_MODIFIED_BY="[Empty name]">
<P>Neutropenia is a potentially serious side effect of chemotherapy and a major risk factor for infection, which can be life-threatening. It has been argued that a low bacterial diet (i.e. food and drinks with low levels of bacteria) can prevent the occurrence of infection and (infection-related) death in cancer patients receiving chemotherapy that causes episodes of neutropenia.</P>
<P>Review authors identified three randomised studies comparing different diets in 192 children and adults with different types of cancer. Other interventions, such as antimicrobial prophylaxis (i.e. prevention of infection via antimicrobial therapy such as antibiotics) and hygiene practices, and definitions of study outcomes also differed between studies, and very limited information on anticancer treatment was given. All studies had methodological problems. Unfortunately, combining the results of included studies was not possible, but at the moment, no evidence from individual studies suggests that a low bacterial diet prevents infection. Data on survival, time from onset of neutropenia to start of fever, duration of empirical (i.e. start of treatment before determination of a definitive diagnosis) antibiotics and antimycotics (i.e. agents that target fungal infection), diet acceptability and quality of life all were evaluated by only one study; for all outcomes, no statistically significant differences between treatment groups were observed. None of the studies evaluated infection-related mortality. It should be noted that 'no evidence of effect', as identified in this review, is not the same as 'evidence of no effect'. No differences between diets were identified, possibly because few patients were included in these studies. On the basis of currently available evidence, the review authors were not able to give recommendations for clinical practice. Additional high-quality research is needed.<BR/>
</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2016-04-09 16:16:34 +0200" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2016-04-01 09:57:16 +0200" MODIFIED_BY="[Empty name]">
<P>Neutropenia is a potentially serious side effect of chemotherapy and a major risk factor for infection, which can be life-threatening. It has been hypothesised that a low bacterial diet (LBD) can prevent infection and (infection-related) mortality in cancer patients receiving chemotherapy that causes episodes of neutropenia, but much remains unclear. This review is an update of a previously published Cochrane review.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2016-04-01 09:58:44 +0200" MODIFIED_BY="[Empty name]">
<P>The primary objective of this review was to determine the efficacy of an LBD versus a control diet in preventing infection and in decreasing (infection-related) mortality in adult and paediatric cancer patients receiving chemotherapy that causes episodes of neutropenia. Secondary objectives were to assess time to first febrile episode, need for empirical antibiotic therapy, diet acceptability and quality of life.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2016-04-04 14:43:51 +0200" MODIFIED_BY="[Empty name]">
<P>We searched the following electronic databases: the Cochrane Central Register of Controlled Trials (CENTRAL) (2015, Issue 4), the Database of Abstracts of Reviews of Effects (DARE) (2015, Issue 4), PubMed (from 1946 to 4 May 2015), EMBASE (from 1980 to 4 May 2015) and the Cumulative Index to Nursing and Allied Health Literature (CINAHL) (from 1981 to 4 May 2015). 
</P>
<P>In addition, we searched the reference lists of relevant articles and conference proceedings of American Society of Hematology (ASH; from 2000 to 2015), European Bone Marrow Transplantation (EBMT; from 2000 to 2015), Oncology Nurses Society (ONS; from 2000 to 2015), International Society for Paediatric Oncology (SIOP; from 2000 to 2014), Multinational Association of Supportive Care in Cancer (MASCC; from 2000 to 2015), American Society of Clinical Oncology (ASCO; from 2000 to 2015), Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC; from 2000 to 2015), European Society for Clinical Nutrition and Metabolism (ESPEN; from 2000 to 2015), American Society for Parenteral and Enteral Nutrition (ASPEN; from 2000 to 2015) and European Hematology Association (EHA; from 2000 to 2015). In May 2015, we scanned the National Institutes of Health Register via clinicaltrials.gov and the International Standard Randomised Controlled Trial Number (ISRCTN) Register (<A HREF="http://www.controlled-trials.com/">www.controlled-trials.com</A>).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2016-04-04 14:43:49 +0200" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) comparing use of an LBD versus a control diet with regard to infection rate, (infection-related) mortality, time to first febrile episode, need for empirical antibiotic therapy, diet acceptability and quality of life in adult and paediatric cancer patients receiving chemotherapy causing episodes of neutropenia.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2016-04-01 10:02:46 +0200" MODIFIED_BY="[Empty name]">
<P>Two review authors independently performed study selection, 'Risk of bias' assessment and data extraction. We performed analyses according to the guidelines of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I>.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2016-04-09 16:16:34 +0200" MODIFIED_BY="[Empty name]">
<P>In the original version of this review, we identified three RCTs that assessed different intervention and control diets in 192 participants (97 randomised to intervention diet; 95 to control diet) with different types of malignancies. For the update, we identified no eligible new studies. Co-interventions (e.g. protective environment, antimicrobial prophylaxis, central venous catheter care, oral care, hygiene practices, colony-stimulating factors) and outcome definitions also differed between studies. In all included studies, it was standard policy to give empirical antibiotics (and sometimes also antimycotics) to (some of) the participants diagnosed with an infection. Two studies included adults and one study included children. In all studies, only a scant description of treatment regimens was provided. All studies had methodological limitations. Pooling of results of included studies was not possible. In two individual studies, no statistically significant differences in infection rate were identified between intervention and control diets; another study showed no significant differences between treatment groups in the number of chemotherapy cycles with an infection. None of the studies mentioned infection-related mortality, but in one study, no significant difference in overall survival was observed between treatment groups. Time from onset of neutropenia to fever, duration of empirical antibiotics and antimycotics, diet acceptability (i.e. following the diet easily and following the diet throughout all chemotherapy cycles) and quality of life were all evaluated by only one study; for all outcomes, no statistically significant differences between treatment arms were identified.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2016-04-04 14:43:40 +0200" MODIFIED_BY="[Empty name]">
<P>At the moment, no evidence from individual RCTs in children and adults with different malignancies underscores use of an LBD for prevention of infection and related outcomes. All studies differed with regard to co-interventions, outcome definitions and intervention and control diets. As pooling of results was not possible, and as all studies had serious methodological limitations, we could reach no definitive conclusions. It should be noted that 'no evidence of effect', as identified in this review, is not the same as 'evidence of no effect'. On the basis of currently available evidence, we are not able to provide recommendations for clinical practice. Additional high-quality research is needed.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-04-15 10:12:29 +0200" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2016-04-04 14:43:35 +0200" MODIFIED_BY="[Empty name]">
<P>Neutropenia, defined as an absolute neutrophil count (ANC) &lt; 0.5 × 10<SUP>9</SUP>/L, is a potentially serious side effect of chemotherapy and high-dose irradiation (<LINK REF="REF-MacVittie-1997" TYPE="REFERENCE">MacVittie 1997</LINK>) and a major risk factor for infection and sepsis. Neutrophils, constituting 55% to 70% of circulating white blood cells, have the ability to identify, ingest and destroy most foreign invaders (<LINK REF="REF-Candell-1991" TYPE="REFERENCE">Candell 1991</LINK>). When the ANC falls to &lt; 1.0 × 10<SUP>9</SUP>/L, susceptibility to infection is increased. The frequency and severity of infections are inversely proportional to the neutrophil count and are directly proportional to the duration of neutropenia (<LINK REF="REF-Hughes-2002" TYPE="REFERENCE">Hughes 2002</LINK>). Patients with both solid tumours and haematological malignancies treated with high-dose chemotherapy have a significantly increased risk of developing life-threatening infection.</P>
<P>Infection-related mortality in patients with severe neutropenia is approximately 4% to 6% in adult patients and 0.4% to 1.0% in paediatric patients (<LINK REF="REF-Hughes-2002" TYPE="REFERENCE">Hughes 2002</LINK>; <LINK REF="REF-Pizzo-1999" TYPE="REFERENCE">Pizzo 1999</LINK>; <LINK REF="REF-Roguin-1996" TYPE="REFERENCE">Roguin 1996</LINK>). At least 50% of neutropenic patients who become febrile have an established or occult infection, and at least 20% with a neutrophil count &lt; 0.1 × 10<SUP>9</SUP>/L have bacteraemia (<LINK REF="REF-Hughes-2002" TYPE="REFERENCE">Hughes 2002</LINK>).</P>
<P>Approximately 80% of the organisms that cause infection in neutropenic patients arise from endogenous microbial florae colonising the skin and respiratory, genitourinary and gastrointestinal tracts (<LINK REF="REF-Barber-2001" TYPE="REFERENCE">Barber 2001</LINK>). Currently, coagulase-negative staphylococci are the most common blood isolates; Enterobacteriaceae (i.e. <I>Enterobacter</I> species, <I>Escherichia coli</I> and <I>Klebsiella</I> species) and non-fermenting gram-negative rods (i.e. <I>Pseudomonas aeruginosa</I> and <I>Stenotrophomonas</I> species) are isolated less often (<LINK REF="REF-Freifeld-2011" TYPE="REFERENCE">Freifeld 2011</LINK>). Invasive fungal infection is another important cause of morbidity and mortality. Predisposing factors for fungal infection include use of broad-spectrum antibiotics, corticosteroids, parenteral nutrition and indwelling intravenous catheters, along with graft-versus-host disease after an allogeneic stem cell transplantation. The most commonly isolated fungal pathogens are <I>Aspergillus</I> and <I>Candida</I> species (<LINK REF="REF-Barber-2001" TYPE="REFERENCE">Barber 2001</LINK>).</P>
<P>Significant advances in supportive care for neutropenic patients have been made since the mid-1990s. Nowadays, supportive care management for neutropenia is directed by risk assessment in adults (<LINK REF="REF-Klastersky-2000" TYPE="REFERENCE">Klastersky 2000</LINK>; <LINK REF="REF-Talcott-1992" TYPE="REFERENCE">Talcott 1992</LINK>) and by evidence-based guidelines for management of neutropenia and prevention of opportunistic infection developed by the Centers for Disease Control and Prevention (CDC, USA) for both adults and children (<LINK REF="REF-Dykewicz-2001" TYPE="REFERENCE">Dykewicz 2001</LINK>; <LINK REF="REF-Hughes-2002" TYPE="REFERENCE">Hughes 2002</LINK>). These recommendations to prevent healthcare-associated infection involve antimicrobial prophylaxis, colony-stimulating factors, a protective environment, oral care, central venous catheter (CVC) care, hand washing, personal hygiene practices, dietary restrictions and outpatient treatment (<LINK REF="REF-Dykewicz-2001" TYPE="REFERENCE">Dykewicz 2001</LINK>). However, despite these achievements, infection continues to be a major cause of morbidity and mortality among neutropenic patients.</P>
<P>With regard to dietary restrictions, it has been hypothesised that a diet for neutropenic patients should reduce pathogens in the gastrointestinal tract by excluding specific foods that may act as a vector for bacteria. The first such diet was developed in the 1960s with the intention of providing a completely germ-free diet (<LINK REF="REF-Reimer-1966" TYPE="REFERENCE">Reimer 1966</LINK>). Since that time, foods have been sterilised by autoclaving, prolonged baking, gamma irradiation or canning (<LINK REF="REF-Aker-1983" TYPE="REFERENCE">Aker 1983</LINK>). Germ-free diets were considered unpalatable; therefore, the US National Institutes of Health, Department of Dietary and Environmental Sanitation, designed the 'cooked-food' diet. Although not germ-free, this diet was aimed at eliminating foods with high bacterial counts (<LINK REF="REF-Preisler-1970" TYPE="REFERENCE">Preisler 1970</LINK>). In a randomised trial, the National Cancer Institute demonstrated that within a decontaminated environment, a germ-free diet offered little advantage over a cooked-food diet with reference to bacterial stool cultures (<LINK REF="REF-Preisler-1970" TYPE="REFERENCE">Preisler 1970</LINK>). Although the cooked-food diet was more acceptable to patients than the germ-free diet, patients who adhered to this diet for longer than four to six weeks often became frustrated with the food selection (<LINK REF="REF-Moody-2002" TYPE="REFERENCE">Moody 2002</LINK>). Occasionally, this diet affected their acceptance of other medical therapies as well, which led clinicians to investigate liberalisation of the diet (<LINK REF="REF-Pizzo-1982" TYPE="REFERENCE">Pizzo 1982</LINK>). Pizzo et al cultured 236 commercially available foods and identified fewer than 500 colony-forming units per gram in 66% of these foods. Investigators proposed that these foods were acceptable for neutropenic patients; this liberalised diet became known as the low bacterial diet (LBD) (<LINK REF="REF-Pizzo-1982" TYPE="REFERENCE">Pizzo 1982</LINK>).</P>
<P>The role of diet in the risk of infection among patients with neutropenia remains controversial (<LINK REF="REF-French-2001" TYPE="REFERENCE">French 2001</LINK>). Dietary restrictions vary in the literature and among institutions. Recommendations range from no dietary restrictions to extensive restrictions. Two surveys (<LINK REF="REF-French-2001" TYPE="REFERENCE">French 2001</LINK>; <LINK REF="REF-Smith-2000" TYPE="REFERENCE">Smith 2000</LINK>) revealed several differences among LBDs used by hospitals in the USA. Furthermore, much variation was reported regarding initiation and discontinuation of the LBD. Few clinical studies have been undertaken to assess the efficacy of the LBD in reducing infection among neutropenic patients, and currently no substantial evidence is available to prove the benefit of the LBD (<LINK REF="REF-Larson-2004" TYPE="REFERENCE">Larson 2004</LINK>). As the LBD may pose an unnecessary burden for patients who already have problems with maintaining adequate oral intake because of complications of high-dose chemotherapy (e.g. mucositis), it would be beneficial to expand our knowledge regarding the efficacy of this diet. This review serves as an update of the first systematic review (<LINK REF="REF-Mank-2012" TYPE="REFERENCE">Mank 2012</LINK>) conducted to evaluate the state of evidence on low bacterial diet versus control diet for preventing infection in cancer patients treated with chemotherapy that causes episodes of neutropenia.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2016-04-01 10:18:57 +0200" MODIFIED_BY="[Empty name]">
<P>The primary objective of this review was to determine the efficacy of an LBD versus a control diet in preventing infection and in decreasing (infection-related) mortality in adult and paediatric cancer patients receiving chemotherapy that causes episodes of neutropenia. Secondary objectives were to assess time to first febrile episode, need for empirical antibiotic therapy, diet acceptability and quality of life.</P>
</OBJECTIVES>
<METHODS MODIFIED="2016-04-15 10:12:29 +0200" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2016-04-04 14:43:26 +0200" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2016-04-01 10:19:02 +0200" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) comparing use of an LBD versus a control diet.<BR/>
</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2016-04-01 10:19:23 +0200" MODIFIED_BY="[Empty name]">
<P>Cancer patients who received chemotherapy causing episodes of neutropenia. Both adults and children one year of age and older were eligible for inclusion. Children younger than one year of age were excluded because of large differences in metabolism and feeding patterns.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2016-04-01 10:19:37 +0200" MODIFIED_BY="[Empty name]">
<P>An LBD versus a control diet.</P>
<P>LBD was defined as any diet intended to reduce ingestion of bacterial and fungal contaminants through exclusion of foods such as uncooked fruits and vegetables, cold cuts, undercooked eggs and meat, unsterilised water, unpasteurised milk products and soft cheeses. The control diet could be any other diet.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2016-04-04 14:43:26 +0200" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2016-04-01 10:20:12 +0200" MODIFIED_BY="[Empty name]">
<UL>
<LI>Infection rate (as defined by authors of the original studies).</LI>
<LI>(Infection-related) mortality (as defined by authors of the original studies).</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2016-04-04 14:43:26 +0200" MODIFIED_BY="[Empty name]">
<UL>
<LI>Time to first febrile episode (as defined by authors of the original studies).</LI>
<LI>Need for empirical antibiotic therapy (as defined by authors of the original studies).</LI>
<LI>Diet acceptability (as defined by authors of the original studies).</LI>
<LI>Quality of life (as defined by authors of the original studies).</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2016-04-04 14:43:23 +0200" MODIFIED_BY="[Empty name]">
<P>See Cochrane Childhood Cancer Group (CCG) and Cochrane Gynaecological Cancer Group (GCG) methods used in reviews (<LINK REF="REF-Module-CCG-2010" TYPE="REFERENCE">Module CCG 2010</LINK>; <LINK REF="REF-Module-GCG-2010" TYPE="REFERENCE">Module GCG 2010</LINK>).</P>
<ELECTRONIC_SEARCHES MODIFIED="2016-04-04 14:43:22 +0200" MODIFIED_BY="[Empty name]">
<P>In the original version of the review, review authors searched the following electronic databases: the Central Register of Controlled Trials (CENTRAL) (2011, Issue 3; including earlier searches in 2008 and 2010), the Database of Abstracts of Reviews of Effects (DARE) (2011, Issue 3; including earlier searches in 2008 and 2010), PubMed (from 1946 to 20 October 2011; including earlier searches in 2008 and 2010), EMBASE (from 1980 to 20 October 2011; including earlier searches in 2008 and 2010) and the Cumulative Index to Nursing and Allied Health Literature (CINAHL) (from 1981 to 20 October 2011; including earlier searches in 2008 and 2010). Search strategies used for the different electronic databases (using a combination of controlled vocabulary and text word terms) are stated in the appendices (<A HREF="http://www.archie.cochrane.org/sections/documents/view?version=25550938942464547197100930214404&amp;format=REVMAN_GRAPHS#APP-01#APP-01">Appendix 1</A>; <A HREF="http://www.archie.cochrane.org/sections/documents/view?version=25550938942464547197100930214404&amp;format=REVMAN_GRAPHS#APP-02#APP-02">Appendix 2</A>; <A HREF="http://www.archie.cochrane.org/sections/documents/view?version=25550938942464547197100930214404&amp;format=REVMAN_GRAPHS#APP-03#APP-03">Appendix 3</A>; <A HREF="http://www.archie.cochrane.org/sections/documents/view?version=25550938942464547197100930214404&amp;format=REVMAN_GRAPHS#APP-04#APP-04">Appendix 4</A>).</P>
<P>For the update, we repeated the same searches in CENTRAL and DARE (2015, Issue 4), PubMed (2011 to 4 May 2015), EMBASE (from 2011 to 4 May 2015) and CINAHL (from 2011 to 4 May 2015).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2016-04-04 14:43:14 +0200" MODIFIED_BY="[Empty name]">
<P>In the original version of the review, we found information about trials not registered in <I>The Cochrane Library</I>, PubMed, EMBASE or CINAHL, published or unpublished, by searching the reference lists of relevant articles and review articles. We searched the following conference proceedings electronically: American Society of Hematology (ASH; from 2000 to 2011), European Bone Marrow Transplantation (EBMT; from 2000 to 2010), Oncology Nurses Society (ONS; from 2000 to 2011), International Society for Paediatric Oncology (SIOP; from 2000 to 2010), Multinational Association of Supportive Care in Cancer (MASCC; from 2000 to 2010), American Society of Clinical Oncology (ASCO; from 2000 to 2011), Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC; from 2000 to 2011), European Society for Clinical Nutrition and Metabolism (ESPEN; from 2000 to 2011), American Society for Parenteral and Enteral Nutrition (ASPEN; from 2000 to 2011) and European Hematology Association (EHA; from 2000 to 2011) (see <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK> for search terms). We searched for ongoing trials in the register of the National Institutes of Health (via clinicaltrials.gov) and the International Standard Randomised Controlled Trial Number (ISRCTN) Register (via <A HREF="http://controlled-trials.com">controlled-trials.com</A>; see <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK> for search terms; we screened both in June 2010, October 2011 and May 2012). We contacted researchers working in this area to identify ongoing trials. We imposed no language restrictions.</P>
<P>For the update, we searched the above mentioned conference proceedings from 2011 or 2012 until 2015, except for SIOP abstracts (until 2014), and we searched ongoing trial registries in May 2015, all by using the same keywords as mentioned in the appendices. In addition, we searched the reference lists of relevant articles and review articles.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2016-04-15 10:12:29 +0200" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2016-04-04 14:43:02 +0200" MODIFIED_BY="[Empty name]">
<P>After employing the search strategy described previously, two review authors independently identified studies meeting the eligibility criteria of this review. We obtained in full text for closer inspection any study that seemed to meet the inclusion criteria upon review of the title, the abstract or both. We clearly stated reasons for exclusion of any study considered for the review. We resolved disagreements between review authors by consensus, with no need for a third party arbiter.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2016-04-04 14:43:01 +0200" MODIFIED_BY="[Empty name]">
<P>Two review authors independently extracted data by using standardised forms. We extracted data on study design, characteristics of participants (e.g. age, sex, disease, treatment, antimicrobial prophylaxis, colony-stimulating factors, protective environment, oral care, CVC care, hand washing, hygiene practices), interventions (description of diet in intervention and control group), outcome measures (as described previously) and length of follow-up. We resolved disagreements between review authors by consensus, with no need for a third party arbiter.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2016-04-04 14:42:59 +0200" MODIFIED_BY="[Empty name]">
<P>Two review authors independently assessed the risk of bias in included studies (i.e. selection bias, performance bias, detection bias (for each outcome separately, with the exception of overall mortality, because for that outcome, blinding was not relevant), attrition bias (for each outcome separately), reporting bias and other bias). We used 'Risk of bias' items as described in the module of the CCG (<LINK REF="REF-Module-CCG-2010" TYPE="REFERENCE">Module CCG 2010</LINK>), which are based on the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We assessed reporting bias by comparing the methods and results sections of the manuscript; we did not obtain protocols. We resolved disagreements between review authors by consensus, with no need for a third party arbiter. We considered the risk of bias in included studies when interpreting results of the review.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2016-04-04 10:23:23 +0200" MODIFIED_BY="[Empty name]">
<P>We analysed dichotomous variables by using risk ratios (RRs). We presented all results with corresponding 95% confidence intervals (CIs).</P>
</EFFECT_MEASURES>
<MISSING_DATA MODIFIED="2016-04-09 16:20:19 +0200" MODIFIED_BY="[Empty name]">
<P>When relevant data were missing with regards to study selection, we contacted the principal investigator of the study. Only researchers of <LINK REF="STD-Van-_x0027_t-Veer-1987" TYPE="STUDY">Van 't Veer 1987</LINK> were able to provide additional information. We extracted data by the allocated intervention, irrespective of compliance with treatment, to allow an intention-to-treat analysis. If this was not possible, we stated this and performed an 'as treated' analysis.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2016-04-04 10:24:28 +0200" MODIFIED_BY="[Empty name]">
<P>Pooling of results for this review was not possible; therefore, assessment of heterogeneity (both by visual inspection of the forest plot and by formal statistical testing for heterogeneity, i.e. the I<SUP>2</SUP> statistic (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>; <A HREF="http://www.archie.cochrane.org/sections/documents/view?document=60533348873545919391101216111740&amp;format=REVMAN#REF-Higgins-2011">Higgins 2011</A>)) was not applicable.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2016-04-04 10:25:40 +0200" MODIFIED_BY="[Empty name]">
<P>In addition to evaluating reporting bias as described in the <LINK TAG="QUALITY_ASSESSMENT" TYPE="SECTION">Assessment of risk of bias in included studies</LINK> section, we planned to assess reporting bias by constructing a funnel plot when we had identified a sufficient number of included studies (i.e. at least 10 studies included in a meta-analysis) because otherwise the power of the tests would be too low to allow us to distinguish chance from real asymmetry (<A HREF="http://www.archie.cochrane.org/sections/documents/view?document=60533348873545919391101216111740&amp;format=REVMAN#REF-Higgins-2011">Higgins 2011</A>). As pooling of results was not possible, this was not applicable.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2016-04-15 10:12:29 +0200" MODIFIED_BY="[Empty name]">
<P>We entered data into Review Manager software as provided by The Cochrane Collaboration (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>); we performed analyses according to the guidelines of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<A HREF="http://www.archie.cochrane.org/sections/documents/view?document=60533348873545919391101216111740&amp;format=REVMAN#REF-Higgins-2011">Higgins 2011</A>). We used a fixed-effect model throughout the review and pooled results only when study groups were comparable, including definitions of LBD and control diet. We summarised descriptively studies for which pooling of results was not possible.</P>
</DATA_SYNTHESIS>
<SENSITIVITY_ANALYSIS MODIFIED="2016-04-04 10:28:28 +0200" MODIFIED_BY="[Empty name]">
<P>As pooling of results was not possible, sensitivity analyses for 'Risk of bias' items (i.e. excluding studies with high risk of bias and studies for which risk of bias was unclear and comparing results of studies with low risk of bias vs results of all available studies) were not applicable.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2016-04-09 16:28:21 +0200" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2016-04-04 14:42:57 +0200" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2016-04-04 14:42:57 +0200" MODIFIED_BY="[Empty name]">
<P>Searches conducted for the original version of this review using the electronic databases of CENTRAL, DARE, PubMed, EMBASE and CINAHL yielded a total of 619 references (n = 373 in 2008, n = 75 in 2010 and n = 171 in 2011). After initial screening of titles or abstracts, or both, we excluded 612 references that clearly did not meet all criteria for inclusion of studies in this review. We assessed the seven remaining references in full; three fulfilled all criteria and thus were deemed eligible for inclusion (<LINK REF="STD-Gardner-2008" TYPE="STUDY">Gardner 2008</LINK>; <LINK REF="STD-Moody-2006" TYPE="STUDY">Moody 2006</LINK>; <LINK REF="STD-Van-Tiel-2007" TYPE="STUDY">Van Tiel 2007</LINK>). We excluded the other four references for the reasons described in the <A HREF="http://www.archie.cochrane.org/sections/documents/view?document=60533348873545919391101216111740&amp;format=REVMAN#CHARACTERISTICS_OF_EXCLUDED_STUDIES">Characteristics of excluded studies</A> table (<LINK REF="STD-DeMille-2006" TYPE="STUDY">DeMille 2006</LINK>; <LINK REF="STD-Fopp-1975" TYPE="STUDY">Fopp 1975</LINK>; <LINK REF="STD-Wilson-2002" TYPE="STUDY">Wilson 2002</LINK>; <LINK REF="STD-Ziegler-1992" TYPE="STUDY">Ziegler 1992</LINK>).</P>
<P>A scan of the reference lists of included articles and reviews revealed no additional eligible studies. By scanning the ongoing trials databases, we identified two ongoing trials (see the <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK> table). Researchers working in this area were not aware of any ongoing trials. By scanning conference proceedings, we identified one possibly eligible study that has not been published in full yet and thus is awaiting further classification (<LINK REF="STD-Van-_x0027_t-Veer-1987" TYPE="STUDY">Van 't Veer 1987</LINK>; for more information, see the <LINK TAG="CHARACTERISTICS_OF_AWAITING_STUDIES" TYPE="SECTION">Characteristics of studies awaiting classification</LINK> table), and we added one study to the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table (<LINK REF="STD-Veber-2010" TYPE="STUDY">Veber 2010</LINK>).</P>
<P>Searches of CENTRAL and DARE, PubMed, EMBASE/Ovid and CINAHL/EBSCO for this update yielded a total of 558 references; 495 records remained after deduplication. After screening titles and abstracts, we excluded 489 studies, and we assessed six studies as full text. We excluded all six studies for reasons described in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table (<LINK REF="STD-Carr-2014" TYPE="STUDY">Carr 2014</LINK>; <LINK REF="STD-Foster-2014" TYPE="STUDY">Foster 2014</LINK>; <LINK REF="STD-Brown-2014" TYPE="STUDY">Brown 2014</LINK>; <LINK REF="STD-Lund-2014" TYPE="STUDY">Lund 2014</LINK>; <LINK REF="STD-Fox-2012" TYPE="STUDY">Fox 2012</LINK>; <LINK REF="STD-Trifilio-2012" TYPE="STUDY">Trifilio 2012</LINK>). We identified no studies by searching conference proceedings, ongoing trial registries and reference lists of the six assessed studies and reviews identified in the update.</P>
<P>In summary, the total number of included studies was three. We also identified one study that has not been published in full yet and is awaiting further classification and two ongoing trials. See <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> for a flow diagram of studies selected for this update.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2016-04-04 14:42:48 +0200" MODIFIED_BY="[Empty name]">
<P>We have summarised characteristics of the included studies below. For more detailed information, see the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
<P>We identified three RCTs (<LINK REF="STD-Gardner-2008" TYPE="STUDY">Gardner 2008</LINK>; <LINK REF="STD-Moody-2006" TYPE="STUDY">Moody 2006</LINK>; <LINK REF="STD-Van-Tiel-2007" TYPE="STUDY">Van Tiel 2007</LINK>) conducted to assess different intervention and control diets (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table for more detailed information). The total number of participants included in these three RCTs was 192: 97 were randomised to intervention groups and 95 to control groups. Two studies included adults (<LINK REF="STD-Gardner-2008" TYPE="STUDY">Gardner 2008</LINK>; <LINK REF="STD-Van-Tiel-2007" TYPE="STUDY">Van Tiel 2007</LINK>), and one study included children (<LINK REF="STD-Moody-2006" TYPE="STUDY">Moody 2006</LINK>); participants had different types of haematological malignancies or solid tumours (all studies provided only a scant description of treatment regimens).</P>
<P>Supportive care measures differed between studies. Investigators in one study treated participants in high-efficiency particulate air-filtered rooms (<LINK REF="STD-Gardner-2008" TYPE="STUDY">Gardner 2008</LINK>); in the other studies, use of a protective environment was unclear (<LINK REF="STD-Moody-2006" TYPE="STUDY">Moody 2006</LINK>; <LINK REF="STD-Van-Tiel-2007" TYPE="STUDY">Van Tiel 2007</LINK>). Investigators in two studies provided antimicrobial prophylaxis for participants, but types of agents differed between and within studies (<LINK REF="STD-Gardner-2008" TYPE="STUDY">Gardner 2008</LINK>; <LINK REF="STD-Van-Tiel-2007" TYPE="STUDY">Van Tiel 2007</LINK>); in the other study, this treatment was unclear (<LINK REF="STD-Moody-2006" TYPE="STUDY">Moody 2006</LINK>). Two studies used granulocyte colony-stimulating factors for some participants (<LINK REF="STD-Gardner-2008" TYPE="STUDY">Gardner 2008</LINK>; <LINK REF="STD-Moody-2006" TYPE="STUDY">Moody 2006</LINK>); in the other study, this treatment was unclear (<LINK REF="STD-Van-Tiel-2007" TYPE="STUDY">Van Tiel 2007</LINK>). Two studies used central lines for all participants (<LINK REF="STD-Gardner-2008" TYPE="STUDY">Gardner 2008</LINK>; <LINK REF="STD-Moody-2006" TYPE="STUDY">Moody 2006</LINK>); in the other study, this treatment was unclear (<LINK REF="STD-Van-Tiel-2007" TYPE="STUDY">Van Tiel 2007</LINK>). No studies mentioned CVC care, and no studies mentioned oral care. Two studies did not mention hygiene practices (including hand washing) (<LINK REF="STD-Gardner-2008" TYPE="STUDY">Gardner 2008</LINK>; <LINK REF="STD-Van-Tiel-2007" TYPE="STUDY">Van Tiel 2007</LINK>), whereas investigators in the other study provided hygiene instructions for all participants (<LINK REF="STD-Moody-2006" TYPE="STUDY">Moody 2006</LINK>).</P>
</INCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2016-04-04 14:42:45 +0200" MODIFIED_BY="[Empty name]">
<P>See the 'Risk of bias' table under <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> for exact scores per study and support for judgements made.<BR/>
</P>
<ALLOCATION MODIFIED="2016-04-04 14:42:45 +0200" MODIFIED_BY="[Empty name]">
<P>For evaluation of selection bias, we assessed random sequence generation and allocation concealment. Both of these items, and thus the risk of selection bias, were unclear in one study (<LINK REF="STD-Gardner-2008" TYPE="STUDY">Gardner 2008</LINK>). The other two studies (<LINK REF="STD-Moody-2006" TYPE="STUDY">Moody 2006</LINK>; <LINK REF="STD-Van-Tiel-2007" TYPE="STUDY">Van Tiel 2007</LINK>) had low risk of selection bias.</P>
</ALLOCATION>
<BLINDING MODIFIED="2016-04-04 14:42:44 +0200" MODIFIED_BY="[Empty name]">
<P>For evaluation of performance bias, we assessed blinding of participants and healthcare providers. In two studies, risk of performance bias was unclear: In <LINK REF="STD-Van-Tiel-2007" TYPE="STUDY">Van Tiel 2007</LINK>, blinding of both participants and healthcare providers was unclear, and in <LINK REF="STD-Moody-2006" TYPE="STUDY">Moody 2006</LINK>, participants were blinded, but blinding of healthcare providers was unclear. In the other study, risk of performance bias was high (<LINK REF="STD-Gardner-2008" TYPE="STUDY">Gardner 2008</LINK>).</P>
<P>For evaluation of detection bias, we assessed blinding of outcome assessors for all outcomes separately, with the exception of mortality, because for that outcome, blinding was not relevant. Three studies evaluated the infection rate: In two studies, risk of detection bias was unclear (<LINK REF="STD-Gardner-2008" TYPE="STUDY">Gardner 2008</LINK>; <LINK REF="STD-Van-Tiel-2007" TYPE="STUDY">Van Tiel 2007</LINK>), and in one study, risk of detection bias was high (<LINK REF="STD-Moody-2006" TYPE="STUDY">Moody 2006</LINK>). Time to first febrile episode (<LINK REF="STD-Moody-2006" TYPE="STUDY">Moody 2006</LINK>), need for empirical antibiotic therapy (<LINK REF="STD-Van-Tiel-2007" TYPE="STUDY">Van Tiel 2007</LINK>), diet acceptability (<LINK REF="STD-Moody-2006" TYPE="STUDY">Moody 2006</LINK>) and quality of life (<LINK REF="STD-Moody-2006" TYPE="STUDY">Moody 2006</LINK>) were evaluated in only one study; for all of these outcomes, risk of detection bias was unclear.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2016-04-04 14:42:37 +0200" MODIFIED_BY="[Empty name]">
<P>For evaluation of attrition bias, we assessed incomplete outcome data for all outcomes separately. Three studies evaluated the infection rate: In two studies, risk of attrition bias was low (<LINK REF="STD-Gardner-2008" TYPE="STUDY">Gardner 2008</LINK>; <LINK REF="STD-Moody-2006" TYPE="STUDY">Moody 2006</LINK>), and in the other study, this risk was unclear (<LINK REF="STD-Van-Tiel-2007" TYPE="STUDY">Van Tiel 2007</LINK>). The following outcomes were evaluated in only one study: overall survival (<LINK REF="STD-Gardner-2008" TYPE="STUDY">Gardner 2008</LINK>; low risk of attrition bias), time to first febrile episode (<LINK REF="STD-Moody-2006" TYPE="STUDY">Moody 2006</LINK>; low risk of attrition bias), need for empirical antibiotic therapy (<LINK REF="STD-Van-Tiel-2007" TYPE="STUDY">Van Tiel 2007</LINK>; unclear risk of attrition bias), diet acceptability (<LINK REF="STD-Moody-2006" TYPE="STUDY">Moody 2006</LINK>; unclear risk of attrition bias) and quality of life (<LINK REF="STD-Moody-2006" TYPE="STUDY">Moody 2006</LINK>; unclear risk of attrition bias).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2016-04-04 14:42:35 +0200" MODIFIED_BY="[Empty name]">
<P>For evaluation of reporting bias, we assessed selective reporting. In all included studies, the risk was low.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2016-04-04 14:42:34 +0200" MODIFIED_BY="[Empty name]">
<P>For evaluation of other potential sources of bias, we assessed differences between treatment groups for the following items: received anticancer treatment more likely to cause neutropenia, co-interventions (i.e. protective environment, antimicrobial prophylaxis, CVC care, oral care, hygiene practices and colony-stimulating factors) and other (as reported in the original study).</P>
<P>In two studies, the risk of other potential sources of bias was unclear (<LINK REF="STD-Gardner-2008" TYPE="STUDY">Gardner 2008</LINK>; <LINK REF="STD-Van-Tiel-2007" TYPE="STUDY">Van Tiel 2007</LINK>), and in the other study, we could not rule out the presence of this type of bias (<LINK REF="STD-Moody-2006" TYPE="STUDY">Moody 2006</LINK>). For a more detailed description of all items, see the 'Risk of bias' section of the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.<BR/>
</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2016-04-09 16:28:21 +0200" MODIFIED_BY="[Empty name]">
<P>None of the articles did allow data extraction for all end points (see the <A HREF="http://www.archie.cochrane.org/sections/documents/view?document=A92329C382E26AA2016292A43EF809F0&amp;format=REVMAN#CHARACTERISTICS_OF_INCLUDED_STUDIES">Characteristics of included studies</A> table for a more detailed description of extractable end points for each article). We calculated all RRs, 95% CIs and P values mentioned below in <LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>, unless stated otherwise.</P>
<P>Unfortunately, because of differences in co-interventions (i.e. protective environment, antimicrobial prophylaxis, CVC care, oral care, hygiene practices, colony-stimulating factors), outcome definitions used and intervention and control diets provided, it was not possible to pool the results of included studies. Also, <LINK REF="STD-Van-Tiel-2007" TYPE="STUDY">Van Tiel 2007</LINK> did not present the data that we needed to perform adequate analyses (for further information, see below).</P>
<SUBSECTION>
<HEADING LEVEL="3">Infection rate</HEADING>
<P>All included studies used different definitions of infection rate.</P>
<P>
<LINK REF="STD-Gardner-2008" TYPE="STUDY">Gardner 2008</LINK> assessed the rate of infection (i.e. major infections, minor infections and fevers of unknown origin; see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table for the exact definitions) and identified no statistically significant differences between treatment groups: 68 out of 78 participants (87%) in the cooked-diet group and 57 out of 75 (76%) in the raw-diet group developed an infection (RR 1.15, 95% CI 0.98 to 1.34; P value = 0.08; see <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). Among 68 infections in the cooked-diet group were 23 major infections (34%), five minor infections (7%) and 40 fevers of unknown origin (59%). The raw-diet group had 26 major infections (46%), four (7%) minor infections and 27 (47%) fevers of unknown origin. Among the 23 major infections in the cooked-diet group were 12 microbiologically documented infections (52%), and among the 26 major infections in the raw-diet group were 22 (85%); this information was not reported for minor infections. Although not explicitly stated, we assumed that investigators performed tests to determine pathogenic organisms in all participants. Among the 23 major infections in the cooked-diet group were 12 cases of pneumonia (52%), seven cases of bacteraemia or fungaemia (31%) and four cases of pneumonia and bacteraemia or fungaemia combined (17%), whereas among the 26 major infections in the raw-diet group were four cases of pneumonia (16%), 17 cases of bacteraemia or fungaemia (65%) and five cases of pneumonia and bacteraemia or fungaemia combined (19%); this information was not reported for minor infections.</P>
<P>
<LINK REF="STD-Moody-2006" TYPE="STUDY">Moody 2006</LINK> assessed the rate of neutropenic infection (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table for the exact definition) and identified no statistically significant differences between treatment groups: Four out of nine children (44%) in the US Food and Drug Administration (FDA)-approved food safety guidelines and neutropenic diet guidelines group and four out of 10 children (40%) in the FDA-approved food safety guidelines-only group developed a neutropenic infection (RR 1.11, 95% CI 0.39 to 3.19; P value = 0.84; see <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). None of the four neutropenic infections (0%) in the FDA-approved food safety guidelines and neutropenic diet guidelines group were documented (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table for the exact definition), whereas two out of four neutropenic infections (50%) in the FDA-approved safety guidelines-only group were documented (i.e. one case of <I>Pseudomonas</I> sepsis and one of respiratory virus pneumonia).</P>
<P>
<LINK REF="STD-Van-Tiel-2007" TYPE="STUDY">Van Tiel 2007</LINK> did not report the infection rate as the number of participants with an infection (defined as a temperature &#8805; 38.5°C or &lt; 36°C with a single measurement, for which empirical antibiotics were administered), but as the number of chemotherapy cycles with infection present. As a result, we could not adequately analyse the infection rate in this study, but we have provided descriptive results: The LBD group had 14 chemotherapy cycles with infection (of which seven were microbiologically confirmed (50%)) among 20 chemotherapy cycles given (70%), and the normal hospital-diet group had 17 chemotherapy cycles with infection (of which seven were microbiologically confirmed (41%)) among 21 chemotherapy cycles given (81%). Researchers observed no significant differences (P value = 0.48, as reported in the original article). Please note that investigators assessed this outcome for all available chemotherapy cycles, but it was unclear whether they evaluated all participants within these cycles; therefore, we cannot be certain that an intention-to-treat analysis was performed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">(Infection-related) mortality</HEADING>
<P>None of the included studies mentioned infection-related mortality.</P>
<P>
<LINK REF="STD-Gardner-2008" TYPE="STUDY">Gardner 2008</LINK> stated that overall survival (no definition provided) in both treatment groups was as expected for newly diagnosed acute myeloid leukaemia and high-risk myelodysplastic syndrome; investigators observed no significant differences (P value = 0.36, as reported in the original article).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Time to first febrile episode</HEADING>
<P>One study evaluated time to fever. <LINK REF="STD-Moody-2006" TYPE="STUDY">Moody 2006</LINK> identified no significant differences in time to fever (defined as time from onset of neutropenia to start of fever) between both treatment groups (no further information and no significance level provided).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Need for empirical antibiotic therapy</HEADING>
<P>In all included studies, it was standard policy to give empirical antibiotics (and sometimes also antimycotics) to (some of) the participants diagnosed with an infection (for more information, see the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table). Only one study provided explicit data on the use of empirical antibiotics and antimycotics (<LINK REF="STD-Van-Tiel-2007" TYPE="STUDY">Van Tiel 2007</LINK>). In the LBD group, the median number of days per chemotherapy cycle with empirical antibiotics and antimycotics was 11 days (range 0 to 22 days) and 0 days (range 0 to 9 days), respectively, whereas in the normal hospital-diet group, the median number was 14.5 days (range 0 to 28 days) and 0 days (0 to 20 days), respectively. Investigators detected no significant differences between treatment groups for duration of empirical antibiotics (P value = 0.09, as reported in the original article) or duration of empirical antimycotics (P value = 0.96, as reported in the original article). Please note that it was unclear whether this outcome was assessed in all participants; therefore, we cannot be certain that intention-to-treat analyses were performed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Diet acceptability</HEADING>
<P>One study evaluated diet acceptability (<LINK REF="STD-Moody-2006" TYPE="STUDY">Moody 2006</LINK>). In the FDA-approved food safety guidelines and neutropenic diet guidelines group, all nine children (100%) reported that they were easily able to follow the guidelines, and seven out of nine children (78%) felt they could follow the guidelines through all chemotherapy cycles. All children (100%) reported some difficulty with the food restrictions, especially avoidance of fast foods and raw fruits. In the FDA-approved guidelines-only group, nine out of 10 children (90%) reported that they were easily able to follow the guidelines, and that they could follow them through all chemotherapy cycles. No significant differences were identified between treatment groups for following the diet easily (RR 1.10, 95% CI 0.84 to 1.45; P value = 0.50) and for following the diet throughout all chemotherapy cycles (RR 0.86, 95% CI 0.58 to 1.30; P value = 0.48) (see <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>). Please note that it was not stated whether all participants were evaluated for this outcome, although it is likely that they were (it was stated that no participants discontinued the study). An intention-to-treat analysis was performed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quality of life</HEADING>
<P>One study evaluated quality of life. <LINK REF="STD-Moody-2006" TYPE="STUDY">Moody 2006</LINK> used the Peds QL Pediatric Quality of Life Inventory Core Module and Cancer Module by self reports or parent proxy reports, or both (<LINK REF="REF-Varni-2002" TYPE="REFERENCE">Varni 2002</LINK>), and identified no statistically significant changes in score from baseline to follow-up for either arm by child self report or parent proxy report (for both Core and Cancer Modules; no further information provided). Please note that it was not stated whether all participants were evaluated for this outcome, although it is likely that they were (it was stated that no participants discontinued the study). However, we are not certain that an intention-to-treat analysis was performed.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2016-04-09 16:37:10 +0200" MODIFIED_BY="[Empty name]">
<P>Neutropenia is a potentially serious side effect of chemotherapy and a major risk factor for infection, which can be life-threatening. It has been argued that a low bacterial diet (LBD) can prevent infection and (infection-related) mortality in cancer patients receiving chemotherapy that causes episodes of neutropenia, but much remains unclear. This is an update of the the first systematic review conducted to evaluate this important topic in both adults and children.</P>
<P>To adequately ascertain the efficacy of a dietary intervention, the best study design, provided that design and execution are correct, is a randomised controlled trial (RCT) in which the only difference between intervention and control groups is the diet used.</P>
<P>In the original version of the review, we identified three RCTs including a total of 192 participants with different types of haematological malignancies and solid tumours, in which investigators evaluated different intervention and control diets; in the update, we identified no new eligible studies. Investigators in all studies provided only a scant description of treatment regimens. In all included studies, it was standard policy to give empirical antibiotics (and sometimes also antimycotics) to (some of) the participants diagnosed with an infection. The first study (<LINK REF="STD-Gardner-2008" TYPE="STUDY">Gardner 2008</LINK>) included adults and defined infection as major infections, minor infections and fevers of unknown origin. Investigators randomised participants to a diet that contained only cooked fruits and vegetables versus a diet that permitted fresh (i.e. raw) fruits and vegetables. Participants were treated in high-efficiency particulate air-filtered rooms, and they received antimicrobial prophylaxis. Granulocyte colony-stimulating factors were used in some participants. All participants had central lines, but neither central venous catheter (CVC) care nor oral care and hygiene practices were mentioned. The second study (<LINK REF="STD-Moody-2006" TYPE="STUDY">Moody 2006</LINK>) included children and evaluated neutropenic infections. Participants were randomised between FDA-approved food safety guidelines and neutropenic diet guidelines versus FDA-approved food safety guidelines only. Granulocyte colony-stimulating factors were used in some participants. All received hygiene instructions. All participants had central lines, but CVC care was not mentioned. Use of a protective environment, antimicrobial prophylaxis and oral care was not mentioned. The third study (<LINK REF="STD-Van-Tiel-2007" TYPE="STUDY">Van Tiel 2007</LINK>) included adults and defined infection as a temperature &#8805; 38.5°C or &lt; 36°C, with a single measurement for which empirical antibiotics were administered. Participants were randomised between an LBD and a normal hospital diet. Use of a protective environment, granulocyte colony-stimulating factors, oral care and hygiene practices were not mentioned, but participants did receive antimicrobial prophylaxis. It was unclear whether participants had central lines; CVC care was not mentioned.</P>
<P>Differences in co-interventions (e.g. protective environment, antimicrobial prophylaxis, CVC care, oral care, hygiene practices, colony-stimulating factors), outcome definitions used and intervention and control diets provided precluded pooling of the results of included studies. This should be kept in mind when the results of individual studies are interpreted. Also, one study did not present the data (i.e. the number of participants with an infection) that we needed to perform adequate analyses (<LINK REF="STD-Van-Tiel-2007" TYPE="STUDY">Van Tiel 2007</LINK>).</P>
<P>Two individual studies identified no statistically significant differences in infection rate between participants receiving intervention and control diets (<LINK REF="STD-Gardner-2008" TYPE="STUDY">Gardner 2008</LINK>; <LINK REF="STD-Moody-2006" TYPE="STUDY">Moody 2006</LINK>); the study that did not present the data needed for adequate analyses reported no significant differences between treatment groups in the number of chemotherapy cycles with an infection (<LINK REF="STD-Van-Tiel-2007" TYPE="STUDY">Van Tiel 2007</LINK>). Infection-related mortality was not mentioned in any of the included studies, but investigators in one study (<LINK REF="STD-Gardner-2008" TYPE="STUDY">Gardner 2008</LINK>) observed no significant differences in overall survival (no definition provided) between treatment groups. One study (<LINK REF="STD-Moody-2006" TYPE="STUDY">Moody 2006</LINK>) evaluated time to fever (defined as time from onset of neutropenia to start of fever) and identified no significant differences between treatment groups. One study provided data on use of empirical antibiotics and antimycotics apart from infection rate (<LINK REF="STD-Van-Tiel-2007" TYPE="STUDY">Van Tiel 2007</LINK>). Again, researchers identified no significant differences in duration of empirical antibiotics and antimycotics between treatment groups. One study evaluated diet acceptability (<LINK REF="STD-Moody-2006" TYPE="STUDY">Moody 2006</LINK>) and no significant differences were identified between treatment groups for following the diet easily and for following the diet throughout all chemotherapy cycles. Finally, one study evaluated quality of life (<LINK REF="STD-Moody-2006" TYPE="STUDY">Moody 2006</LINK>) and identified no statistically significant changes in score from baseline to follow-up for either treatment arm by child self report or by parent proxy report.</P>
<P>In this review, we tried to perform intention-to-treat analyses, because they provide the most realistic and unbiased answer to the question of clinical effectiveness (<LINK REF="REF-Lachin-2000" TYPE="REFERENCE">Lachin 2000</LINK>). However, for assessment of infection rate and use of empirical antibiotics by <LINK REF="STD-Van-Tiel-2007" TYPE="STUDY">Van Tiel 2007</LINK> and quality of life by <LINK REF="STD-Moody-2006" TYPE="STUDY">Moody 2006</LINK>, it was unclear whether these outcomes were assessed in all participants, so we cannot be certain that an intention-to-treat analysis has been performed.</P>
<P>'No evidence of effect', as identified in this review, is not the same as 'evidence of no effect'. It is possible that no significant differences between treatment groups were identified because participants included in these studies were too few to reveal a difference (i.e. low power). Also, baseline imbalances between treatment groups (as included in the other potential sources of bias assessment) might have played a role.</P>
<P>Risk of bias in included studies varied. Often, bias could not be ruled out because of lack of reporting. However, at the moment, this is the best available evidence from RCTs comparing an LBD versus a control diet.</P>
<P>Even though RCTs provide the highest level of evidence, it should be recognised that data from non-randomised studies are available. <LINK REF="STD-Trifilio-2012" TYPE="STUDY">Trifilio 2012</LINK> compared the neutropenic diet (ND) versus a general hospital diet (GD) in participants with adult hematopoetic stem cell transplantation at one centre. As far as we are aware, this is the only non-randomised study that compared ND versus GD. Researchers analysed the electronic medical records of 726 consecutive recipients; 363 participants received ND (from October 2004 to August 2006), and the next 363 participants received GD (September 2006 to August 2008). In the GD group, significantly fewer microbiological infections were confirmed compared with the ND group. No differences between groups were detected for length of hospital stay, days to engraftment, neutropenic fever, duration of antibiotic therapy and overall mortality. No information was given on quality of life and diet adherence, although the change to GD was received well by participants. Results of this non-randomised study seem to be in accordance with results of the three included randomised studies. The design of the study and possible confounders require caution in deriving conclusions.</P>
<P>We are awaiting the results of two ongoing studies (<LINK REF="STD-NCT00726934" TYPE="STUDY">NCT00726934</LINK>; <LINK REF="STD-NCT00947648" TYPE="STUDY">NCT00947648</LINK>).</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2016-04-04 11:17:08 +0200" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2016-04-04 11:16:15 +0200" MODIFIED_BY="[Empty name]">
<P>At the moment, no evidence from individual RCTs in children and adults with different malignancies underscores use of an LBD for prevention of infection and related outcomes. All studies differed with regard to co-interventions, outcome definitions used and intervention and control diets provided. As pooling of results was not possible and all studies had serious methodological limitations, no definitive conclusions can be reached. It should be noted that 'no evidence of effect', as identified in this review, is not the same as 'evidence of no effect'. On the basis of currently available evidence, we are not able to provide recommendations for clinical practice.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2016-04-04 11:17:08 +0200" MODIFIED_BY="[Empty name]">
<P>Before definitive conclusions can be reached about the efficacy of different LBDs, additional high-quality research is needed. Future trials should be RCTs performed in homogeneous study populations (e.g. with regards to anticancer treatment received). Valid outcome definitions should be used, according to existing guidelines (such as <LINK REF="REF-Freifeld-2011" TYPE="REFERENCE">Freifeld 2011</LINK>). Possible risk factors and preventive measures for neutropenia and infection should be taken into account. Finally, the number of participants included should be sufficient to obtain the power needed for reliable results.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2016-04-04 11:15:27 +0200" MODIFIED_BY="[Empty name]">
<P>We thank A Gardner, K Moody, JMJJ Vossen and FH van Tiel for answering our questions and, when possible, providing additional information. We thank the peer reviewers of the initial review for their helpful suggestions: Steven Jubelirer, Karen Moody and Mario Cruciani. The editorial base of the Cochrane CCG is funded by Stichting Kinderen Kankervrij (KiKa).</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2016-04-04 11:17:18 +0200" MODIFIED_BY="[Empty name]">
<P>Elvira C van Dalen performed data extraction and 'Risk of bias' assessment of included studies. She analysed the data, interpreted the results and wrote and revised the review.</P>
<P>Arno Mank designed the study and wrote the protocol. He identified studies meeting the inclusion criteria, contributed to the review manuscript and critically reviewed it.</P>
<P>Edith Leclercq developed the updated search strategy for the CENTRAL, DARE and CINAHL databases and ran the searches in these databases. She identified studies meeting the inclusion criteria, contributed to the review manuscript and critically reviewed it.</P>
<P>Renée L Mulder performed data extraction and 'Risk of bias' assessment of included studies. She contributed to the interpretation of results and critically reviewed the manuscript.</P>
<P>Michelle Davies designed the study and wrote the protocol. She identified studies meeting the inclusion criteria, provided general advice and critically reviewed the manuscript.</P>
<P>Marie José Kersten provided general advice and critically reviewed the manuscript.</P>
<P>Marianne D van de Wetering designed the study and wrote the protocol. She contributed to the interpretation of results, provided general advice and critically reviewed the manuscript.</P>
<P>All authors approved the final version.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2016-04-04 14:46:31 +0200" MODIFIED_BY="[Empty name]">
<P>While performing the review, review authors adapted some of the information provided in the protocol: In the protocol, we stated that patients with compromised immune systems (acquired or congenital, or patients with cancer) who are likely to receive chemotherapy causing episodes of neutropenia were eligible for inclusion. However, we focused the review on oncology patients only. Furthermore, to avoid missing potentially relevant information, we changed the definition of the control intervention from "no low bacterial diet" to "any other diet", and we changed the rather strict definitions of our outcome measures to "as defined by the authors of the original study". We expanded our search: We added ongoing trials databases, and we added an additional conference (i.e. Oncology Nurses Society). Also, we improved the search strategy for the CENTRAL, DARE and CINAHL databases. Since our protocol was developed, the 'Risk of bias' criteria used by The Cochrane Collaboration have changed; we used the most recent version for our review. In addition, we included assessment of reporting bias by constructing a funnel plot when we identified a sufficient number of included studies. Pooling of results was not possible, so this was not applicable to this version of the review, but it might become relevant when the review is updated.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2016-04-04 14:49:43 +0200" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2016-04-04 14:47:01 +0200" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2015-11-17 12:16:24 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Gardner-2008" MODIFIED="2012-06-13 11:23:53 +0200" MODIFIED_BY="[Empty name]" NAME="Gardner 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-06-13 11:23:53 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gardner A, Mattiuzzi G, Faderl S, Borthakur G, Garcia-Manero G, Pierce S, et al</AU>
<TI>Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2008</YR>
<VL>26</VL>
<NO>35</NO>
<PG>5684-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Moody-2006" MODIFIED="2012-02-21 15:00:34 +0100" MODIFIED_BY="[Empty name]" NAME="Moody 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-02-06 15:49:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moody K, Finlay J, Mancuso C, Charlson M</AU>
<TI>Feasibility and safety of a pilot randomized trial of infection rate: neutropenic diet versus standard food safety guidelines</TI>
<SO>Journal of Pediatric Hematology and Oncology</SO>
<YR>2006</YR>
<VL>28</VL>
<NO>3</NO>
<PG>126-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Van-Tiel-2007" MODIFIED="2012-02-21 15:00:40 +0100" MODIFIED_BY="[Empty name]" NAME="Van Tiel 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-02-21 14:54:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Tiel FH, Harbers MM, Terporten PHW, van Boxtel RTC, Kessels AG, Voss GBWE, et al</AU>
<TI>Normal hospital and low-bacterial diet in patients with cytopenia after intensive chemotherapy for hematological malignancy: a study of safety</TI>
<SO>Annals of Oncology</SO>
<YR>2007</YR>
<VL>18</VL>
<PG>1080-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2016-04-04 14:47:01 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Brown-2014" MODIFIED="2016-01-28 12:10:18 +0100" MODIFIED_BY="[Empty name]" NAME="Brown 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-01-28 12:10:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brown LE, Chen H, Frangoul H</AU>
<TI>Significant inconsistency among pediatric oncologists in the use of the neutropenic diet</TI>
<SO>Pediatric Blood and Cancer</SO>
<YR>2014</YR>
<VL>61</VL>
<NO>10</NO>
<PG>1806-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carr-2014" MODIFIED="2016-01-28 12:10:51 +0100" MODIFIED_BY="[Empty name]" NAME="Carr 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-01-28 12:10:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carr SE, Halliday V</AU>
<TI>Investigating the use of the neutropenic diet: a survey of UK dietitians</TI>
<SO>Journal of Human Nutrition and Dietetics</SO>
<YR>2014</YR>
<VL>28</VL>
<NO>5</NO>
<PG>510-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DeMille-2006" MODIFIED="2012-02-06 15:51:23 +0100" MODIFIED_BY="[Empty name]" NAME="DeMille 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-02-06 15:51:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>DeMille D, Deming P, Lupinacci P, Jacobs LA</AU>
<TI>The effect of the neutropenic diet in the outpatient setting: a pilot study</TI>
<SO>Oncology Nursing Forum</SO>
<YR>2006</YR>
<VL>33</VL>
<NO>2</NO>
<PG>337-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fopp-1975" MODIFIED="2012-06-13 11:24:34 +0200" MODIFIED_BY="[Empty name]" NAME="Fopp 1975" YEAR="1975">
<REFERENCE MODIFIED="2012-06-13 11:24:34 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fopp M, Gasser A, Eigenmann B, Jungi WF, Meuret G, Senn HJ</AU>
<TI>Prevention of infection in patients with agranulocytosis through isolation and whole-body decontamination</TI>
<TO>Infektprophylaxe bei Patienten mit Agranulozytose durch Isolation und Ganzkörperdekontamination</TO>
<SO>Schweizerische Medizinische Wochenschrift</SO>
<YR>1975</YR>
<VL>105</VL>
<NO>35</NO>
<PG>1123-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Foster-2014" MODIFIED="2016-01-28 12:11:17 +0100" MODIFIED_BY="[Empty name]" NAME="Foster 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-01-28 12:11:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Foster M</AU>
<TI>Reevaluating the neutropenic diet: time to change</TI>
<SO>Clinical Journal of Oncology Nursing</SO>
<YR>2014</YR>
<VL>18</VL>
<NO>2</NO>
<PG>239-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fox-2012" MODIFIED="2016-01-28 12:11:36 +0100" MODIFIED_BY="[Empty name]" NAME="Fox 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-01-28 12:11:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fox N, Freifeld AG</AU>
<TI>The neutropenic diet reviewed: moving toward a safe food handling approach</TI>
<SO>Oncology</SO>
<YR>2012</YR>
<VL>26</VL>
<NO>6</NO>
<PG>572-5, 580, 582</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lund-2014" MODIFIED="2016-01-28 12:11:52 +0100" MODIFIED_BY="[Empty name]" NAME="Lund 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-01-28 12:11:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lund BM</AU>
<TI>Microbiological food safety and low-bacterial diet to protect vulnerable people</TI>
<SO>Food Borne Pathogens and Disease</SO>
<YR>2014</YR>
<VL>11</VL>
<NO>6</NO>
<PG>413-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Trifilio-2012" MODIFIED="2016-04-04 14:47:01 +0200" MODIFIED_BY="[Empty name]" NAME="Trifilio 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-04-04 14:47:01 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trifilio S, Helenowski I, Giel M, Gobel B, Pi J, Greenberg D, et al</AU>
<TI>Questioning the role of neutropenic diet following hematopoietic stem cell transplantation</TI>
<SO>Biological Blood Marrow Transplantion</SO>
<YR>2012</YR>
<VL>18</VL>
<NO>9</NO>
<PG>1385-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Veber-2010" MODIFIED="2016-04-04 12:40:27 +0200" MODIFIED_BY="[Empty name]" NAME="Veber 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-04-04 12:40:27 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Veber Y, Kokunova E, Smirnova M, Ivanova O, Kucher M, Afanasyev B</AU>
<TI>Nutrition support in allogeneic stem cell transplantation. Comparison of standard and modified regimens, single-centre experience</TI>
<SO>Bone Marrow Transplantation. 36th Annual Meeting of the European Group for Blood and Marrow Transplantation, EBMT; 2010 March 21-24; Vienna, Austria</SO>
<YR>2010</YR>
<VL>45</VL>
<PG>S350</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wilson-2002" MODIFIED="2012-02-06 15:52:12 +0100" MODIFIED_BY="[Empty name]" NAME="Wilson 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-02-06 15:52:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wilson BJ</AU>
<TI>Dietary recommendations for neutropenic patients</TI>
<SO>Seminars in Oncology Nursing</SO>
<YR>2002</YR>
<VL>18</VL>
<NO>1</NO>
<PG>44-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ziegler-1992" MODIFIED="2012-02-06 15:52:18 +0100" MODIFIED_BY="[Empty name]" NAME="Ziegler 1992" YEAR="1992">
<REFERENCE MODIFIED="2012-02-06 15:52:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ziegler TR, Young LS, Benfell K, Scheltinga M, Hortos K, Bye R, et al</AU>
<TI>Clinical and metabolic efficacy of glutamine-supplemented parenteral nutrition after bone marrow transplantation. A randomized, double-blind, controlled study</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1992</YR>
<VL>116</VL>
<NO>10</NO>
<PG>821-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2012-07-14 11:21:35 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="MIX" ID="STD-Van-_x0027_t-Veer-1987" MODIFIED="2012-07-14 11:21:35 +0200" MODIFIED_BY="[Empty name]" NAME="Van 't Veer 1987" YEAR="2007">
<REFERENCE MODIFIED="2012-06-13 11:33:14 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Van't Veer-Korthof ET, Dooren LJ, Guiot HFL, Palmer JG, Vossen JMJJ</AU>
<TI>Prevention of infections in granulocytopenic patients by a cooked-food diet in combination with selective GI decontamination and partial protective isolation</TI>
<SO>Blood; 29th Annual Meeting of the American Society of Hematology; 1987 Dec 4-8; Washington (DC)</SO>
<YR>1987</YR>
<VL>70</VL>
<PG>239a</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2016-01-28 12:12:36 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00726934" MODIFIED="2016-01-28 12:12:21 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00726934" YEAR="6934">
<REFERENCE MODIFIED="2016-01-28 12:12:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00726934</AU>
<TI>The effectiveness of the neutropenic diet in pediatric oncology patients</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT00726934</SO>
<YR>(accessed 4 May 2015)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00947648" MODIFIED="2016-01-28 12:12:36 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00947648" YEAR="7648">
<REFERENCE MODIFIED="2016-01-28 12:12:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00947648</AU>
<TI>Are neutropenic diets beneficial to improve outcome?</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT00947648</SO>
<YR>(accessed 4 May 2015)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2016-04-04 14:49:43 +0200" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2016-04-04 14:49:43 +0200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Aker-1983" NAME="Aker 1983" TYPE="JOURNAL_ARTICLE">
<AU>Aker SN, Cheney CL</AU>
<TI>The use of sterile and low microbial diets in ultra isolation environments</TI>
<SO>Journal of Parenteral and Enteral Nutrition</SO>
<YR>1983</YR>
<VL>7</VL>
<NO>4</NO>
<PG>390-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barber-2001" NAME="Barber 2001" TYPE="JOURNAL_ARTICLE">
<AU>Barber FD</AU>
<TI>Management of fever in neutropenic patients with cancer</TI>
<SO>Nursing Clinics of North America</SO>
<YR>2001</YR>
<VL>36</VL>
<PG>631-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Candell-1991" MODIFIED="2016-04-04 12:39:55 +0200" MODIFIED_BY="[Empty name]" NAME="Candell 1991" TYPE="BOOK_SECTION">
<AU>Candell KA, Whedon MB</AU>
<TI>Hematopoietic complications</TI>
<SO>In: Bone Marrow Transplantation Principles, Practice, and Nursing Insights</SO>
<YR>1991</YR>
<PG>136</PG>
<ED>MB Whedon</ED>
<PB>Jones and Bartlett Publishers</PB>
<CY>Burlington, MA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dykewicz-2001" MODIFIED="2012-06-13 11:35:44 +0200" MODIFIED_BY="Anne Lawson" NAME="Dykewicz 2001" TYPE="JOURNAL_ARTICLE">
<AU>Dykewicz CA</AU>
<TI>Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2001</YR>
<VL>33</VL>
<NO>2</NO>
<PG>139-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Food-Safety-2005" MODIFIED="2016-04-04 12:41:34 +0200" MODIFIED_BY="[Empty name]" NAME="Food Safety 2005" TYPE="OTHER">
<TI>Gateway to Government Food Safety Information. Advice for Consumers 2005</TI>
<SO>http://www.foodsafety.gov (accessed 4 May 2012)</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Freifeld-2011" MODIFIED="2012-05-18 08:44:51 +0200" MODIFIED_BY="[Empty name]" NAME="Freifeld 2011" TYPE="JOURNAL_ARTICLE">
<AU>Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al</AU>
<TI>Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2011</YR>
<VL>52</VL>
<NO>4</NO>
<PG>e56-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-French-2001" NAME="French 2001" TYPE="JOURNAL_ARTICLE">
<AU>French MR, Levy-Milne R, Zibrik D</AU>
<TI>A survey of the use of low microbial diets in pediatric bone marrow transplant programs</TI>
<SO>Journal of American Dietetic Association</SO>
<YR>2001</YR>
<VL>101</VL>
<NO>10</NO>
<PG>1194-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>British Medical Journal</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2016-04-04 14:49:43 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="BOOK">
<AU>Higgins JPT, Green S (editors)</AU>
<SO>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]</SO>
<YR>2011</YR>
<PB>The Cochrane Collaboration, 2011. www.cochrane-handbook.org</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hughes-2002" MODIFIED="2010-08-30 10:34:07 +0200" MODIFIED_BY="[Empty name]" NAME="Hughes 2002" TYPE="JOURNAL_ARTICLE">
<AU>Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al</AU>
<TI>Guidelines for the use of antimicrobial agents in neutropenic patients with cancer</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2002</YR>
<VL>34</VL>
<NO>6</NO>
<PG>730-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Klastersky-2000" MODIFIED="2012-06-13 11:39:03 +0200" MODIFIED_BY="[Empty name]" NAME="Klastersky 2000" TYPE="JOURNAL_ARTICLE">
<AU>Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al</AU>
<TI>Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2000</YR>
<VL>18</VL>
<NO>16</NO>
<PG>3038-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lachin-2000" MODIFIED="2012-02-28 11:08:35 +0100" MODIFIED_BY="[Empty name]" NAME="Lachin 2000" TYPE="JOURNAL_ARTICLE">
<AU>Lachin JM</AU>
<TI>Statistical considerations in the intent-to-treat principle</TI>
<SO>Controlled Clinical Trials</SO>
<YR>2000</YR>
<VL>21</VL>
<PG>167-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Larson-2004" NAME="Larson 2004" TYPE="JOURNAL_ARTICLE">
<AU>Larson E, Nirenberg A</AU>
<TI>Evidence-based nursing practice to prevent infection in hospitalized neutropenic patients with cancer</TI>
<SO>Oncology Nursing Forum</SO>
<YR>2004</YR>
<VL>31</VL>
<NO>4</NO>
<PG>717-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-MacVittie-1997" MODIFIED="2016-04-04 12:42:13 +0200" MODIFIED_BY="[Empty name]" NAME="MacVittie 1997" TYPE="JOURNAL_ARTICLE">
<AU>MacVittie TJ</AU>
<TI>Therapy of radiation injury</TI>
<SO>Stem Cells</SO>
<YR>1997</YR>
<VL>15</VL>
<NO>Suppl 2</NO>
<PG>263-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Module-CCG-2010" MODIFIED="2016-01-28 12:06:39 +0100" MODIFIED_BY="[Empty name]" NAME="Module CCG 2010" TYPE="OTHER">
<AU>Kremer LCM, van Dalen EC, Moher D, Caron HN</AU>
<TI>Cochrane Childhood Cancer Group</TI>
<SO>About The Cochrane Collaboration (Cochrane Review Groups (CRGs))</SO>
<YR>2010</YR>
<NO>1</NO>
<PG>Art. No.: CHILDCA</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Module-GCG-2010" MODIFIED="2016-01-28 12:06:57 +0100" MODIFIED_BY="[Empty name]" NAME="Module GCG 2010" TYPE="OTHER">
<AU>Williams C, Quinn G, Jess C, Bishop T, Hayes J</AU>
<TI>Cochrane Gynaecological Cancer Group</TI>
<SO>About The Cochrane Collaboration (Cochrane Review Groups (CRGs))</SO>
<YR>2010</YR>
<NO>4</NO>
<PG>Art. No.: GYNAECA</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moody-2002" NAME="Moody 2002" TYPE="JOURNAL_ARTICLE">
<AU>Moody K, Charlson ME, Finlay J</AU>
<TI>The neutropenic diet: what's the evidence?</TI>
<SO>Journal Pediatric Hematological Oncology</SO>
<YR>2002</YR>
<VL>24</VL>
<NO>9</NO>
<PG>717-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pizzo-1982" NAME="Pizzo 1982" TYPE="JOURNAL_ARTICLE">
<AU>Pizzo PA, Purvis DS, Waters C</AU>
<TI>Microbiological evaluation of food items for patients undergoing gastrointestinal decontamination and protected isolation</TI>
<SO>Journal of the American Dietetic Association</SO>
<YR>1982</YR>
<VL>81</VL>
<NO>3</NO>
<PG>272-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pizzo-1999" MODIFIED="2012-06-13 11:43:30 +0200" MODIFIED_BY="[Empty name]" NAME="Pizzo 1999" TYPE="JOURNAL_ARTICLE">
<AU>Pizzo PA</AU>
<TI>Fever in immunocompromised patients</TI>
<SO>New England Journal of Medicine</SO>
<YR>1999</YR>
<VL>341</VL>
<NO>12</NO>
<PG>893-900</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Preisler-1970" NAME="Preisler 1970" TYPE="JOURNAL_ARTICLE">
<AU>Preisler HD, Goldstein IM, Henderson ES</AU>
<TI>Gastrointestinal "sterilization" in the treatment of patients with acute leukemia</TI>
<SO>Cancer</SO>
<YR>1970</YR>
<VL>26</VL>
<NO>5</NO>
<PG>1076-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reimer-1966" NAME="Reimer 1966" TYPE="JOURNAL_ARTICLE">
<AU>Reimer AO, Tillotson JL</AU>
<TI>Food service procedures for reverse isolation</TI>
<SO>Journal of the American Dietetic Association</SO>
<YR>1966</YR>
<VL>48</VL>
<NO>5</NO>
<PG>381-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2016-04-04 12:42:30 +0200" MODIFIED_BY="[Empty name]" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3.5</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roguin-1996" MODIFIED="2012-02-06 16:18:31 +0100" MODIFIED_BY="[Empty name]" NAME="Roguin 1996" TYPE="JOURNAL_ARTICLE">
<AU>Roguin A, Kasis I, Ben-Arush MW, Sharon R, Berant M</AU>
<TI>Fever and neutropenia in children with malignant disease</TI>
<SO>Pediatric Hematology and Oncology</SO>
<YR>1996</YR>
<VL>13</VL>
<NO>6</NO>
<PG>503-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smith-2000" NAME="Smith 2000" TYPE="JOURNAL_ARTICLE">
<AU>Smith LH, Besser SG</AU>
<TI>Dietary restrictions for patients with neutropenia: a survey of institutional practices</TI>
<SO>Oncology Nursing Forum</SO>
<YR>2000</YR>
<VL>27</VL>
<NO>3</NO>
<PG>515-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Talcott-1992" NAME="Talcott 1992" TYPE="JOURNAL_ARTICLE">
<AU>Talcott JA, Siegel RD, Finberg R, Goldman L</AU>
<TI>Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1992</YR>
<VL>10</VL>
<NO>2</NO>
<PG>316-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Varni-2002" MODIFIED="2012-02-06 14:51:39 +0100" MODIFIED_BY="[Empty name]" NAME="Varni 2002" TYPE="JOURNAL_ARTICLE">
<AU>Varni JW, Burwinkle TM, Katz ER, Meeske K, Dickinson P</AU>
<TI>The PedsQL in pediatric cancer: reliability and validity of the Pediatric Quality of Life Inventory Generic Core Scales, Multidimensional Fatigue Scale, and Cancer Module</TI>
<SO>Cancer</SO>
<YR>2002</YR>
<VL>94</VL>
<NO>7</NO>
<PG>2090-106</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2016-04-04 12:42:51 +0200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Mank-2006" MODIFIED="2016-04-04 12:42:51 +0200" MODIFIED_BY="[Empty name]" NAME="Mank 2006" TYPE="COCHRANE_PROTOCOL">
<AU>Mank A, Davies M, Langeveld N, van de Wetering MD, van der Lelie H</AU>
<TI>Low bacterial diet to prevent infection in neutropenic patients</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2015-12-17 12:36:59 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-12-17 12:36:59 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006247"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mank-2012" MODIFIED="2016-01-28 12:13:11 +0100" MODIFIED_BY="[Empty name]" NAME="Mank 2012" TYPE="COCHRANE_REVIEW">
<AU>van Dalen EC, Mank A, Leclercq E, Mulder RL, Davies M, Kersten MJ, van de Wetering MD</AU>
<TI>Low bacterial diet versus control diet to prevent infection in cancer patients treated with chemotherapy causing episodes of neutropenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>9</NO>
<IDENTIFIERS MODIFIED="2015-12-17 12:39:30 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-12-17 12:39:30 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006247.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2016-04-04 14:46:26 +0200" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2016-04-04 14:46:26 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2016-04-04 14:46:26 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gardner-2008">
<CHAR_METHODS MODIFIED="2016-04-04 14:46:26 +0200" MODIFIED_BY="[Empty name]">
<P>Randomisation performed by the Leukaemia Department Data Management Office using patients' early risk of mortality scores as a stratification factor</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-04 14:44:41 +0200" MODIFIED_BY="[Empty name]">
<P>153 patients (median age in cooked-diet group 64 years (range 17 to 88 years), median age in raw-diet group 63 years (range 47 to 84 years); sex not reported) with untreated acute myeloid leukaemia (75 in cooked-diet group and 69 in raw-diet group) or high-risk myelodysplastic syndrome (i.e. 10% to 19% blasts in marrow or blood) (3 in cooked-diet group and 6 in raw-diet group). Patients were treated with remission induction chemotherapy on an ongoing leukaemia department protocol<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-04 11:19:16 +0200" MODIFIED_BY="[Empty name]">
<P>Diet that contained only cooked fruits and vegetables (n = 78) vs diet that permitted fresh (i.e. raw) fruits and vegetables (n = 75)</P>
<P>Participants in the raw-diet group were instructed to eat a fresh fruit or vegetable each day</P>
<P>All participants were treated in high-efficiency particulate air-filtered rooms</P>
<P>All participants received antimicrobial prophylaxis with levofloxacin, valacyclovir and, depending on the protocol, itraconazole, voriconazole (n = 14 in cooked-diet group and n = 8 in raw-diet group) or a lipid preparation of amphotericin B; no further information was provided</P>
<P>All participants had central lines; CVC care was not reported</P>
<P>Oral care was not reported</P>
<P>Hygiene practices (including hand washing) was not reported</P>
<P>Granulocyte colony-stimulating factor was used only when neutrophil recovery was delayed (i.e. by 6 weeks) or after a major infection had developed. Its use was equally infrequent in the cooked- and raw-diet groups; no further information was provided</P>
<P>If fever of unknown origin or pneumonia occurred, patients received intravenous ceftazidime or equivalent; if fever did not resolve, antifungal coverage was broadened; no further information was provided</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-04 11:19:25 +0200" MODIFIED_BY="[Empty name]">
<P>Infections, including:</P>
<UL>
<LI>major infections (defined as pneumonia, bacteraemia, fungaemia or pneumonia accompanied by bacteraemia or fungaemia);</LI>
</UL>
<UL>
<LI>minor infections (no definition provided); and</LI>
</UL>
<UL>
<LI>fevers of unknown origin (no definition provided).</LI>
</UL>
<P>A diagnosis of pneumonia required a compatible chest x-ray or computed tomography scan. Bronchoalveolar lavage was performed to isolate a causative organism if no resolution had occurred after 3 to 5 days</P>
<P>A diagnosis of bacteraemia as a result of frequent contaminants required 2 positive blood cultures</P>
<P>No definition for a diagnosis of fungaemia was provided</P>
<P>Overall mortality (no definition was provided)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-04 11:19:30 +0200" MODIFIED_BY="[Empty name]">
<P>Median number of days on study: 24 days (range 10 to 47 days) in cooked-diet group and 24 days (range 6 to 42 days) in raw-diet group. Participants remained in study until they were discharged from the high-efficiency particulate air-filtered room to the outpatient setting, usually after return of neutrophil count to &gt; 500/&#956;L, or after 6 weeks for those in whom neutrophil recovery was delayed</P>
<P>All participants remained on the correct diet while in the study, although some did not eat a fresh fruit or vegetable each day as suggested</P>
<P>206 patients were eligible for this study, but 53 refused randomisation; they all chose the cooked fruits and vegetables diet</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-04 11:21:01 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Moody-2006">
<CHAR_METHODS MODIFIED="2016-04-04 11:20:25 +0200" MODIFIED_BY="[Empty name]">
<P>Random numbering was used to assign participants to treatment groups; participants were randomised in blocks of 10, stratified by disease (i.e. leukaemia, brain tumour or sarcoma)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-04 11:20:33 +0200" MODIFIED_BY="[Empty name]">
<P>19 children (18 years of age or younger, median age in the neutropenic diet group 4.4 years, median age in the FDA food safety group 4.1 years; 8 boys and 11 girls) with a medulloblastoma (2 in each group), acute lymphocytic leukaemia (5 in each group), osteosarcoma (2 in each group) or Ewing's sarcoma (1 patient in the FDA food safety group). Participants received active treatment with myelosuppressive chemotherapy. Exclusion criteria included co-morbid immunosuppressive disease, myeloablative chemotherapy in preparation for bone marrow transplant, documented fever or infection at time of enrolment, inability to tolerate oral feeding and concurrent radiation to the central nervous system or gastrointestinal tract</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-04 11:20:40 +0200" MODIFIED_BY="[Empty name]">
<P>Both FDA-approved food safety guidelines (<LINK REF="REF-Food-Safety-2005" TYPE="REFERENCE">Food Safety 2005</LINK>) and neutropenic diet guidelines (i.e. not eating raw fruits (except fruits that could be peeled by hand, such as oranges and bananas), raw vegetables, aged cheeses, cold meat cuts, fast food and take-out food; all produce cooked to well done, eggs must be hard-boiled) (n = 9) vs FDA-approved food safety guidelines only (n = 10)</P>
<P>Participants were instructed to start to follow their diet on the first day of the chemotherapy cycle and to continue the diet until completion of the study period</P>
<P>Protective environment was not reported</P>
<P>Antimicrobial prophylaxis was not reported</P>
<P>All patients had central lines (a Broviac/Hickman or a Port-a-Cath); CVC care was not reported</P>
<P>Oral care was not reported</P>
<P>Hygiene practices (including hand washing) were included in the FDA food safety guidelines, so all participants received them</P>
<P>Use of colony-stimulating factors: 4 participants in the neutropenic diet group and 5 in the FDA food safety group received post-chemotherapy filgrastim</P>
<P>If fever was detected, the participant was admitted to the hospital and was started on broad-spectrum antibiotics as per the standard of care; no further information was provided</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-04 11:20:51 +0200" MODIFIED_BY="[Empty name]">
<P>Infections, including:</P>
<UL>
<LI>neutropenic infections operationalised to include febrile neutropenia defined as an oral temperature &#8805; 38°C as measured by parent or documented by clinic/hospital staff and an ANC &lt; 500 × 10<SUP>9</SUP>/L or admission to hospital and treatment with broad-spectrum antibiotics for presumed infection and an ANC &lt; 500 × 10<SUP>9</SUP>/L; and</LI>
</UL>
<UL>
<LI>documented infections such as positive blood, urine, stool or sputum cultures or positive radiographic evidence of infection including abscess, pneumonia or typhlitis.</LI>
</UL>
<P>Time to first fever (defined as time from onset of neutropenia to fever)</P>
<P>Acceptability of diet (assessed by interviewing participants and their parents qualitatively using 7 questions)</P>
<P>Quality of life (assessed using the Peds QL Pediatric Quality of Life Inventory Core Module and Cancer Module by self reports or parent proxy reports, or both; <LINK REF="REF-Varni-2002" TYPE="REFERENCE">Varni 2002</LINK>)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-04 11:21:01 +0200" MODIFIED_BY="[Empty name]">
<P>Length of follow-up: not reported (median number of chemotherapy cycles in the neutropenic diet group 5 and in the FDA food safety group 4; no significant differences). Participants were followed until neutrophil recovery (defined as ANC &gt; 500 × 10<SUP>9</SUP>/L on 2 consecutive complete blood counts)</P>
<P>All participants received their assigned diet and planned chemotherapy. Diet adherence rate was 94.1% in the intervention group and 99.99% in the control group</P>
<P>21 patients were eligible for this study, but 2 were not included: 1 refused to participate because of depression and 1 suffered from a new-onset psychosis and therefore was not approached</P>
<P>At baseline statistically significant differences between treatment groups were noted in history of febrile neutropenia (all participants in the neutropenic diet group vs 5 out of 10 in the FDA food safety group) and in quality of life (core module lower in the neutropenic diet group; no significant differences in the cancer module; study authors stated that this was most likely secondary to the small sample size)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-04 14:46:24 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-Tiel-2007">
<CHAR_METHODS MODIFIED="2016-04-04 14:46:24 +0200" MODIFIED_BY="[Empty name]">
<P>Randomisation performed by using a predetermined randomisation schedule produced by a computerised randomisation programme</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-04 14:46:22 +0200" MODIFIED_BY="[Empty name]">
<P>20 cytopenic patients (mean age in the LBD group 51.8 years (range 40 to 69 years), mean age in the normal hospital-diet group 53.3 years (range 30 to 68 years)); 5 women and 15 men with acute lymphoblastic leukaemia (4 in the LBD group and 1 in the normal hospital-diet group; see notes) or acute myelogenous leukaemia (6 in the LBD group and 9 in the normal hospital-diet group; see notes). Participants were treated with remission induction chemotherapy; no further information was provided (see notes)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-04 12:48:27 +0200" MODIFIED_BY="[Empty name]">
<P>LBD (i.e. omits raw vegetables, salads, soft cheeses, raw meat products, most fresh fruits, tap water and spices added after cooking; bread, cheese and ham were individually packed; yogurt desserts, soda drinks and soups were served in single-serving containers) (n = 10) vs normal hospital diet (no further information was provided) (n = 10)</P>
<P>Participants started their assigned treatment as soon as possible after inclusion</P>
<P>Protective environment was not reported</P>
<P>All participants received antimicrobial prophylaxis including ciprofloxacin (500 mg every 12 hours, orally) and fluconazole (50 mg every 24 hours, orally). This was adjusted or switched to alternative drugs according to the results of surveillance cultures; no further information was provided. It was started before initiation of chemotherapy and discontinued when leucocyte counts had recovered to &#8805; 1000/mm<SUP>3</SUP>
</P>
<P>It was unclear whether participants had central lines; CVC care was not reported</P>
<P>Oral care, hygiene practices (including hand washing) and use of colony-stimulating factors were not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-04 12:48:33 +0200" MODIFIED_BY="[Empty name]">
<P>Infection (defined as temperature &#8805; 38.5°C or &lt; 36°C with a single measurement for which empirical antibiotics were administered)</P>
<P>Duration of empirical antibiotics or antimycotics (no definition provided)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-04 12:48:16 +0200" MODIFIED_BY="[Empty name]">
<P>Length of follow-up was not reported (total number of chemotherapy cycles in the LBD group was 20 and in the normal hospital-diet group 20; total number of days within chemotherapy cycles was 406 in the LBD group and 509 in the normal hospital-diet group, it was not stated whether this was a significant difference; median number of days per chemotherapy cycle in the LBD group was 18 (range 4 to 34 days per chemotherapy cycle) and in the normal hospital-diet group 24 (range 1 to 39 days per chemotherapy cycle), this was not a significant difference)</P>
<P>All participants received their assigned diet</P>
<P>Number of eligible patients not randomised was not reported</P>
<P>It was not stated whether the difference in diagnoses (i.e. acute lymphoblastic leukaemia or acute myelogenous leukaemia) between treatment groups were significant. Also, the exact treatment received by participants with each diagnosis was not reported, thus making it impossible to know whether participants in 1 of the treatment groups received treatment more likely to cause neutropenia</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ANC: absolute neutrophil count; CVC: central venous catheter; FDA: Food and Drug Administration; LBD: low bacterial diet; n: number.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2016-04-04 12:47:36 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2016-04-04 12:47:36 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brown-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-04-04 12:47:36 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT; questionnaire paediatric oncologists</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-04-04 12:47:32 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carr-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-04-04 12:47:32 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT; questionnaire dieticians</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-13 11:09:13 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-DeMille-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-13 11:09:13 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT; no control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-04-04 12:47:28 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fopp-1975">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-04-04 12:47:28 +0200" MODIFIED_BY="[Empty name]">
<P>No randomisation of LBD vs a control diet</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-01-28 12:05:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Foster-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-01-28 12:05:29 +0100" MODIFIED_BY="[Empty name]">
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-01-28 12:05:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fox-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-01-28 12:05:33 +0100" MODIFIED_BY="[Empty name]">
<P>No RCT; review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-01-28 12:05:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lund-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-01-28 12:05:36 +0100" MODIFIED_BY="[Empty name]">
<P>No RCT; manufacturing of LBD products</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-01-28 12:05:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Trifilio-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-01-28 12:05:40 +0100" MODIFIED_BY="[Empty name]">
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-13 11:09:16 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Veber-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-13 11:09:16 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT; infection not evaluated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-13 11:09:18 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wilson-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-13 11:09:18 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT; review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-04-04 12:47:16 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ziegler-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-04-04 12:47:16 +0200" MODIFIED_BY="[Empty name]">
<P>No evaluation of an LBD vs control treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>LBD: low bacterial diet; RCT: randomised controlled trial.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2016-04-04 12:47:10 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2016-04-04 12:47:10 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-_x0027_t-Veer-1987">
<CHAR_METHODS MODIFIED="2012-06-13 12:30:00 +0200" MODIFIED_BY="[Empty name]">
<P>RCT, but method of randomisation not clear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-13 12:42:29 +0200" MODIFIED_BY="[Empty name]">
<P>42 granulocytopenic children (age (see notes) and sex not reported) with aplastic anaemia, acute lymphocytic leukaemia, acute non-lymphocytic leukaemia or granulocytopenia of unknown origin. Anticancer treatment not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-04 12:47:10 +0200" MODIFIED_BY="[Empty name]">
<P>Cooked-food diet vs standard hospital food (numbers per group not reported). All participants received partial protective isolation and selective gastrointestinal decontamination</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-04 12:47:06 +0200" MODIFIED_BY="[Empty name]">
<P>42 children had 55 episodes (29 episodes in cooked-food group and 26 episodes in standard hospital-food group) of &#8805; 10 days with granulocyte counts &lt; 500/&#956;L</P>
<P>Cooked-food diet (637 study days):</P>
<UL>
<LI>3 septicaemias, 2 major infections, 2 minor infections and 5 episodes of fever of unknown origin; no deaths from infection;</LI>
<LI>number of infections per 1000 days at risk (i.e. granulocytes &lt; 500/&#956;L): 11.0 days; and</LI>
<LI>number of febrile episodes per 1000 days at risk (i.e. granulocytes &lt; 500/&#956;L): 7.8 days.</LI>
</UL>
<P>Standard hospital-food diet (925 study days):</P>
<UL>
<LI>9 septicaemias, 5 minor infections and 13 episodes of fever of unknown origin; no deaths from infections;</LI>
<LI>number of infections per 1000 days at risk (i.e. granulocytes &lt; 500/&#956;L): 15.1 days;</LI>
<LI>number of febrile episodes per 1000 days at risk (i.e. granulocytes &lt; 500/&#956;L): 14.1 days;</LI>
<LI>number of infections per 1000 days at risk and number of febrile episodes per 1000 days at risk: no significant differences between treatment groups; and</LI>
<LI>for all other outcomes, no level of significance for the difference was mentioned.</LI>
</UL>
<P>No definitions of the outcomes mentioned were provided</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-04 12:47:00 +0200" MODIFIED_BY="[Empty name]">
<P>This study has not been published in full text (checked 4 May 2015); the information provided here is based on a conference abstract in the 1997 edition of the Annual Meeting of the American Society of Hematology and on additional information provided by study authors (i.e. from the abstract, it was not clear whether participants were children; however, study authors were able to confirm that participants were indeed children; exact age range was not provided). From currently available data, it is unclear whether this study fulfils all inclusion criteria for this review</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES>
<P>RCT: randomised controlled trial.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2016-04-04 12:46:54 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2016-04-04 12:46:54 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00726934">
<CHAR_STUDY_NAME MODIFIED="2016-04-04 12:46:54 +0200" MODIFIED_BY="[Empty name]">
<P>Effectiveness of the neutropenic diet in paediatric oncology patients</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-06-13 11:21:21 +0200" MODIFIED_BY="[Empty name]">
<P>Method of randomisation not clear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-04 12:46:54 +0200" MODIFIED_BY="[Empty name]">
<P>Patients (1 to 30 years of age) with different paediatric malignancies receiving a cycle of chemotherapy that predictably renders neutropenia at least 70% of the time or has a risk of febrile neutropenia of at least 20%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-04 12:46:54 +0200" MODIFIED_BY="[Empty name]">
<P>Low bacterial/neutropenic diet (e.g. excluding raw food and vegetables) vs FDA-approved food safety guidelines</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-17 19:43:03 +0200" MODIFIED_BY="[Empty name]">
<P>Neutropenic infection, documented infection and quality of life</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-05-17 19:40:38 +0200" MODIFIED_BY="[Empty name]">
<P>September 2007</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2016-04-04 12:46:54 +0200" MODIFIED_BY="[Empty name]">
<P>Principal investigator: Karen Moody</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2016-04-04 12:46:54 +0200" MODIFIED_BY="[Empty name]">
<P>No full-text publication was available as of 4 May 2015</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2016-04-04 12:46:48 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00947648">
<CHAR_STUDY_NAME MODIFIED="2012-05-17 19:21:44 +0200" MODIFIED_BY="[Empty name]">
<P>Are neutropenic diets beneficial to improve outcome?</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-06-13 11:22:21 +0200" MODIFIED_BY="[Empty name]">
<P>Method of randomisation not clear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-04 12:46:48 +0200" MODIFIED_BY="[Empty name]">
<P>Patients (18 years of age or older) with acute myelogenous leukaemia, acute lymphocytic leukaemia or myelodysplastic syndrome who will be receiving myelosuppressive chemotherapy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-04 12:46:48 +0200" MODIFIED_BY="[Empty name]">
<P>Raw diet (i.e. cooked food and raw fruits and vegetables) vs cooked diet (i.e. standard neutropenic diet with only cooked food)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-17 19:28:24 +0200" MODIFIED_BY="[Empty name]">
<P>Infection rate, incidence of fever requiring intravenous antibiotics and death rate</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-05-17 19:30:00 +0200" MODIFIED_BY="[Empty name]">
<P>July 2009</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2016-04-04 12:46:48 +0200" MODIFIED_BY="[Empty name]">
<P>Principal investigator: Alison Gardner</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2016-04-04 12:46:48 +0200" MODIFIED_BY="[Empty name]">
<P>No full-text publication was available as of 4 May 2015</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES>
<P>FDA: Food and Drug Administration.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2016-04-04 14:45:26 +0200" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2016-04-04 14:45:08 +0200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-04 11:19:39 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gardner-2008">
<DESCRIPTION>
<P>It was stated that participants were randomly assigned to different treatment groups by the Leukaemia Department Data Management Office using patients' early risk of mortality scores as a stratification factor, but no further information on methods of randomisation was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-04 11:21:12 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moody-2006">
<DESCRIPTION>
<P>Random numbering was used to assign participants to treatment groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-04 14:45:08 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Tiel-2007">
<DESCRIPTION>
<P>Randomisation performed by using a predetermined randomisation schedule produced by a computerised randomisation programme</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2016-04-04 14:45:10 +0200" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-04 11:19:42 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gardner-2008">
<DESCRIPTION>
<P>It was stated that participants were randomly assigned to different treatment groups by the Leukaemia Department Data Management Office using patients' early risk of mortality scores as a stratification factor, but no further information on methods of randomisation was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-04 11:21:15 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moody-2006">
<DESCRIPTION>
<P>It was stated that participants' diet allocation was concealed from the investigator until after the patient had consented to participate in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-04 14:45:10 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Tiel-2007">
<DESCRIPTION>
<P>Randomisation performed by using a predetermined randomisation schedule produced by a computerised randomisation programme</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2016-04-04 12:48:06 +0200" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Blinding of patients (performance bias)</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-04 11:19:48 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gardner-2008">
<DESCRIPTION>
<P>Compliance with the assigned diet was facilitated by placing notices of this diet on participants' charts and by using diaries in which participants recorded what they ate each day. As a result, participants were not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-04 11:21:19 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moody-2006">
<DESCRIPTION>
<P>It was stated that participants and their parents were blinded to the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-04 12:48:06 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Tiel-2007">
<DESCRIPTION>
<P>No information on blinding of participants was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2016-04-04 11:21:24 +0200" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Blinding of health care providers (performance bias)</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-04 11:19:48 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gardner-2008">
<DESCRIPTION>
<P>Compliance with the assigned diet was facilitated by placing notices of this diet on participants' charts and by using diaries in which participants recorded what they ate each day. As a result, healthcare providers were not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-04 11:21:24 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moody-2006">
<DESCRIPTION>
<P>It was stated that the medical team was blinded to the intervention (so low risk of performance bias), but that the primary investigator was not. It was not clear whether the primary investigator was involved in participant care, so we cannot know for certain that the risk of performance bias was indeed low</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-13 11:07:23 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Tiel-2007">
<DESCRIPTION>
<P>No information on blinding of healthcare providers was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-11" LEVEL="STUDY" MODIFIED="2015-11-17 12:16:24 +0100" MODIFIED_BY="[Empty name]" NO="11">
<NAME>Blinding of outcome assessors (detection bias): infections</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-13 10:53:00 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gardner-2008">
<DESCRIPTION>
<P>No information on blinding of outcome assessors was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-13 10:59:31 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Moody-2006">
<DESCRIPTION>
<P>The primary investigator assessed all infections and was not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-13 11:07:25 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Tiel-2007">
<DESCRIPTION>
<P>No information on blinding of outcome assessors was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-17" LEVEL="STUDY" MODIFIED="2016-04-04 11:19:48 +0200" MODIFIED_BY="[Empty name]" NO="17">
<NAME>Blinding of outcome assessors (detection bias): time to first febrile episode</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-04 11:19:48 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gardner-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-13 10:59:32 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moody-2006">
<DESCRIPTION>
<P>No information on blinding of outcome assessors was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-14 11:31:44 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Tiel-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-23" LEVEL="STUDY" MODIFIED="2016-04-04 11:19:48 +0200" MODIFIED_BY="[Empty name]" NO="23">
<NAME>Blinding of outcome assessors (detection bias): duration of empirical antibiotics or antimycotics</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-04 11:19:48 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gardner-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-14 11:31:35 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moody-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-13 11:07:28 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Tiel-2007">
<DESCRIPTION>
<P>No information on blinding of outcome assessors was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-12-21 15:37:00 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-19" LEVEL="STUDY" MODIFIED="2016-04-04 11:19:48 +0200" MODIFIED_BY="[Empty name]" NO="19">
<NAME>Blinding of outcome assessor (detection bias): diet acceptability</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-04 11:19:48 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gardner-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-13 10:59:36 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moody-2006">
<DESCRIPTION>
<P>No information on blinding of outcome assessors was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-14 11:31:44 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Tiel-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-20" LEVEL="STUDY" MODIFIED="2016-04-04 11:19:48 +0200" MODIFIED_BY="[Empty name]" NO="20">
<NAME>Blinding of outcome assessor (detection bias): quality of life</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-04 11:19:48 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gardner-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-13 10:59:38 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moody-2006">
<DESCRIPTION>
<P>No information on blinding of outcome assessors was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-14 11:31:45 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Tiel-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2011-12-21 15:34:00 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2011-12-21 15:34:00 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2011-12-21 15:34:00 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-12" LEVEL="STUDY" MODIFIED="2016-04-04 14:45:26 +0200" MODIFIED_BY="[Empty name]" NO="12">
<NAME>Incomplete outcome data (attrition bias): infections</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-04 11:19:55 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gardner-2008">
<DESCRIPTION>
<P>For all participants, the outcome of infections was assessed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-04 11:21:29 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moody-2006">
<DESCRIPTION>
<P>All participants were evaluated for this outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-04 14:45:26 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Tiel-2007">
<DESCRIPTION>
<P>This outcome was assessed in all available chemotherapy cycles, but it was unclear whether all participants were evaluated within these cycles</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-13" LEVEL="STUDY" MODIFIED="2016-04-04 11:20:02 +0200" MODIFIED_BY="[Empty name]" NO="13">
<NAME>Incomplete outcome data (attrition bias): overall survival</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-04 11:20:02 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gardner-2008">
<DESCRIPTION>
<P>For all participants, the outcome of overall survival was assessed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-14 11:31:36 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moody-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-14 11:31:46 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Tiel-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-14" LEVEL="STUDY" MODIFIED="2016-04-04 11:21:34 +0200" MODIFIED_BY="[Empty name]" NO="14">
<NAME>Incomplete outcome data (attrition bias): time to first febrile episode</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-04 11:19:48 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gardner-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-04 11:21:34 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moody-2006">
<DESCRIPTION>
<P>All participants were evaluated for this outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-14 11:31:47 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Tiel-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-24" LEVEL="STUDY" MODIFIED="2016-04-04 12:47:42 +0200" MODIFIED_BY="[Empty name]" NO="24">
<NAME>Incomplete outcome data (attrition bias): duration of empirical antibiotics and antimycotics</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-04 11:19:48 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gardner-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-14 11:31:36 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moody-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-04 12:47:42 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Tiel-2007">
<DESCRIPTION>
<P>Unclear whether this outcome was assessed in all participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-21" LEVEL="STUDY" MODIFIED="2016-04-04 11:21:41 +0200" MODIFIED_BY="[Empty name]" NO="21">
<NAME>Incomplete outcome data (attrition bias): diet acceptability</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-04 11:19:49 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gardner-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-04 11:21:41 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moody-2006">
<DESCRIPTION>
<P>It was not stated whether all participants were evaluated for this outcome, although it is most likely that they were (it was stated that no participants discontinued the study)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-14 11:31:48 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Tiel-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-22" LEVEL="STUDY" MODIFIED="2016-04-04 11:21:45 +0200" MODIFIED_BY="[Empty name]" NO="22">
<NAME>Incomplete outcome data (attrition bias): quality of life</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-04 11:19:49 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gardner-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-04 11:21:45 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moody-2006">
<DESCRIPTION>
<P>It was not stated whether all participants were evaluated for this outcome, although it is most likely that they were (it was stated that no participants discontinued the study)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-14 11:31:48 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Tiel-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2016-04-04 12:47:49 +0200" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-04 11:20:09 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gardner-2008">
<DESCRIPTION>
<P>No protocol was mentioned in the manuscript (and we did not search for it), but all expected outcomes are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-04 11:22:00 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moody-2006">
<DESCRIPTION>
<P>No protocol was mentioned in the manuscript (and we did not search for it), but all expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-04 12:47:49 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Tiel-2007">
<DESCRIPTION>
<P>No protocol was mentioned in the manuscript (and we did not search for it), but all expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2016-04-04 12:47:58 +0200" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-04 11:20:15 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gardner-2008">
<DESCRIPTION>
<P>Differences between treatment groups in baseline characteristics related to outcome:</P>
<UL>
<LI>Received anticancer treatment more likely to cause neutropenia: unclear (no large difference in types of malignancies, but stage of disease and exact treatment including doses not reported)</LI>
</UL>
<UL>
<LI>Co-interventions (protective environment, antimicrobial prophylaxis, CVC care, oral care, hygiene practices, colony-stimulating factors): no large differences for protective environment, antimicrobial prophylaxis and colony-stimulating factor use; not reported for the other items (maybe not used at all)</LI>
</UL>
<UL>
<LI>Other (as reported in original study): not reported</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-04 11:21:55 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Moody-2006">
<DESCRIPTION>
<P>Differences between treatment groups in baseline characteristics related to outcome:</P>
<UL>
<LI>Received anticancer treatment more likely to cause neutropenia: unclear (no large differences in types of malignancies, but stage of disease and exact treatment including doses not reported)</LI>
</UL>
<UL>
<LI>Co-interventions (protective environment, antimicrobial prophylaxis, CVC care, oral care, hygiene practices, colony-stimulating factors): no large differences in hygiene practices and use of colony-stimulating factors; not reported for the other items (maybe not used at all)</LI>
</UL>
<UL>
<LI>Other (as reported in original study): a statistically significant difference in quality of life (lower in neutropenic diet group) and history of febrile neutropenia (greater in neutropenic diet group)</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-04 12:47:58 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Tiel-2007">
<DESCRIPTION>
<P>Differences between treatment groups in baseline characteristics related to outcome:</P>
<UL>
<LI>Received anticancer treatment more likely to cause neutropenia: unclear (differences in types of malignancies were noted, but it was not reported whether this was statistically significant; stage of disease and exact treatment including doses were not reported)</LI>
</UL>
<UL>
<LI>Co-interventions (protective environment, antimicrobial prophylaxis, CVC care, oral care, hygiene practices, colony-stimulating factors): no large differences in antimicrobial prophylaxis use; not reported for the other items (maybe not used at all)</LI>
</UL>
<UL>
<LI>Other (as reported in original study): not reported</LI>
</UL>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2012-02-08 15:27:46 +0100" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2016-04-04 12:46:30 +0200" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2012-02-21 14:08:01 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Cooked diet versus raw diet</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3367780788091193" CI_START="0.9843331703040943" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.147098515519568" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="57" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.12605931515411492" LOG_CI_START="-0.0068578796841858615" LOG_EFFECT_SIZE="0.059600717734964545" METHOD="MH" MODIFIED="2012-02-21 14:08:01 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.07879604848852265" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="78" TOTAL_2="75" WEIGHT="100.0" Z="1.7577147991330797">
<NAME>Infections (i.e. major infection, minor infection and fever of unknown origin)</NAME>
<GROUP_LABEL_1>Cooked diet</GROUP_LABEL_1>
<GROUP_LABEL_2>Raw diet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Cooked diet</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Raw diet</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3367780788091195" CI_START="0.9843331703040943" EFFECT_SIZE="1.147098515519568" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="57" LOG_CI_END="0.126059315154115" LOG_CI_START="-0.0068578796841858615" LOG_EFFECT_SIZE="0.059600717734964545" MODIFIED="2012-02-08 12:21:16 +0100" MODIFIED_BY="[Empty name]" ORDER="6" O_E="0.0" SE="0.07807621819874366" STUDY_ID="STD-Gardner-2008" TOTAL_1="78" TOTAL_2="75" VAR="0.0060958958482178315" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2016-04-04 12:46:30 +0200" MODIFIED_BY="[Empty name]" NO="2">
<NAME>FDA food safety guidelines and neutropenic diet guidelines versus FDA food safety guidelines only</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.186137931997251" CI_START="0.3874809966123065" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.5032645730371855" LOG_CI_START="-0.41174959191583527" LOG_EFFECT_SIZE="0.04575749056067514" METHOD="MH" MODIFIED="2012-02-08 15:23:56 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.8445902432305311" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="9" TOTAL_2="10" WEIGHT="100.0" Z="0.19602545393700946">
<NAME>Neutropenic infection</NAME>
<GROUP_LABEL_1>FDA+neutropenic guideline</GROUP_LABEL_1>
<GROUP_LABEL_2>FDA guideline only</GROUP_LABEL_2>
<GRAPH_LABEL_1>FDA+neutropenic guideline</GRAPH_LABEL_1>
<GRAPH_LABEL_2>FDA guideline only</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.1861379319972505" CI_START="0.38748099661230656" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5032645730371855" LOG_CI_START="-0.4117495919158352" LOG_EFFECT_SIZE="0.04575749056067514" MODIFIED="2012-02-08 11:39:37 +0100" MODIFIED_BY="[Empty name]" ORDER="1" O_E="0.0" SE="0.5374838498865699" STUDY_ID="STD-Moody-2006" TOTAL_1="9" TOTAL_2="10" VAR="0.28888888888888886" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.0179246499561403" CI_END="1.2494565604603394" CI_START="0.7774577719174864" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.985596120935539" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="18" I2="1.7609014534536145" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.09672116171872" LOG_CI_START="-0.10932319062429702" LOG_EFFECT_SIZE="-0.006301014452788488" METHOD="MH" MODIFIED="2012-02-08 15:23:56 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.31301208174107664" P_Q="0.3344175976392022" P_Z="0.9045823377465975" Q="0.9317159085046024" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="18" TOTAL_2="20" WEIGHT="200.0" Z="0.11987478669614053">
<NAME>Diet acceptability</NAME>
<GROUP_LABEL_1>FDA+neutropenic guideline</GROUP_LABEL_1>
<GROUP_LABEL_2>FDA guideline only</GROUP_LABEL_2>
<GRAPH_LABEL_1>FDA+neutropenic guideline</GRAPH_LABEL_1>
<GRAPH_LABEL_2>FDA guideline only</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.447482272059855" CI_START="0.8359342448305753" DF="0" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="0.16061325344007646" LOG_CI_START="-0.07782788312362628" LOG_EFFECT_SIZE="0.04139268515822508" MODIFIED="2012-02-08 14:59:21 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4961954898540255" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="10" WEIGHT="100.0" Z="0.680488050868289">
<NAME>Diet was easy to follow</NAME>
<DICH_DATA CI_END="1.4474822720598548" CI_START="0.8359342448305754" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.16061325344007638" LOG_CI_START="-0.07782788312362621" LOG_EFFECT_SIZE="0.04139268515822508" MODIFIED="2012-02-08 14:59:21 +0100" MODIFIED_BY="[Empty name]" ORDER="9" O_E="0.0" SE="0.14006150392018057" STUDY_ID="STD-Moody-2006" TOTAL_1="9" TOTAL_2="10" VAR="0.019617224880382755" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2966670704479846" CI_START="0.5759669458512209" DF="0" EFFECT_SIZE="0.8641975308641975" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="0.11282848184509744" LOG_CI_START="-0.23960243957388336" LOG_EFFECT_SIZE="-0.06338697886439294" MODIFIED="2012-02-08 14:59:32 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.4807950701660959" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="10" WEIGHT="100.0" Z="0.7050243784671548">
<NAME>Able to follow diet throughout all chemotherapy cycles</NAME>
<DICH_DATA CI_END="1.2966670704479846" CI_START="0.5759669458512209" EFFECT_SIZE="0.8641975308641975" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.11282848184509744" LOG_CI_START="-0.23960243957388336" LOG_EFFECT_SIZE="-0.06338697886439294" MODIFIED="2012-02-08 14:59:32 +0100" MODIFIED_BY="[Empty name]" ORDER="10" O_E="0.0" SE="0.20701966780270623" STUDY_ID="STD-Moody-2006" TOTAL_1="9" TOTAL_2="10" VAR="0.042857142857142844" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2016-04-04 14:45:40 +0200" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2016-04-04 14:45:40 +0200" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Flow diagram of study selection.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA0oAAAI3CAYAAAClEatGAABOQklEQVR42u3dD6RV+fo/8B9JkiSS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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2016-04-04 14:45:27 +0200" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAmMAAAJ9CAIAAAD2duLBAAArZ0lEQVR42u3dsY4dRb7H8ZGQEIED
B34CnsERGhFBxDtBOIElCP0WiEe4gksIRGSIXXuFHTgY72YL1+o7w1xxZ890n9PnnPpX17/q89UE
1uD9ube6+v+tqu6uvrgAAAD7mQAAwBxMCQAAUwIAwJQAADAlAABMCQAAUwIAwJQAADAlAABMCQAA
UzIlUPi6un+BaRCAKQHMa3LnDwCYEgBTAkwJgCkBpgRw/nVFkwBTAgDAlAAAMCVTAsWvq9k/A2BK
ADNqdIkBTAmAKQGmBHDsdXXh+gKYEgAApgQAgCmZEihzOU0Pll5dYgBTAgDAlACOnFnu/w0ApgQG
vpysvgJMCeCoOSUApgQAgCkBHHtdWXoFmBLA7EV18DcAmBJgSqYEmBIAUwJMCeD068p9SoApAQBg
SgAAmJIpgdLX1eyfATAlAE/0AEwJgCkBpgRQ4Lry7CvAlAAAMCWAUy4q7QAwJYAVl5aLC2BKAJSJ
o/rD/Y6hQZgSIEgvVmJek3oFUwKjX1TaAUzJlAAApmRKAOdcV16pxELfoEmmBMwbADAlAKYEmBIA
WSKub+gnTAkMf125T4lDQyh9gykB1RBgSqYEoPbh2JprsYEpAdeVRgCYEsCqSYNLDGBKAMDhUmsU
xZQAADAlAPMGnN1D9v8GTAkAA5daoyimBGDegKP6BpgSMG9wiQFMCcC8AacOpzQIUwIA9o2ilF+m
BMwbXGJgSqYEoPaBKZkSAFOiZM212MCUgOtKIwBMCWDVpMElBjAlAOCImjv7ZzAlAMATPUwJYOe6
svoKpmRKAHuq4V+fFtEmWBpFaRCmBJjSvAFgSgBMiWMKrnZgSgD/4UjXF+bLro7BlAAAymRKAEAB
QSrCTAkA+P+Cqx2YEgAApgSw96LSCDhQc71SyZSA60ojQMdgSgBrJw0uMTAlUwIAyJIpAQClaq71
BqYEXFdKIUwomRLA2mroEoOewJQAmBJkyZQAmBJFCq7FeaYEoBQCTAkAAFMCAMqV2snqK1MCAMCU
AIBzZ5b7fwOmBICBS63VV6YEsDNRcH3BDJIpAezTpPoIMCUApsTxNdfqK1MCTMmU2NM3wJSA6+qC
JsGUTAkAIEumBAAUL7juUzIlgPvXlOsLYEoAi5okS4ApATAljq+5Vl+ZEnBdKYXYM4r669Mi2oQp
AQCLpiRLpgQAMCVTAnhQB70JgJWy1DGYEgAApgSwPGnY8xsATAkMfDlZfQWYEsBRc0oATAkAAFMC
OPa6svSKhS6hezAlMPpFdfA30D10DKYElEKmhL7BlABUQ+gbTAng9OvKjSjoG0wJAABTAgDAlEyJ
kXt/uS8F2iEd63udvsGUQIKuv/QHILrXgSkBpgSYkikBpjx4XVleA1kyJdBD7y/tM+/MYWWXU36Z
EjBpYEqAKQEckqXrC2BKIGenD1gH870InNBJtAlTAmZ+wG43K/gWL5gSqKFJssQmptTrmBIYzpT2
6AFTMiXQY+8nM2wkS72OKQGz1WKzVQBMCXQ4STVhBZgS6EpscXNKAEwJpOz6DAeAKYFtTGn1FWBK
gCmPSAYedg+1lymBPL3ffUpsoUm9hSkBBRFgSqYEsGKq6hIDUzIl0EPZchWgZs2lSaYEjO4BMCXA
lAevK6uvAFMCTHkw2fWF2e6hbzAlkKb3R0wo42ar6EaT+gZTAqohU4IpmRLAClm6vjBTc93AZkqg
fY156xEAUwIAwJQAkKTUTlYymBLI2vsVLABMCSyN8ff/BtDrwJRQs0rWrItlNLj+pm8wJZBblq4C
bDI+A1MCxvgAmBLACg1rE8z2DQ3ClMCgF9X9P7i+8LBv7PkNmBJocXQ/2SEdTAmmBKr5jCnBlEwJ
MOUR4a4vzNRc9ymZEhjclACYEjC6B8CUAM6esJqqZh9FlTqDdkhnSgDTHjW6xJKeQSvzYEqAKcGU
YEpgw+vK8hpT6htMCQDGOic4eM9vwJRAi9VQwULl2SpTMiWQqWYVXGHzfCOOkqWOwZTAcKZEN8sM
xcc6vvLGlABTTiYKZn5gSqDzCURQnUVqTTqhYEogXMAuMaac3MNmSgDoe7ijQfQH/QDmfC4EZJ2t
gimBfHWQg2F8xpQAMJbY4uaUYErAzA9ZewjDgSmBfDMSdGBK4zOmBBJXQzMSRJ9BPYEpAbIMr7Ou
1tSrAk4fUwKJS2FcQSx+fVm1Mz4DUwIdOjjiQqNM4zMwJYBVgnQJx838VEgwJfT+TEN7V2t9TRqL
gCmhGk4RM7OgFTZP1XZgSquvTAkwZYi97IXWhyl3Ap0+pgQyyTLFmwAu1cqVMa5vWNdlSiBDp6/1
lgjAlEwJ4LCMi1RYq6+dydLpY0pg9FKIpOfOiARMCezO/KYk9ykBMCWwwcwv9MGN4lI31wGYEkhv
Sj7rab3B6QNTgik9hYjDSwL6hi7BlDBvaP0q8KRJdlNaP2dKIHcdjHOw6UgHncQZBFNi0CJYYScd
67p9LDaY/8Hph1IYtY95hf21ncoO+p42YUqg6ZllrjmlJ0266XVW5pkScF1V2k7WxRt9Bic7pIMp
gbxTYVdu3lUBpmRKALGTVHe5kppyskM6UwJJJ2dG9zDzA1MCNeZnqS8l74Du6SSuGv1BP4A5ZcnM
0Asq45stWOp4GpkpAXORWJ95JrOD8Zl2ZkogR9mKfpejfZ8xJVOCKYEe3GD3n/5WHTQIUwKsU/j6
Kj4PdvkDTAnUNmWuFTYPu+4f62gcMCWSKa34/Cz01fLipgxKtqdBhVGUL4wyJZBv5lfhmAv6LHqP
HkUge68DU0LNqrFGWv66it8hHXodmBI6aI0dOLWwVcE6Yx29jimBwD4aocmMbiCzngTsJDIlgKgZ
tgkK9gwowZQAU5Y0pe959dQa5qlMibH7aOkvfuRdfTWhzDvKqdbrKJMpMfQsqs3MaLub/+E0Qeob
TAmmPGt0n+iY0eXMr3gpdwaZEmQZOOcb9i1+l/9W077od22dWabEoGUli89CJ6xl9yO1tWnl01f8
37Imz5QAu89U1bIvmKqz1WRZc09gMCUwdPm2y1rSsc7k6WWmBCqULaac7Nzdl4PP7Nj2I2RK6KAp
n1MI3TU0XTLAlEBWU3oKMekxV3iGxbgBTAmmTJnMlP2Nzzz7ypTAiDO/6DobHcuUnlAFUwK15w0j
H3PNUVTGEQmYEhhxtprU7nnHOmX3YahwBzSiHay+MiXGrYOu/w5mfnVMOeV8Llr5ZUpgrPkZuzNl
5QklmBKwTybWyjLo7dIpz31KnZkpMWrXTLhDetJnX9WBOrPVdDvKgimRb07J7nHtk/HB11ymzNs3
FCKmBHLYvVo1zPU8cMTSa9ycsk7HU9WZEuOKR18NvRf1MDZRgw+7m5377kwJHbSHHdJTPJOZtA4k
+r73wwNWe5kSaN2U0c83JqqGSfeqjXuLP7qdk74DOqzdmRLJ5mft16zoJyftr115PSBizpqib6S2
O1MCg5oybraa7hnjqe5zpOl6XYoxJVMC45pyCnsjXs2yRtLZGglTAoUryxT2+mC6HdIL1qy8O/Cp
XTVHfoMvyzMlxr3+o485ukFcuVO23RKqXSylvqyiVZkSIQXLeqMSk32Kab+bnfUGvYspEVKhio9q
cz0rmGglM/uzrxXOXalnjCsPzkI/2MmUQLHrP+JaNe1D8Ulkhb4RNz/L+y0BpgRavz51ez2kkem7
/syUGK5slV13rfN0TIWCGHTA7a9FJ5Vl9Hs+iS5qq69MifJlpWBFiL5HUuf6D22K9t9brzxFa7k/
V24QdYkpMYQpp7pfsGp/6mM/0uz9eap4311hZ0oMVFmY0hnseOTXcrI9gZkSIT0posiGrr4GXlQx
ZSV0x6KHp7Ll5Aor8xETyrhO6EuuTInRR/cVfGbml/qYB/+6mfkfU4IpwZT1ekv0E9c0xpQYuyeN
vUVA5SdUo2ckw5rSEE0jMCXC5w2N34uq8JZY3B2jOjOSiGOOkFm114dyvSUylXs3iS+ZElGmnDw5
mX9sriy4Bif7vjIlBjdlruf1mRJbXYN6AlMi5EItu/ITsfpaefeflltjqU3KV5ngj7KlaGejVaYE
zJlQr50j3FChVyQan1VIZkoASGnKPvZQjDtm9ymBEyuLe/6VJyJZvmA8xW81kOgZFqZkSgBVy1bQ
nnNT8+/57IRHHHPqSfaUZwc+pgSQZnSvGm64NtD+GbRcxJRo+lrK6AbJ6GkUBaaEq9SIJHEytDNT
gimhb/AZmBI9FkRzHdUwuynT3U0AUyJNQSn+dsFsZSm1TU+uZKas0+umtPeDQ59eVui0AnJU2FL1
JWNyT8OpkefBeZ/JGnyBhCkBoOrML/W67pjKZMqBRsrZy1bE3cRcyd4Smb30cu2hmrQiPYwdquip
8qe32ppfoqBygtyQKDnjubPTYZflbtB5kd5wzug7y0icKZkSW82wO/ie18hVjilRtCeV/hQDUy61
c5Y3W2re80vx7dIK16DWYMpGpzvemYt2Q8RgNldyujdbqr3LETc+SzQ/y9gaTMkNWkOniq2wpWpZ
9N2EXN+nrDnhCx03uAaZkhu0BpCy1yX9rrXVV6bkhpAhc+hgfPDk+/9EUJdO8eXLyR0QrcGUWdqO
JmuOSOKeFcqYPKV6vqnCvCrjmFLpYEpgaDdInurulhDhsyyjqDpSt/oKFCtbZlGS9xTcoF43+PgM
TGkVJZMmQ2U5+G52U853ZmrOeJgSTNmiG1KsoqQ2JbDt1Z1i5JdrhwemdC2ZYetRmO8biS6TRP05
7w4PTMmUKNPCEdd/xuQKo/uMb8Snc3DN3X/UOqZsTpbaEPXHZ95syVjB09UKpmRKlO5JFmBz1izJ
1WbYFVYFJjs8MCVGGyan+3rGFP9dDm+JTHXfATXzU+KY8pQe6W3cOpWl5nvrKXalSfRmS4UrotqX
wphS2WdKtFtcmLKDMaX+vKT2LO+AmhUwJVq/lirsr50ouYOOEfrBzrgjb9/HdWTmPiVa7JeaN9GX
3EOTp5xvtkRfGok2yetGPOaUOL2vaEZg81rGlI6ZKZky0xRQJ0GFvhHU36rdpyx1qNGr3INf2opa
mWuJJncuWt2jjnXaT46+lVjHZ7q0604nKHAVeUtk6Q9IsZKR9CuSAFOCKZHelBWmlYPvY15hh3Rz
A6ZEeVmGrgqOvNv4lPDNlppP1WbZ4z7XGZzcaWJKpJtFjZmcd0aScYZtVSB7OzMlmHLcZLAOUzIl
8vekbA9PkmW0yWp+rbPluXvcMadOZkpuMPMLaeT2d7P0XLT+DKaEa0lrAGBKcIMGAQCm5IbyPcl9
nbrJKd5sAZiSGFQWX3LeLNmwD2BKMCVT5jalMyiZKYHYi0dlMa0EmDJ/27mpk+2dubzJ3mwBmDL3
FEozAsY6kpkSTLm2NYBpYbv8gtvVSs6bzJRMOeIILuij80F7gqdLzjhv2B9yzj8hOXsyU443ygi4
XZRuBOcuV/bxmTUSgCmz1sHilSudzDz72oEpQ79dKjl1MlOixTOdaLaa8YuMFb4+n9fBD/8gefBk
pux/5lfnq+jt3zGKnq365Fa1VYEKnZkbJDMlpmH7pbtc4AbJTIl6bgjtl0H3G6rtShN09yVRct4q
E9TOklMnM2XvTRZ/LyrjqDNu3DB4cuo3WwCmNKdMMwaPnq3WuU9pR2kATIlwuxc0ZYXOY/ev7HbP
+E1NyXWSmXKsaWWinXTKTij/WrvTH2oOFzK+2VK8q0jOnsyUY2ky0Ri8ZhHXSSr0ukTJnvaUzJRq
1tT+GDxjBb9v4inmib5cyXmvFG6QzJSDloBcb2rHzVbNSGqewaBmr5Bs/zbJTIlkboirs0wZnRy3
klFnnQBgSjQ6ggut4N4uZUqAKbGohynb3cRc9xu8JZI02RdGJTMlTWa1TsRsFQCYEjVMmXoEFzTD
tkcPAKZkSq1xQL2+T1lhRFIn2Sq3ZKYcte2SbA4wJX/uJs7uGZM9hSTZGglTcnC+pVcz7NTtzJSS
mZIpU1bDXP2ywsrPNPwePXZLkNxZMlOOMuGrsN9N+9/GMouqaZ1Eb4m40yyZKVFjWpniOVKmrGZK
AEzpZJitMuUGZ9C9KIApY8U2pfo+ZbrZqqfqJytsAFMmbbigeYPZKta3c/vJwCajVaZkyoFmqwA6
duSaXzIlU/Y5MCwySPSs4P5/Ykq7R0/731uVHJ28P6HBWsqU/a8bmK12k9zHU0gRjSzZyjxTmqI1
vXwfeo3Z04QpJXdsyixfN2LKZO5ptg+t+SVTDmhKepC8Sa9jyuaUFvQGYehsdfK9CMlVkkOfuJac
PZkpB9JkljG4p5AADFJFmbLzc2wEt+bYznyqNl0y0GshzfRKuhM2wvws3THH3QFNl9zHmy3WoiWn
NjpT9jwayt7jVZaliWmuN1uKh0vOnsyUMIJD4KqAOiu5D1NmeSNOLS7Qb8r2obxfcn441QZTSpa8
pmhM7lP2Oudb88sGR3ChsZ6qzbveIFly5WTPvqpZQ48NmRIAU4KDmXKbmnLCf90qGTiqdFh9RecO
niKfBI67lnIlZ3yzZYp5P1hy9uSslZNC0P6QM8s8OHr/Ju/MAUw5uhUyjuAqbM3MlNnHOsV7i+S8
yelqHVMOOTKqchOUKQc3pW9xSzanxBS9O2uFsWFoTSwbHvF/IWNyB3NKyZKZ0vXf7gjOiQbQ8nyD
KZmyCZ9l/Ey05KTJnvaUfGyvc5+SLJsbvgV9L2KK3Lmb0iyyoeMSypSdLxrEPR2TbtPXsoftG/Ed
JBs0SM5e65jSOKtpU6LLLi158OR0T9Uy5VimjJ43MCXMsCV3241dz+d3oPaTQ79x4wsJkgGmRL2Z
X/QxJ5r52dNEsuRek5mSKZmSKUdPtiuNZKZkyhp3E6fmv8tRf7cEydmT465BybmSmXKkthv4O+BL
l5M7c5KNGySfPM5mSvRpSncyUHO9QXL25P0j7AarB1OOZUq7UmHzUZRkyfvrBlP2c+XX2RkuxYex
Qo95Cri3KrlyMsCUMLpPOcOWnH0lQ3J/yc1WKqYsPBoiS6aUvCc5xU4akusk5ypETHnu8CrX/fOk
3+VhHcmS+1tvYMrh5pSOObSPRvxfkFwhmRsk1xy7MyXaNaVehJWl1vNNkjOO3ZmyxdFQxq8i7xw2
ADClc1zp/vmU4avIoVNMY/CkyftDzvknJGdPTidLpmzRZ0HJ1SbZg7ez5P1jpoKPv0nOmzyl+vIl
U45YDRufRLJOZ+Mzu+BK7qDgM2WB4pKoxxuRSO5pJQNgSgSc7FQ78E3euMifDMyOzKy+DjShxGSH
dADmlKgsy3R7VTMlgI7rBlOe13Cp9m+bEn6tdwp+u1RyhWRgTf20+oomTFnHZ3EvUwa1huTJt0Qk
b5Fs5wEMZ8q8rSF58i0RyZsmM+UQCwhTtr2qi/fUOrdsWUey5P7WG5jSzK9duyd6U9Ob2qmTuUHy
yi7nPiVTFpBN3P6NQ/V4bHux2F9XctI+rKg1NM4K2mXRA40AwJTbtV2SdbBcz2Qbg3eTXPPuuORc
yVOeHWWZcsR5cKJxg/s6eZPj3pmTnD25goOZEs2ZssJ4ls8mX7CR3HsyU/YpnrwrmUwpuU4ywJTO
cW61B92O8vUMyXXGlJI7S269eDKfFYniDta1MNmVRnIv3Vg5a0WWfIPuTTlZ5ZbMlMM1XLZdgzN+
L8IbF6mTuUHy+kLKlOh5dG9GItm4QfL5swJP9OCsCStTss5khQ2djt2ZcgifTUk212dKyUyJZmVp
9bXnE5zoTe2pyg58k/ciJC8sjdjvRnLNfKbs2ZQZh/NmJNhk3iA5e3KiPsyUzc0p070lwpRYP+yz
27hkphyv7VK98phuH/PJnibJk7lB8ppeN7lPie5H99UcLDld8pTt+3SS+xhhM+VAs9Up+PanZ18l
p6tZ6G/szpT9y6z4aKvas0KDv9kimSnBlExZ7zRPpb9/G1cNKwg+9HKyW0rGZGBlUWr9OJ2w88VQ
arE06f4AdnUH0LnRNUQ7powYZ+0P0QEAtFBFmXKUdYPG19nX/BIIulKmsKdqJedNZkrksHtEsk6F
nVLo+SbJB4uGJ3rQs3V8FR3cILn/mux6brCyqIY744bJalXCZG6QfGyVs0M6mFLycPMGu9JIXspc
80umRJ+yNCORDGxrd6Zs7hxPwftkjnyCWIcpAaZUwatOKDPuw2K1qrNk32yRzJRM2a4pM+4oi26u
FMmSmZIpE2w4XtPuOhW4QTJTYqq20JHoLlfE1WW1qoNkepDMlEh2viN6vyIr2bhB8vmzAm+JAKwj
WbLk+fCWn7tmysLnOGKENfjdRMUldbKmkHxsRWLKnuc6CV6bzfkVSatVHSTTg2SmZMoc87PUW/9I
zptc8y6X5ETJU55vFzJl4XPc+OieKSV3M4oCmNJsdcq1T561O8kAU2IbU06pdv+JnrhbB+tmhU2y
5CnP+hlTNneOmRJdjvyK9xbJ/SWbU/Z//QdNK4uP4MgSTCmZKZkyvSmrTYKLfLs8+v0Tq1Wpk7lB
cgeFlCnNosxIJFfdudeIRHLc2J0p+5+fPQyf0m6jwzqSgd4KvoZo0DpB3/Mq6+C8O/BJZkqAKZly
g+QK03fJGZODuorkpMl/Ddatvg4zyii9RprRlIAZtmRzSlS1TvRTiAWPOfXe62BKyRzMlFlNWWEe
nOi8W63qINlatOTUI2ymHMuUZiSSs4/u0fHV3focwzlrbQSXrjN59lWyZMlMicSzqOgnzWp+/0Sy
FTbJ2ZOzzgT4qW9TVjtma9Go1nsld5DsPmX/13+6nU4rrKJUeFNTcq5koJ+CryH6XkOouYpi7U5y
nTGl5OzJTEmWjjDByo/k+n1D40jeo2GmZMqzBnGaF64UyZ0l23lgmMl4tofB0n3/xGpV9mRukMyU
SNm/E+1Vq6xkT6724JvkjMlMieYqYB97r0vOngwsabj143TCzh9nhT6LyJSsw5QAU+ae+aXbbTzL
3jFWq7InT3YsksyUNGkMDmxypUjOnjxZfXX9G8EB3CC5j/mGWtycz5I6ON3efpKz92fJkpnSGDx3
j9cako0bJB/V8ay+gilZx+ge2Cfglm85MWWB0zyl+iJjUCmsttUAnzElwJTJZn6JvsgYMYKr85US
q1WpkwGmZErfLgaAs8Znk/uUTHlyOAEDUEWZsofR0LC7BgPbzhskp05mSrRlSvuOSq6fHF0NJUtm
SmPwkrPVuNsAkiWr4JLbqXVM2e7kL0Ubxj2hKlkyN0geYvZCeyP0HmuDkusnT96ZkbxRrys4k2FK
4ywA6Gr4Xrw+M+VYpjSelbz5vMFeSJJnu1zLa/5MeW7b5dKkq1RyteS4/ZskZ09ON5NhygQzPxVc
ck/JcSM/ybmSE81kmDLBzM+cUnLeZKCf2YuGGMGUk/tnkjdNnux3I5kpMfhyB7CnM3uDUPIGbis0
+GPKBCfYCQJTSu7SlHV2lHWfsp8xC8CUkiW3mazEn3smABw1ppQsmSmZsukeDwDdrzdMdrPrXpaV
d8SwLbjkKXiTdCD7rMD1ULK4NG7Knaiy4zjJklfa1343krNWe9prZEI5bfF2ecSXoiVLBtboJ6J+
Frc7UzZnyqn6XtXcIJkpsfF0re2expSNyrKmgyNudEmWHD3yk9xBcvQUkynbUo5mBI6arUqWHDqn
DLll63pup6ZwMJhS8iDJWd4gUIhHnwpLllwhOW46Ijl1cpbxGVO2MrvfZGwYd8ySJS8J2HsXkius
n5W1O1M25LPot5dUcMn1k4ENJzDeEunQlBVqliIumSzRfRWNErBz1vE53j/akix5il8Hkyy5wsyP
KROIJ1RpWhvdjCklS063jKEQt1tZbJICppTMZ0yJw6acyu1VFvRcnGTJ9CD5/OSWuxxTntpk8U+o
RnyzDWjhkpEsear43SSmbGLyN4W95+vsoKfLRLLkOqb0lki713+Cz5B6k1rydmsk3CD5YPdrvYQy
X9+mrDkPliyZHiT3V/CZsrnRULW73PZ9llwh2dulkjesz5Pd7MxWJUseeY0E3cw3gmYFpZ6LZMqB
TDn5iqzkLZKBOj5jyqZHQ9HPZGtq9HSlSJbMlOPO/ADUXCOR3E1yxLvjIY+Iu54HMaW3niVXTuYG
yZvMg0MqJ/M1JUubiknuOJl1JGedY9De+QPwjD1eBZdcofa5Mye5hRLNlJ1PVU0rJWeXJXBwptHy
zlBMOZApvfUsuX4y0EIVZcpOZvfZ1zqANWXL3n6SM8pSLT73NPjeMrDVGonk1MlTwB49Qeu6TFnG
lFPz3xKZfGFYct1kbpDcTRVlyobOcfRdbmDLKuNpT8m1TFnc7gpxmdOsDQGg1/kGU444qPftYslW
MtDxeoNnX/kMSN+xJUtO2YddzKf1m9BRDNDHxSJZcvapKlOe1W/uPzcYesrL2j3opXXJkrlB8gmV
rf3HrZnyXFOGdqOIrlP2JWLJkulBcpv9ueD/BaYsdo4jRve5+qVkyXu6tL39JDMlU5YfuDGl5D7m
lABTOsfmlJIlA630OvcpWznHFd7lqLB+4g1CyZIlb1XrdqIa/8gEU+YQs3YAgI0nSBoCAACmBACA
KQEAYEoAAJgSAACmbLxRAAAjwZTHmVKyZMmSJUtmSr1HsmTJkiUzpXMsWbJkyZKZ0jmWLFmyZMlM
yZSSJUuWLJkpmVKyZMmSJTNlH6Z89+767dur168vX758/Pe/X7x48ejVq6fX11+8e/em2eQ/rq9f
XF39dHn5348f/9fFxXePHv3w9Onfvvji9zftJse1huu/TvL1H9dXL64uf7p8/N+PL/7r4tF3j57+
8PSLv33x5vc3zSY7g9n7RkTdYMqjz8S//vX85csnNyfg4c/NifnnP79qMPm358+/f/LkRmMPf270
9o+vWkyOaw01q07y89+eP/n+ycVc57gpjl/946sGk53B7H0jqG4w5XHtdTMwmT0H939u/k5TyTfT
u1mT3f+5+TtNJce1hppVJ/lmcnBxqHPc/J2mkp3B7H0jrm4w5RHtdTNaOXga7n6WRi71k2/mfAdl
dvezNP+rnxzXGmpWneSbGcPFus6xNHuon+wMZu8boXXjCFOe//3oiE9aF/zl/uN89+76/qT+228v
Pv744oMPbn8+++zixx93p/n/8z+vN0/+4/p6aWl0drH036+3T45rDTWrTvL1H9dLC2uzS22v//16
82RnMHvfiK4ba+V3/++c3LilzsrswZz5y4PH+fbt1f22/vDD23b75puLr7++/cNHH62a41dOfnF1
tVJme1ZKKyfHtYaaVSf56sXVxTGdY3adrXKyM5i9b0TXjVWmfPgXdmSzE3L35/tmevib+79fH7Xn
2KJN+fr15exE/pdfbg/4/fd3f//q1dPNk3+6vDzKZz883T45rjXUrDrJlz9dzvSAO+Y6x9Mfnm6e
7Axm7xvRdeNEUx6c3j3U0s4vZ//C/qhtTXn3wPHOz88/X3zyye0Rfvnl7n968eLR5sl3r22s//nu
0fbJca2hZtVJvnvof301fPTdo82TncHsfSO6bhxtyj13+A6q6EyrrV8TXnMkx96nnB2wfPrpbcjn
n8/fN948+WHfe/Kfn5h5+Bc2T45rDTWrTvJ8HdzbOTZPdgaz943oulFy9fV8U+6PKmXKgnPK9967
PdRff505DWfOKYskdzOnLNIaapY5pTM41JyyYN0415THzuSOnT6uXPidtrtPufRz/n3K85N7uk95
fmuoWXWS3aeUPDVzn7JU3Tj32df9tx6P/QvrV18PTnOLm3Ln2aq7nzvWv99aObmDZ18LtoaaVSfZ
s6+Sp62ffS1eNwq8T7n0aOvKv7DmMdqlI3n4l6u9T7n/TJzzPmXB5A7epyzYGmpWnWTvU0qetn6f
snjdsEfPEb3HHj11ku3Rkz3ZHj2Sx92jhykn+77WSrbva/Zk+75Krn8G7fvaiimn/9ur/vHyXvXP
Gky+mf8tPa168/uXz1pMjmsNNatO8s3sYf5Zxz8X1p69fNZgsjOYvW8E1Q2mPKX3LH3/bHbtu5Hk
pa9Izt5BbCQ5rjXUrDrJS98gnL3/1EiyM5i9b0TUDabU4yVLlixZMlPqPZIlS5YsmSmdY8mSJUuW
zJRMKVmyZMmSmZIpJUuWLFkyUzKlZMmSJUtmytymBACMBlMaZ0mWLFmyZHNK51iyZMmSJTMlU0qW
LFmyZKZkSsmSJUuWzJRMKVmyZMmSmZIpJUuWLFkyU45oyqVd8N/8/mbA5KWd+9+9Ozd56Sslv79p
95jjel3cMcclx/W6jFe3vlGnnSPqBlMefSae//b8yfdPlr6stvSd7l6T//wa3JPlr8Gdnvzb8+ff
P3my9OXLf3zV4jHH9bq4Y45Ljut1Ga9ufaNOOwfVDaY8rr0yfsk94xfGbwaAhw754ubvNHXMcb0u
7pjjkuN6XcarW9+o085xdYMpj2ivm3HQwRN897M0Juop+Wa8efBCuvtZGnsuJd+MCtcd8sXSCLH+
Mcf1urhjjkuO63UZr259o047x9WNMqZ8+D8vHrh43P/5N8/85f4DuP7jemm5YHYBYfbL3d0kv3t3
fX9Z5ttvLz7++OKDD25/Pvvs4scfdxdqZr82Ppv8x/X10uLJ7HLKv19vf8xx1TDumOOS43pdXDtn
PGZ9o07dKGnK+wkR6t3zF/7685m/PHgAVy+uVp7gPasH3SS/fXt1/2r58MPbk/7NNxdff337h48+
WrVKM5v84urqmEOeX0upfMxx1TDumOOS43pdXDtnPGZ9o07dqGTKY+d5fx3uQZ8VMeX6fnn50+VM
e98xdyqe/vC04+TXry9nl2J++eU2+/33d3//6tXa5J8uL4/q8T883f6Y46ph3DHHJcf1urh2znjM
+kadulF49XVWcifYa8eXcaY8dvX17lHm9ef40XePOk6+e2R85+fnny8++eQ2+8svd//Tixdrk+8e
7F7/892j7Y85rhrGHXNcclyvi2vnjMesb9SpG42aclZpRy3DrondP7+c/+Xs2b3Pg7PRcfLskPPT
T28jP/98/s7/yuSHffrJgUPe/pjjqmHcMcclx/W6uHbOeMz6Rp26MbQpT7hPaU55cNT53nu3wb/+
OnMhNTunLHLMlecNRY45LtmcUt8wp2zIlA9vc4aa0n3KNXcyln5avk95/jHXvxd1/jHHJbtPqW+4
T7nqTmGR+5T7D33/qymefY1O3nk67u7njvVvKG/77GvBY46rhnHHHJfs2Vd9Y/Ls61GmnM549nW/
ye5z8r/lfcpS71Puv5bafJ+y4DHHVcO4Y45L9j6lvjF5n7IymxybPXrWJNujp06vsw9L9qtb36jT
zq3v0dOZJif7vq5Otu9rnV5nb8/sV7e+Uaed7fvakKFvxkTzT3D9uVzw7OWzoZL//NrA4+WvDZye
fDNCXHqe7eb3L5+1eMxxvS7umOOS43pdxqtb36jTzkF1gylP6fFLX1abXVXvPnnpC3azdy+OSl76
ztzsPYZGjjmu18Udc1xyXK/LeHXrG3XaOaJuMGVbPV6yZMmSJbeWzJR6j2TJkiVLZkq9R7JkyZIl
M6VzLFmyZMmSmZIpJUuWLFkyUzKlZMmSJUtmyvZNCQAYDaY0zpIsWbJkyeaUzrFkyZIlS2ZKppQs
WbJkyUzJlJIlS5YsmSmZUrJkyZIlMyVTSpYsWbJkphzRlEu74L/5/U2zyUvfBHj3bsTkuL6R8Zi1
htboqYpGtDNTHn0mnv/2/Mn3T5a+rLb0ne5tk//8ztyT5e/MjZUc1zcyHrPW0Bo9VdGgdmbK49or
7mvdcckZv4oelxzXNzIes9bQGj1V0bh2Zsoj2utmHHTwBN/9LI2J6iffjLAOdp27n6XRVk/JcX0j
4zFrDa1RPzljrVtryod/4bT2Xdo9aH/a7H+d3Xxo5S8Pbl80+8vrP66XlgtmFxBmv9xdOfndu+v7
CxHffnvx8ccXH3xw+/PZZxc//ri7NDH7HfNukuOu/4zHrDW0Rv3kjLVuA1Oe9j/f/6//9ef1v1yj
4Ye/vHpxtfIE71k9qJz89u3V/f7x4Ye35/qbby6+/vr2Dx99tGpdopvkuOs/4zFrDa1RPzljrTtu
9XVJObMztr9+v7IR1wQejDrBlEvJs7+//Oly5lzeMXeOn/7wdPPk168vZxcffvnlNvv993d//+pV
z8lx13/GY9YaWqN+csZaV8CUS7+c/QtrTHnwXyloyvUiv+PuUeb15/jRd482T757SHrn5+efLz75
5Db7yy93/9OLFz0nx13/GY9Za2iN+skZa12ZOeUJC54FTblnplvclPNn9z4PTvPmybODrE8/vY38
/PP5e90dJ8dd/xmPWWtojfrJGWvdcaa8v6w6879fmEeeYMr9gRuasps55Xvv3Qb/+utM1zlz5td4
cuV5Q+PHrDW0RvdzyoLtfJYpT3uIZuWc8uSQNQdzwtO2Pd2nXPo5/25iy8n170W1fMxaQ2tMA9yn
LNXOx71PuX8uWHP19ZwHYk8zZQfPvt793LH+ndxukuOu/4zHrDW0xtTvs6/F2/ksU953ZBFTTuue
fV16IfKolyyPPccdvE+5v/ec89ZjiuS46z/jMWsNrTH1+z5l8Xa2R88RvccePdmT4/qGfVi0htbo
tdYx5dG9x76v2ZPj+oa9PbWG1ui11jHl0b3nZkw0/wTXn8sFz14+azD5z/31Hy/vrz9WclzfyHjM
WkNr9FRFg9qZKU/pPUtfVptdVW8keembbbPr9d0nx/WNjMesNbRGT1U0op2ZcpR+KVmyZMmSmdI5
lixZsmTJTMmUkiVLliyZKZlSsmTJkiUzJVNKlixZsmSmZErJkiVLlsyUvZoSADAaTAkAwBnTJw0B
AABTAgDAlAAAMCUAAEwJAABTAgDAlAAA9GBKAACwxP8C6hwDzXZhCKIAAAAASUVORK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2016-04-04 14:45:27 +0200" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-001.01" SETTINGS="SHOW_ROB_TABLE:NO;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Cooked diet vs raw diet, outcome: 1.1 Infections (i.e. major infection, minor infection and fever of unknown origin).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvAAAACQCAMAAABZE687AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///9BjlLGAAAbcElEQVR42u1dfXAbx3V/JIg7HACBPAi0PizJpKg4HbdVaooSCX7E
Y0iO46gd90NJM2ntyvnDcaeZOJ2oaeImozjO1FESt24mX3KSOk6qtFEUj/yhJG1F1jYJykRkJuMk
TeWQAi1Zom2Sd/wCQPAIort7d8AdcAABAiRh8f1sEXu3b9/t2/vtu3eLh7sqERCI9YNqHAIEEh6B
QMIjEG992ISK6YovabMtLNjMOwONYci1h5TSGz5QljpAoLHxiu1dk9Hc9cXpKx2kR1dtfG3UZFNG
naE/2YNRGSBdfc3OibnMYHXaZu/JNTajpmJGTZnmrvz66ECkqEY9qdJuQzmPuC8eLaO+0kF6tPtc
jkOpdYb+9EClogd6j+Y2g9ZpONq6xmZUTkhT1+nwdvUQvh/heQ/ZTvKch1WEeIcieXjuiASKy6Gt
KilOnpYCAZCOcHxS4ki5kKOME0epuDhe6AVylNqASI5Tir7SMQ4Jeth6gedc9bq9hrp6F8c5fKw/
RAw8HO+pRMp3wSLtn89p552s+/V38IqhTiH2CV4+ZQbP1a5zwi/AK+yzdtB5pqUWPPvPuFromCjv
rArbG1rOuAcboabVKWlXpjZnQi01Drqd+xvmoTDH4QM71P5kftb/PbAtkGMq4LKVoq909KpX2T/x
z9a2zur2Gupm+flX22f0/tS1uISW2gokfEyl0t62Nza00Rk5MdMzazfUeaR4xB+Na2bUtpxx7alb
34TvAC/7jMOwh/zZC83DMEe2N7Q7tsA8eIbIFg9DP1OleRgeUUtzMDRM6gsLNgO7Q1MQ/TOPB56A
aiWk9M+HFqqXr68M4W/g6MAULQyDR/l8TLc3VeeCWLXng5BM82r4IrRUXhQfODgwTQvdcH3iFDXj
fe1Ou7Eutt2zgTh6DXHwDENsfRM+CKrzToJ3H7mS94LXy85zche5MibgE4dIuZPWMXTSak3+0CFI
FBhq/qIvMQPi7y9eJPNrpmtvJ995oHNm+frKEPye6VtkHRjs9zd3xXR79brEBRB3L/6MdC8F0s/e
yovhH+xTC+6g/+YtNDjs658z1dXtTmxIm5GAfd71HsPXwI1aSZLgAOkY+agiW5MnW31gg1M9PXHo
ozv16aGVqmhVoSsqktMvQgQu0bh9Izh6w31x8rl8faVDcPob6Kd89a5QR61ur1YntDfQ3r5iMkGq
xLXkLmfrJ1nvRn/R3EHXBc5y/l5jXRQuXzAsDupndx0T3tk3J8UCLnBA0yD0AweDTaRMzvpYX4Ru
1ZO6OOxq0EOaJq1E5EcDTjoXCjnK5E28Ug1vHyTFK9DBe7kO8lmCvtIx2T83Ss089HeXwKbbq2GK
1FXDBtpbrT+kdzvJaFQeJs99mXoJ56Hqh+GvKMsn+t5trDsMb29KX8dTZ3cdE36se2FLbfckhM9H
Dp6fgpHzD0deYtGt3e7vHek+ODUwCQsvzv6LKj3BR7UVeyLfMPAcHO/bVtBhTnTWCf1Tf8ouKYRg
NdrK7LL1lQ5H59vI3+cHpjcNuHV7DXXOoOunpKT1J9wc2XN+uhKXafhOehM6FZp2nfuqakbqSkXr
/MHdlOrOIDNj5PzByPnJtehmFSaPIdYTMLUAgYRHIJDwCAQSHoFAwiMQSHgEosIIL7l5br8rBD5z
inwgd9ZgKLmf411KAZJLIsBgWeUTCmtkkDNpyqO617m0VmeukQgoIHEBXgIl4MiS0ErmvhO1CvTq
ytlHqoV6UMt+pnaG3Bx3RCHHY7J19uMALm3JvvcObr87VNIpKPA0lWSB5OI5T8oCkasDcMf0c2Hn
V8ECww9Ats5OzvzvrZ9daNtuys9vhJzp+t/vOvGF2Vvf/dLSkkuiEXrCYevmGf0xIBymzSzkTD3J
o/rVbeEltW4L5xiJxtnYt/fCjk9F6ze/UqU3zZA1970RYDZ2eguodUwkpZP1Eiz7mZL5932/9CUn
4/M3do8Qwbv7uxOjjz7GakabL199YM/nlFJOQWGnCS7YS7Dgq62/9DVTC0IXiGAycs9Liva1se9b
tqufvvWhhZW2wODhPw4LIPTM2fWUZfJPzT8XAvW6F1Nz1QMBN5snCtxEWjymSwPU3iEoEHI66thU
dzr1vGdNIBB4XEuWtoYvQL9qdAd8NBdeIuKii4+x/tQLHOfK2ZLliDO5kJOzO62y8HoD1FM7AzEq
S1XHBIeXJZn3ujhOCFk0YbYyETWXO0tgnvzXx/6KWr4+TacX7qhjYxEjfc/KqueJNJ/Xgyp2J0gO
vl5Sx0DL09cPKAxBHDYD2/WEPQm/oynb3OH0Sj3RVQgJ+gkX+vNbwAlkFDhf1m8YGGOIBfOwCVgm
ZdL+BGzULJjrmPQKPSufQFltLDYLvbRP6UxwNf+cI/u+B7RjWq46wBhLQLHBzYIpcy/5ov9rsLft
2QW2NXE5K+/5fldbnt9YjZ/bRy53+87N73dOtRBnAovOjvtZf2b8o7WtudLAWY64h8ndMjEfbbP6
8rjrpjYFRtvObW5xuVoayI5N7vYoSzK/rfX1V/23ZLdQbWUiai53lkSCeIg4+ZeAMS1fn+B7/hdl
Vusgfc/Kqu9NQCJ/rqPd2SY2tjvGGtQxSOfpExxWE1EWIMZmv3JYil9UaxxwYZVi4GPE6mP5LRD8
4k6/Y7yx5b/Nv2GgBKEWJGERove6JuAwCQrfr1nwAZhZ7Rh+uh/8R10mX6fmn79O5uSHWcbSnJqr
TtwX83fPZ7YYGYanyeB71FMe25iV9zwyBHyegNwBG8l//F4YjrHDhMfgCVbZAX+5cCqXA2M54nvV
4vkjnuzcXqp6D1H8CDxKLBgi2gDOjmnZ2Yuw9aenLDxLXLcVaC73h9O53DqC/tBCnxxckPxBu5av
T/A0DKvTXdb7biKDX2m3G/tl7iULi/qjc/1h0MYgnafPaL1rF02Zrpp1t34MBNeenXwjX6eOz2pl
23r89e2eJSzgo3v6z5LOO8y/YQDqO58SyEgmgx5/64OwxyU0/mAnxywYWiULDDG87c1PhLdvU6Mo
7d8tcN83G+G1q4uv/dNrNGPJtoNsjyw2wn2sxTff/PsRQwuy+1hjX6L6hgds6hY5NTc8cKzxcsIo
cDmRO4a/OvjSnC3wzEd2nDwJryaohsYdYdr4m5/fumUwHLMODmt2sOPS8tmHTrs23RC2iOEf/6gy
9t7X/vVLVPXzRPYBXfW3vtbx8kc3zGVpTdkahro/+Ovjm3aEM8JLx7Z/9F/9nKP9yPWjStUNZ08C
s/PKjvt06xszm5CePDmxredJPQLuCYczImCyeczVuuPNz8IVdQxuoUOmy/RJUXi1KqGEbVdOPpmY
S3z32KTNE6Xz68qOl46VehtVWAx/YtO9F05sym/BWCu8+RVgY3IpoXJIk4lIT3nC1QklEX2cWPBs
4uoXZdvII9SCq6tkgXFZ0jt59eeaewyy0EbPP7d3vq2T066pNFc93WLq6iCZsH2g5dKyJGcbSKlo
W8t77tUFQvlzbr0nO+o6TnqraUq66UdHB0bPDAzN5myXyhE/aMq6NqnmOrd1ct6qLNX3vP6L7vZo
Dq2qrVG4y0IrRy58PAlGF8g/LV8faDq9lMfGLUEluCXLM5qgxPuDsRBoYxA0qrPPKpGkltRJb5N3
1djbxxJqX96+Sh5+LPjx4NgSFswF+2OKOiZZFszPVhktiNrbt7Brpx02rHZI4wh4vU9DDewCytFR
H7uss/zzH8M+NUb8gZqrnm4R8z5DWhwGX4M6yZtIx2MwWJMmBct7tkG9KnBgF+S7Z4PhYGtwmLTa
qQRSy4G0P8Khyctgy9GI5YjzTI50uSmH1EhfW+8IzXsfDaSuajQ723noJ5a/RdDy8mke+mG40UKr
DTrhTfgNtMMzer4+waOpxHq97+aYppNFND09PblWOze2O890BvQx0PL0VRmBr/d2OsB5r08dxpgA
/aPsDDqCn5K8AedqMMbesaQFHa5nO7+mj8mcyiHdglFvxwQIXP2vVAsWIFjPLPhtsE56YRUsMBB+
ZiDCfSb0HJzq2w5y8IPULC3/3NEH/ex3llquuo4XQn9oPxCaBH9wVl1cskX7e0A+94gI2i++tLxn
uX/mx+rhZgcm8sTwsHEO7BtJqz2uUOowtD/PDzRsftGVa3WS5ohPMbnJYEMih2pvHOa9MNIcueHF
5/UKV9/1MPV7XVtftPAumq00D90ffIeF1x4no2KHLWRO/C5o+foEe16MVevWq303ocbiwSimu1il
5Zx04Nw+nzYGep4+k3FVT0XuIlP0xPTN3SSy77WNgaOBzd7xyU9ujpBztwqwsqDPuFHfwksH+p/y
ZfyGgcm4qhqiPxfAbZ+67Ty1oNoOwhRzgVvOLm56sPu1Fe9+IfnwEmxtf3m8YJWc8+LQJyyfLxOo
4CerlAu8cHHD7UU9XWd0Z6wsMmsHXyRWFpnVQCGE55PVziJ+79b7rgTYnWNgHfVe64iJyaS19bng
/klXWWTWDq5xoSwylUJ4BOKaQRUOAWKFkL3IkKgAwqOHR6wQsn9rXgEPCcT0YMS6AhIegYRHIJDw
CMQ1APO3ZjKAxU2snOvGVhO3/CgbClfLcjTFInogM3m92dJaM6TUccnqX2qHmGfoMkc2pQu0gmil
0diBVNvUbllUD4oolPDy0qfIQtzyo3x8L1ytRooieiAami2hNXtOyNb9S++QxaX4nlUS00e10mic
IVknjc0WGSldeEjDho0NmSyzv4w+sjq82me6AlbPmRQ3B5chXIAjzhIpfVZnHV9ejqHo0ksIafSr
t2hyVPrlUjRWrB6KuEwX2S89GCgo8MgMlMSSuyNmlQoPB0WLg6F3Xwbh2ZCLplEVs6PXPK5RLHsM
z+ZZEWoLFy1q6hY5z0kvRLnYmDrnMeR8dmHgXgLhVYcuLx11FnX5Lz2eKUJtwaJi8d0osoF2USzx
GOrcyW2XWOxxkPBWlCnklFTYKC+zOwUvpRStVy7nnF86PkPSF3fTqt6vipmuXM7p5N/iAyyvmHB5
OyQX0kgURYxsivXwepSoXUPBXMwKI2Ut4ld3mj/KF9EUrbZg0aK6mkvY3D/j3YZaXvoAhgUX4zGy
NKZ3mNqW/abp2gZmS1bmxUdcZoRVSRddzJZErHQEhSuT6OER6OFzxfAIRBnB6B2osN/tY0iDWFdA
wiOQ8AgEEh6BQMIjEEh4BAIJj0Ag4REIJDwCgYRHIJDwCAQSHoFAwiMQSHgEEh6BKDfO1iHhEesH
0num65HwiHWDxjcmJqWKJHyAQd/yOQ0V7MPrAMXN8UkJQqpkLU8uVkntbYQ+geOOKFTWsUa/GtT6
r7g43hUqu1bT4OhwkT1KkuPdZEzc+6n91KW5eS6pQB1XC+D25lHtDJj0pI7AjneE49zMCjrmHqLf
RXYo6cZutbGP7Bbo7hAfyPt67LUCfX/6mzsqpz+29MsEw+FG6Em96L5tW6rYCLQoXf2/uLj38VPt
H6r60eY7vx4OQ5UnuqC41Nei1U/br3x6w4RCZJ3xN4+thSnhcHhmU2je0/r43b99aKGMWr/73IAy
f2P3SDhsrlI2tJGRETsn7C1H5h/reuA0TNK3z2+dHefbSWnkS4nQt2dyKlbcfggb9MzfGLqgHoGc
BhCrpNMXP0nHlo75ng9V/VvbL69rntAZP/qNVrVxtVL7SuiNBMAPqI5wI4QrjPCz9AW/drFiXjNr
EdIc4XkPcPQ1worAc4Luo3YO2WAOuobhPZCAz9A9i2MJ2OhQa2OdDq/Qw97He6a9aa3CxZmgAPPQ
1QWL5dR6W58TNls8++V29ncehoehCwRoHlZfQ/tTuDhESoktSTiQ592kt1eZ9WwCu6F2HoaagbWO
6WMujKdfc/sXuoGz82ND9HV5SoW+Adc3DhsBJqaVyiV87aDzTEstGb8e8EjxiD+qeyQYgiog0Vg3
fBbeyzslqB6tluYv6rWv6ApugvhahYsdjjHgwddr4k6p2NlOtC5AjHNNmCtCl+nfJHi9ZEzuph9J
umO7Wqqur1bmh3OrDU2Z9SQgeq8rxQum9W71DLEx/yL0+tKEv/NKSo/jaD/RVPNflUl4EtDQURvz
VC7h4zDs0Sgb2+75cMpZKuAlPNr1FCn+Q/Crzrbt4GgQdnI/5NiqUwekotWqtXodp9QSJBf0S/27
jwYvlVHrXPAstWrW3XpDxsncqFquxqoqTdMlYcpRz+/kjuekgt2sB4Kz/taP6fuY1ifoH23M/f1H
d1elArX70/cGV/+8/WNQf987K5PwyYzPCiQ88S37NMrW7X7oSehM8ZiQ6c7I3wTJGYrbh4nPm4xf
jI18JPI+drYgdSfuXSvrhCRPeCC2v/xgx/byaf11O78PINJtHwLLsCGofvTpY6SXJucvzoXfF/lI
oceJxO13wtdNWtk4XhpgY35r+5mXk1bLAd73wjcg8qMKXaPx0IgGNvpmKjiGB0mCA6wQhbsuGCaC
BN7749GkPT1nB3lvh13zQzemmq/V673r2bufORjvgoXyaX13+tk9lnZV0fHaTw4taVN+P0gKE23i
vEP25PJOBwlkQuqWNxKPLnLkAkti+ByxYhW07aZrNBVI+DHfBI3hv2WvXMI7oGkQ+omfkuAw3Ji+
/+ToQhqnvNDJg8D7BHZH9Uc87FLDTmHXnBQLuGhxw1o93SkBw2zq9cYs3nq+bCyyGMV5r28XuT2w
ABmCQfgxOWzTLnJTHwgQ5zx4HRut+AUIKoeXWvVMXZ+4gab0EYi62+EYraZj3sURi2I+ste07kg2
hHvraauenh5601WBqPaRGH77PVC5hA+fjxw8PwXH+7aBP/iO9FcGJJaE/7Q5H/65BM/bpmubSbjs
qx6DPS62ljD2ZGJz7flJWlyAr6yNLQvsPmIqtL9u4LlyTiOq1XVi+ubuEav68e7ZgyEZzoYis83s
wjISOhjpJmfZB1tAcO0p9Dhue1f0fOoIE82RSMhPS/qYh2qn6X1uMKPVianm89NQuehyA2y+VDn9
KfzZktIWx1RhYdv8VS8glo9AHl9dPzO33KZrZMyp6xa9429FwkPvuwr79sDpkJC0pYADyLmq7hLy
kYerSlbaenygx5uYgrck4RGI5RC+wu4p8JQg1hOQ8AgkPAKBhEcgkPAIBBIegahYGLIA9Dez6pup
BculXoW4sq9K1F5DuhJvI5WZubLRasT6IbxYka/WltVuySvSO1H/g697XM8hjSzL2mu2WSljN6Qr
iIyl5IrwcmXm0mpcoxCV6eHNPlXMdKvGDb3MZMQVc8B64LFSdDS8JB6xfgmf17MSdhvoIa6OHyb/
iysRw4vIdSR81l2d5YacNQ9WjPBi1vWlwiMlxFuW8IxllvwQryVniV5+nd+05vTxLOhNxfGQx+O/
NYiOpx89vCE8obejbCM7asmIYJjkCkUImuaVOMAKxmGISgXmwyNWFJgPj0Ag4REIJDwCgYRHIJDw
CCvIFaABflQJnZCR8Aj08No8kJc/tWSLL6oK1Shn18plm+EIxEp4eLG0yxF+JYBYcdTkcrf0l0Cy
qGXQshTJ1E+PRC3HRq0w/B6JbskpecZhQyKCphEy2uoq9NQd48+bUpnB+J3oWzaIr4hOLEH47Iz4
dFFlfkZFKpeRZg9beeu0xqy2+ocul31UWNF0+2sYJY9YGcZcrohO5CC8XNjQiXK+Mc3ImLformj+
FLNqRYxxEKsR0ujxRiG3mXKBVx0rxstFzEi8cUWsfAwvLn1VFJd/8TSn2RckgL4eUR5UL+1kc7rb
HE4+w6eLci7t1suOcpYAOvk1CuHL4WcqrRM11mGIISM+FWqnEtNZybRuYtiSxcw7DaO4dmerzgJt
eUY0/EpbLWcIYOZ6CTdrGctchd4BylYPKFqDW07jst6y2mQ2XVY+/BJGFGhj9tRAlJnvqcWt1LoX
iEW2LPGhESU+ckJOucnCaWJqk9W06C+eZAJxJec0YmVnwKp66LL497K2KfqFe2IZJExyOD0qOqoX
V/uApTYXl3nTikBci0DCI5DwCAQSHoG4BpD7+fDmm97ilpeM+WB68wwN6Xwxy1sN0+OexIx1Yesn
umctOqsZmuv4pljU01KL/iIj3bKC7FhOGzH/OrxV3stynq+bSXg5m3iZ9ZnkFbNap9ftZdGiTdai
c2YmJgKR5/nwxsfEGx8BL+vf/Vs9LT77OfG6EmOlrlfOzXer2YDERZQ1pMlwlcYU9ozUeMjztHgz
W02Z9cb8ebpLzApJwPBSjhwxVWaotORUENHFI/IS3kiWJfZlPS2+QG6JVv5cLDxIkq1mRjkiP8T6
DWnEwt9iY5C0DGlyVea8cVhqiogEBdxIiCKmWK4ZpDVouUzCa3QqnC9p/smZTDRRMz9PZYbipoN1
G0RZ0OviPErW3kDuHQHjxvUmGQJOCOU8lKnl1tUmPFg+NCN/gFxA+rxhQ7ZitCgW5Liz5pOIccuK
YPS28dcnxLriGqWfFew37+/peZ27pbCW7atMeFHNh9Q+UuQUTWmSxi1DWZQzf/1h2JFWLKaXe2TI
7aRlCz05rzqaiJxpAN6zLhObBcFrp2dGcdldxNOHnLqPrvPQfW51nzYjJIEXVVcdcnHOEClkXgq8
4QS5agh2hwiOENQH6kFx0P2aDiIuOXmXZNGynLAJxi11QxCE9IdWTm/roukKYw0pCaD9b6oSjIpT
gmyfoO3P6onheGmROQEES1PSvTAZMCcgd5eFDz1zjPCjiniO099xO+LwmGd2w5eroDFc9+BTIL76
sLrv0j9vDVPphhdYqTEMj0Vh+sl4uNH4YPhGKvPY4gL8h1TtiSacJ+aePlYV/59Tcbrbo7ds+GFy
+pEqc8tVCmkqGEXeiKKDXy6+49VdTDMMzwE4hmCYuuTjc3cBvH8jSHG6zzuhCp1KlRx2EOJZQTqJ
4eefB4gJIHXAGwo8zS3AH7/B5FMt/5a0PLAGqzSVzvgVlEakcVjSlkw6veAljr6DfCxS/sMGgCHC
YFJe9IJdu8NNlTpI1WJWhN7zYPXlfURdbZJMmtgH4PiIIikxMOloJy17kfCItcHxJvLHtxUgKLGV
QvpB6XK/o4ZskLtQ4sZtEmjrONWSvpxIq7IXd6Dr6zvo2k3VxhdIOP990e7lGmrYNSStg7acR8Ij
1gbXxbxQH3mWuPRfQRMPYP81NM3RikmhHvgJEJ0AXBP4VOlYEzRoEZACXoHNDzPuSRKqL/5miAYt
p2OnwTavfuuZ1vEFtSWnIOERq48xZys3wxF6LtzBzZMoW76dj6v3T+4oTNzAxQjhR+IOjUE/m+ef
1O6aavnoNEDN5kyFkw9L4PrgFtrglnYP2NvH2e6R+H5Nh7+Oi5I4v9e9glbhW/wQ6wro4RFIeAQC
CY9AIOERCCQ8AoGERyCQ8AgEEh6BQMIjEEh4BKJY/D/gO0Hqy0NDAwAAAABJRU5ErkJggg==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2016-04-04 14:45:27 +0200" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-002.01" SETTINGS="SHOW_ROB_TABLE:NO;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 FDA food safety guidelines and neutropenic diet guidelines vs FDA food safety guidelines only, outcome: 2.1 Neutropenic infection.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA6oAAACQCAMAAAA2q2Z6AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///9BjlLGAAAeK0lEQVR42u1dC3AkR3n+9ZiZnd31SjOSzMn22dJJOCkIJNxDd3rF
xeogXA7qqihDpUL5MKTKQIVHUlwBJqmYEFKAK65gAqnYqQqBK0hMHAoMB3Zy2thoV3e3HIKQxBU7
0kl35zvZJ2lG0mm1j1lp093z3pdWjz3NSv+n0k7P391///34++/umX+3TgIEAuF91GMTIBCoqggE
AlUVgdhNaBC9IUe4k2CSfF7nQkkA7W2dnUvLZXOMPKVVwnZyjSg7RZiWP1m5pNe4v/8BQHyis/Pl
hq1iX4kAm27oVzheWnYJlhdntvB3tVsgUDVreq2Bf/4fStSUxCUbHGPJ8zX1iqp2QmRykn7OfOXg
t74B/zEC8Pi3yua4fFcFTTs5uVZUJ0xaIkxOTq5H0sfnbi7D0+0Ai6mtYm8nr2JDrz4/filry+IU
UY9ztPBkzWoqrc3KUvgvS9WUxN2oqZp6bgEsPwvvAHg3XIAhNv2F2cc3RJ8ESogXQgojhcM8+SCX
AJlqQgLfREmSIMZByQk8SyQFhCRNq5wSeEIn0AKCFA4b+VmUeIwegBt8wSA7yyorqQ+I/VcgDiq7
j/t9zS72ml/Q2Qv8KZs9k8umAZUXTDqAGI6DFvZXtY0HYZXK0urnBD9bmmjHBM0Rp4mkyWRBb2Gz
fWsSol7TkQBvjgHfQ3FHXNzPc/4kb9ZU7wtU1QrxRiBzXQYEcNr7Pwr2JaHzYCBwsMOgZAAi5PLs
K9B08EzgQDMJr5zpPQQdQ/6Fg53kblXs/wSbQMcCl3vvo6GWw373mvl07/lVmsLJt1hZJfAylfRj
MAMfYreHjvwo64pvPOJfYez/PTjWaVGZXB0Hzxi00NCZwMEmW14O3g6t0FjVJk7q3b505LXQkdtI
YO62yBLniAsp6UTvclpvYbt9axAjwNa4bzv8qj4GtNtOfr3HEXffXGb5iJQxa2r2Bapq+a0FM6DE
WEEOlL6oEuvTTAtFlpMzZApMwcQ49OcpdgukITRB7RtMheAoHIKJJCGRLLPwTZoiBePtkaQemrji
yvwpmJjU6U6+JcsqKumLUTE6zmYAH4RUVzoBJqbIJQ2+cbCXyEyuDIQM2iHYP8FChrw8icuSrNVs
6OMXFtmkAXdmn6ZFv7fPzznjkntDH4VVM73VvrW3Ww0/cv4FvaZ3PPs0rcJtfb2cMy558VQIVsz0
B82+8CQaPSNJxLgq99fB/wCf4SDLRcjCJKJrBQyQwP0Aw3mrUGJMoQfCejj8UxgZuB/YMCMx/TRv
Pw0x1NEUzsz9JsHFl5WVK1JWMUnF43yGJ5Ky8dDDudIN6OxX4DNkaeVk3x9hNH1uHyCJcra8s7FV
TRut5niJjAzpcgZj/dAukeklWlfnimt+84kvvGnArKbVvjWHyEiY66aBhejA6Y/Qmq6OnjfjWhdI
3NlHLgRhMOLsC1wAV4x7yfRxHHrCPfC6grinI5EMxMg6xkk8CooCdKyRSwOpEEtkIwb2llOJM4KZ
P0azWHxdqCtCK5S0gchIJfWxEzpQNLauMgs02DcUYcVoab0DDOmtyXOweaC6NmzQf/hh1hrTvxju
p8e9Z/neEWfcMjzwUpH2rT0MBo+wTYz46i+H+2hNQ8IRs6azNO44XH3JqQyKgsdKFUNJkU1qFs5E
fskWJpGIHeWDrumwSEbNdKtTBWMw1sWUpeO/yTqNh33uUxkfdNNcbEHadYhpIcvP9oVdHTbfvMVr
IS1f0hl4jsh4JnIGAvoub6yRaWFbh8Wjgy1px9rCAXdem8ab0tslH4a26rbx/Lmv0knFf3+DAu+n
I3ou+g5n3INwb5fdwrF8CWsI6rmkUdMsm21mZ0d+xx2XdtSU93RNvaaq4fbsL2eVLLGsr0Emb4qb
3J+4h+wv1NgH6QIuEL1TJ09dPJ74+Tyty9vOq+TuQCC+4Mx1calD35vNXUhKpFeM/HQeOLdcb/N1
YaoILU/SPeIDg8SONpK/rMK6/jEJouAfvfljPcWckKCHGlPDxxcuzOext2hTF7+Y+LlT3teiIMxW
uZWFAXpMtBBfbD/3dTZncYdbHXG9sd+kFfLH7nK1by2CH2Q1/Y2F4PnbWE2FI62OuPlYx4o9lgr6
wlOo2zGv64chstYA9U2m33d+uWqjwn9p/DMXEptdVUB7/58PAgKxY1WVq0+vkUJOrtQ1LHDVEmDk
7SvA+Wc2a/BWj55XcVwidrCqIhA7Gvi6PgKBqopAIFBVEQhUVQQC4WFVVYICPxSIQ6v7yX+49KtW
8dwQLwS0ClJuDcIMRaNGAlvNfsRfQROUk8i/4ZIDpUoOa6DwYV4BLXysIIURcpdL2GrQajI3/JSc
pRavnEXUcvxQLg6KnraZbwYIGi9qtooCn9Oq3+sVNZ8GIxuvZDzI86c00qh6JbknAALGS00jx/ih
YNwLlXT6q96xNH/zxbd+Pntkr8tzr4wL5XcGv/3o0lvf8fO1U24NmKto8TIq8l5dA5OTtIAiHEtX
bIskqrTkzpupd16Cu9/4jdb2cxkza15ad7mdAP/wLb4d9DiWxOKpe94WFd9KUz80//i1L6WfbL/w
Mk049VhW424aSsxdO3Z5Tqu+i20F4wKWkt/feCX/qee/WnPz6cy9w1Mk4cnR4ZXprzzJYqb3X73+
2QNf8EIlnVb1U5AFMZLiTOc96nEZ8EnUhbKNzDjshatTgsCcK4NMwzV4A8nxpO0A03RM1Gy/Tb/f
9iU1fUEFv7ZJiZPshbxAWDrFCznF8C9lvpW2/+XmwGRmPoxtAZ73jayVfoS9yOgPJ01/2qTok1l+
20+yMjB/SVYXLcALYmHJK/BOiJH/FeAUs/6mHy61c8f0cp0YfTdkR8uapDbeB4rIaYaPblz02S5v
Aszuhwys0vYgxbevQqMxuTcP+OTBSAI8ASEDGaFsJTXOD4pPaDP8mQ1fYh0ZEMchDXuAkb7J5eDX
DWZ7+v2yEln2RB3rncH9dHBotusINB72K/TVSA1OM7+spjH/GebQN3ONmWR4i3s45c73/q3ttzl3
tcDX8ROBI5v15RFHD0+DdvgNq2NB/1AH6P6lzLfS8r/cHHSZmQ/j0mzmct/RtTIMvuGIBtNHRveY
Pq6vC/Yts/yWn2SFJTN/SVaXpp9klnpPF6Q4SYYVR7ojAy92mvW3/XBTi+nlDOS9tdV4En6/fJvP
+PrO7uv1c4aPbrj3R5YDHNTRt2NPkkk8wZOhUK/Va+KEHpOFl72zjxtZgZXyUyrnPyJ19vlmDH9m
w5dYx4P6K8BZSPJ0O6c9qKQv6TE+eMmLe9XFUeh9JOCyAQKM/wzgVTIyPsqm1RRMhJgzaJLtV17I
zzE1Ac/YfpvJlgJfx6nxzbli0s2ECI9BCxxIwfgEdTDX/UspLP/LzcEhc3Jv6IMO/7VSEh0g8jwG
j1s+rmdtiQw/ycrg8Jdcrg+FdH9bJ2IvaqvRK9EVrS/abtXf9sO9wtlepvYYfbF1nHOK6xaeXs6O
Hl8WJk0f3cOwf8pWdOgWqRyxaODIXhADvjZhH/8EjbGdCz0ArlfrW6OSk6PLqdFJ05/Z8CU2FbK7
m3Zz3VLw8CdJJQ/sEzqFZq9V0qGq3PWxUTjssgEDIPcQOxbLTmdH6RtzOXpPZyO9Aj3Xf+7OIcsw
Yvtt6r6krrqSBJtyp4oQTIx+NZ6KncjB/febsgywyGCs9y3tm3/7yiGz9ObVnxnMy0l0YjSl/M3o
e4BKRH1ce0yJFqJ9p++oXKIR2j5GyX+2eqnQtZ2Dxn5e5vtbyMRp1Z/64cpmgxcK+xxRwRtOcd3C
s3709Q/EKAsmf86WAuDqhYQcA0ikeyaI1ZnPXEpNvjfxcTZtgIccxl6EZvJftpKy0N8v0PFJKrlK
R7ZdycfiN9OxOkgMc+Pwd6SS70nNpkNsyox6qJLOhzXy/PVfGC7xhk9nVHfg4wZeP8AbKwUFHAtC
eeH6GKl31HTRZI6Nht+mfmqlkywfzvgW1FwWBu4j+yTmUeramVr+l5uDwz9zCa5UssqT+YG7iAoV
+r1afpKVdoblL5mAK0WWH43EGlBPnhT5d9ZfKbMf7hnNxLgCU+OCkhRiKcqKyT/q9NqUE+lkzrF+
7uLlcS6ny3Kvd1S1PabF2stXUkuPxpJx05855qwkt6Qlcg3mih+gu5Hrm2GKwMOveVFVfWFZfoau
eEAxfTrT0E13Qz8mdoKt2Z+CrjEYdeRIyj8kOR6E1g79TK2LTPyG3yboVWUegJYP59HuLfguksmR
3uik7mVqPZigc7zlf7k5GP6ZlGMD/NpYJVmmoke6p/L8Xg2JsutYRvB2yfVFS+aINZghfwMkZNff
8MN1lOvClwcezTc1eQP6qf7z/oFGU37Sf51WGv9DmkSmaVGYFpknZ/oliGkPsphoSkmGAx4Zx9wA
t0YlW/r8ZwbCpj+z4UuspxGFNnnAR+raqg/PpAij00wzfLE/VeQqfyndBlT15oUE/7n48/B0dK/p
05k9v/Q4FTgKo+1MSS4mjl+0Hfp+Gn8ndzQ+D72xJV43osujEdNvUx/DF48nLs6Davpw1i9dmNvs
XhXkTwAxYUSWjgvPmxHUt9L2v9wUDP9M6sPojy08W5FEPnhCzvN7pfltP8kKS2b+krQu/tGFdxc5
AIqCwAEnQPQlR/0NP1xHuS48Ap8rYBR13rT+yzlVFYbaDPmz575Yb6V57mogOabCYkNH08VJkhTa
QfQfYLIMZ9ubhr3ix9pY5KuHXOdM2sFzytFzPa2GP/OcsNxgpQnULyQeIBPrtxffMkx2sCMNM+Dr
YHPu7PzDexLx5z1RxUo8axS4o+9XlXs7l/bbXNulFLEBrN8Pt+1makvSeBrT+5JbksYrqERVhVy9
fx17zNJ+mzxkULG2Huv3ww1U4FbrD8zUdrMEfzK4JWlqSVURCMT2qyo2AWJXofD3hVbQqiIQ3sNi
ASVUG4KjExwCgaqKQCBQVREIVFUEAuE1ON/xUCX7Mw9OogrMr6/oZduhbr0Um6zahiQyuqKgZBfd
jrYI0prl2dFGSLV4SMU4OiRw3DjkUAFPJm+5qrIOUCsZReS/6GX7NbU6yr+Jqqkbz1RYslqkB1wE
VVpLU/NDNqE4R1sCx41TDgm/YHwbVLWk4ZQcHVVyKODkunWzg7ou+kY4G6ESLKWyNNXb6ln+e5C+
v870EU+qqkQnZbWI4aygZzyxDvLeGNqQRNLGJ8M1jKqUH9pQp3l8Uo5UOf02ob7SviFDTpVKj4cd
vRCqkZpJKptct0Za1bXWddNqrmV28AK4RifaquyWyRS08Vno1u7fJbBWQ1vAi7DJq3se6021DOJW
qKrq2QWQWg3hJM9JdOt2AFL1WgaxqQVwqfND1RnnXU2VJGnrh4/qOYlu3ZJfLdsQaFG336pKqrk9
NS7OuVrVD4YL0uzUOXb7qlaqZHebq5Kd0FizbnRdVMDRJkDezfa2zK7EOjxrVOyWnYwy3Vu+52ts
XOwCzxrU1J2uq9uwQUBUxaoiEDsANWtVG7HvELsKTDHDNfh9fOhZg0CgqiIQCFRVBAJVFYFAoKoi
EAhUVQQCVRWBQKCqIhAIVFUEAlUVgUCgqiIQCFRVBAJVFYFAoKoiELsTDSK2AWK3oe1/V/3Qe0MI
Tv7Jl2tGaHQtR+wqJV1J//bZlTkabGGftzfyDa9xuABGILwCJdnsF9SXJ175zg2mo6B/3rg+NbHU
IIbOtim1o6phBvOu1e+IYBfZB1qQF3IKxPWUTUIzQC5ppBd5/pRG0/p2lKGOB1m9bjECpMmVoMDn
CkoOhqlMQ1Qm7RTPB+OUqOV4IaiAxJMOCSbX4GvzIfCHzb53lKf5eT7QRrkO5eJGeoNms6FjIaSA
Y8h4tw+bc76761KT114tkWD2+uUDL9fxwaakVhOqGono/zrefCR/VrpfgJaeYf+QBO+AExGSMh1K
gSbqm922xYZXF8aaaZBPKjtIVcM9wcBYyy1epQUPk8/TPWJwKK/k6UAP+TzU83CQyNQyFvxxzyFK
fngo4O+5G5YT7wVtRVyDr82H6J/VyxFHedLK5cThm9A4FHp46KgR30xpBw2tpWzoWDgoefwHX6aT
IT9X//rF+en/ZGteg1z8+trVm6klzp+TWmtlAXxKEELA0x/I0kSBF2WDvG+8AVIwOAG/CyvwOUpZ
nVmBFp8emxzwyWIkQYNn+rp2kKpmQJkgH7cUb8rSz2fh0nh+ye9bpZ8i7B+HNIkb3w9MMb8GExMw
CDnum9AirMXX5gO/44y1y1tKt2ehDgSY3W8JkEi3vw6ed+RK6mPBs+vdaSnoa7gzdfka2ZnOtej6
WMH1xrWGS/9XfyzQNK14XlWbxvxnDjZl6DwbUtKJ3mVzBQTjpPuI/MPweXiP4FegfrpeyVwyY182
GbyBjKKdgwdplXO3tswL1+nnXpDl/JJPXKOfJ2kMlYpcToIZ2gsPaqD83qW1+Np8IP6KI9ZZnu94
9zW9t09a8b7f6jZyXdVHDhsLHoT205AovMt36er07JyxJ13n/9x3Xpny1fG+oOyhBbHrYU0nTALU
7Y0lzk5laTjb3vgHyuUVRoa6uz8M4p2fvedXV1aiU7HmQ5/Ugn8lPl5/57/dliKx98GHTRaf+e7l
lZ2jqv033v+Pe67c2gppX6ZN3kT+O/NKftYZcx+9/HCFtT4JPbPy0Fn/V/7nq6usQ0rztflAxiTk
l3fjM8KpjO+uz3763h9aAjAaW2g8SpMbYwFMlt7B6luf4levJDfLpgWGrjQkGjxsVckM3QN6/zS/
+S++BwMGvY78XzmR+MMYXSBxE5CF+fSl5NTHyf6IIAbWekG+1UaoqngsHkrH6raj5KjZ6qViYnp3
sdZn+FDmUmY2dTm1+fLkS2SddPXCkhyz4xnNxpULbCx4ENwH6pYzs8GOvXtuN/ah6/1v+/Rd9/jS
2Z8sKR56jFPsYY2igH6YsAwPvORQYQXkT6SXc5x5DzAmyP1kf0SbB+61skPdDlJVbklL5LblkdYQ
KFrxpmygXVRHl6CK3oF1NDREAt3LXF/76haVJycyyVzJL4qWE+nlVd6z/SZzC0tp7f+6Ovg9xrq2
paLr7fw9++698WRiUfTaw9bCQeiDrjEYJXOsQvZp99onRLRX/Lz20wEBRKFVZOcZ7xKgW59pxe6U
kgwHaPC2HfU94KLQJg9syytdMRi7HYrqAgdd3SSGh64u+Gv6fIx0wxj8mJ71ZCHWtsbEUurpilEe
if6o0NpNxoH/IU0a4I30Bs3OTMfCIO/x3utRFlJpKdW59453Gs9RofT1dXd1dOW01KI6I3uxLoXd
OnkxcfziAjwRvQt6Y7+pOMZHNzzX4P/iLxR4oWGxaT/ZobTWz8CBABvHM99b2dN0cZ4Gs/C1HaSq
gfqFxAPbchg4FT+eGJ4rFnM2nljaPwez+xOJ+AFKmB1eOh5XAUbqORAXhM2Wd7JhcWn/Ajx3NZAc
o1wdNBvGWKgFtM8vJWO5rnvu2lPiqVvrnr37Xp/LJBYU2bu1qPzFQqXdt1BRwlDmugyImkK4zPPR
6X3JjWb1HrTbFXH1tRZjBiTXNqHhtcaaeLFwHe8Aj7y9skM1v0/BsV9jEHKlnx0HfzJYJiefq6+5
Z3NKd1DRtNvneI57qXasCr6uj9iNqwj8eSkEAoGqikCgqiIQCFRVBAKBqopAoKoiEAgvqqqqw7qF
wlBxqB6qj+q5FlZxkCG2Ao7XdSUyrGr9KStqKmI3LYCZaVXpIHMYWYsMdgRJUzQlAoGoolW1VJKZ
V4lcVKehdd6YYZamIOU2mjDJaxOG9yRC7CCr6lwSF5BUp0pKa6RGIBDVs6qlNlpqmR0YtR1eMKqe
26ni/IW4FarKlrVFraZUxAB7YQHsOeVQUV0Rt2ABXGA+qe209qtQxspuDyRJ8tgy3HsSIXaQVTUX
s/TACOxTEecaN2+9y1LikEQgqgj0V0XsQqC/KgKBQFVFIFBVEQgEqioCgUBVRXgKao3w/NcakdPJ
FFUVgag5q6rm6bG6gSlALTInVMRRLYxVqzhbIRC7eQEsbW5RgI94EYiSaCxl4iRgPjSq8XqvFQRV
f7fQijCI5p1qpWfa53gN0eAIeXlNFuYrxzY7885BQOBmdVfxXEtVCz1W7aCus3kRlruqZPpnSqU4
FuQ1L2a6wlLBK+6wiO1YGam7mKdT/Rsrmxbcjqlqua6RLJPqMqtFmElFWUgFCRAIhFtVzdVpJQdB
aoW2v5iuquuYS27J2gKBqNG9qrT2gkba+LrH7QZbUQK0r4jdjvq1DVtJE1fCsObZ0aJfLqQ6cqjF
uKsFMWhYd+dWdVfzdDJtLL5odXisWltKPWj4sLodVB13qpS/x3YmN86edP01jn6tE2ArnJfAK98H
g6jsHCTv1H7jxy2OXt/iM5stPwJyPtrYIi75zDbkr7pGRStsh0KlRtS+plpn9dYx/oZHr+PcX93a
mVrd6olftQzRZoazi0sBs3W/AkG/gH9LNBWxa3TXa0awSja1ylwat35FLq2PEyo27l5v8TZQ8mQl
1+KCr+sjEDUBVFUEAlUVgUCgqiIQuwqOYyW16OZ2Q6flzjfwzex5HOw39IuWmv90zvWITS26CS98
olcoB6LKkEyvqS14Fm7zqq3Kbw0Xqfxz1WLv627kMXa+ihRRmfz4gkjX0znnIzaD15p5wHTIQwVC
7NAFsPFbqfbPrDp/QlU13/wr9murhb+zajJxRpp81TIzhDXFYBchEHkL4Dzz5HQxzXNdhTK/tupW
PJfnq9O/lZIKF70V6Gb+wrpMHtV4OxHVHbEzVXUNm+b6QTi3b2rFRlAqpn1SRcppaahUMg++MYzY
JaqqrnfAq0WDhfdqpaq4PlUvsyxA1BwUGdugYlW13/ircLRLbi0pqVRSBQovrUuTyy+A8UxpuxGm
HxF2iS6ItKve8kulfJY7K+AaWSPGTkBCZX5KyiFebJ6KJ//WAx/YPNs1xdzKBXClRklSpXyFUsvq
WuGBslr+61nKiyGVj0NN3W5ErMvIENVVLX6zrnyO3kilTCuMiVQkXrI5QOaQRz5+YSvYVgX1xdSP
+c4YF0v1JJdLjfPOEZbUfL9yB8FmrPM13Mepr45aVATj8Fh18pHUkrOGmcctKaqrNzA43ERWt5kr
gmLZs3DTMX6EqG+AC2o6Kaz/NR0DRRT8JGU4yQdIXDzA++PkTvLxMkupifw39PWy6GsOm5lZTIAm
AcXP8htkPR+hBUrZdDGQIAk+pWb1BFpAkFxsiTwSWLIaZJf8NDbIpDXoAL44aL7qqKqhDZJkXyTr
+Ma4N5PaEc4Y/Ve67QMmK0pyMrYSMppk0J2CWNkkUwxpLVtqS2ElRi31kq4OEIXgZb7bQfv28GmA
livaTIttrIi5avg2nPalfXeT+ydf5UncofnM3FFyt3I9uKT37A+bPsICTwnXV93rRP7VOUpfSM/Z
3a/nI7TZkkNC6SfiNcqP6uK1/GB6xRX9lMgIRFa+paT8jVzmB40WHUBYhBeEKlpVj0Na3ze3oFHd
3s1qOOy8bWsELkOpwOiT8uA4QLoFxLQr17gMz0zA+GG6HpYnUsQ8cXqSKVkZYCky+2dSLPD0JXnO
ldc3If+MXP6Y5DhqEfV8blox8XgIZVgoHZKnXCmfHmfl/F4LKLas+fL7JiAkWHQA7gQ886Mq71U9
ratVTI2ozl7VtFx7egCiimweyuiHvf300MmVjtBzMsg8CfaALOhJRqwMBANmaEQGDvIy9xD96zNy
WAwhn1ZEvPYeOK3pR9CkXJcWG+WME2Isj60tfz8pW3CIOfvQl9o/t3utKqJGMRKFbj4SiXDdeREx
QtRtmWMjGVNAqWMkxUiiufKYSesVM5dJsXNkShZUBHIMxHqSoP4HBpe4i229zTZdkm2UJMo5o/5Z
4mRUVURtITk0DHPUTvJzeeZMmAPJT8b5iNJhK+GjInQ/Sq4d0EXsVEoDWXRy48ba9POa5D7oIJYy
JrPMlNsY0NBX8nNQnkVolqYm5uFJGil+jHHphKNRSyZaThdja8jqgk1Ld8OYS5Ff830fUFURtbVl
bVoYVES6g5vw5Z3Czt3DpwIAC+H2Brol28OIvS18qpdcG/gMUW21SUgGnXnExxb1M4ufZYR6MogD
iT0NBrcTwuPkcqCZX34hT4reIjRTvMS8qDxLxRtnZ8BzWYGqxsJQu8GWlPM9XdZkvqoa8hNk0/yJ
rGt+6g9tWRvW4V4O4WUdr+DxpZxarkbRZ08kNs1jumsZVRWxK8Bn1kgQStXVL3JbXm7Ot8rPb55t
6ee4qKoIxA4F7lURCFRVBAKBqopAoKoiEAhUVQQCgaqKQKCqIhAIVFUEAlEe/w+MQZwMCuLRbgAA
AABJRU5ErkJggg==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2016-04-04 14:45:27 +0200" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-002.02" SETTINGS="SHOW_ROB_TABLE:NO;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 FDA food safety guidelines and neutropenic diet guidelines vs FDA food safety guidelines only, outcome: 2.2 Diet acceptability.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA6oAAAEwCAMAAACJwHwgAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///9BjlLGAAAxvUlEQVR42u2dC3QkV3mgf7VUVV3dPS1VS8KjYcaWRopNCDixZqy3
1rg1hvgMOT6HGE5OWBzDnphkT4I3J3Oc4OVkHJZdAhxvcJaXzTkB4yWsWUMwYbABq9dG3ZpRMxZe
x3HWRBppbM/ItqQqSaNWP0pS77233v1S69GaLun/ZtRVdR//vbdu/fdRVX/dGgkQBKl+PHgKEARV
FUEQVFUE2U/UitWRj3AbYYr8XuaCSQD1tra25ZWSMUYeV8sRO7WBlxUiTNOfKj+nl7ivPwkQn2xr
+1XtTokvJwPbPtGvc7y04shYjp9xhr+r7kKGKlnSS7X8s39fpKTEL1lru5aqvqTVoqptEJmaor+z
Xzz+rW/A/xkBeOhbJWNcPFzGqZ2a2sirDabMLExNTW0mpw/NX1mBJ1oAllI7Jd4KXsETvf7sxIVV
Ky/2LGp+tjM85VpNpaVZWw7/12IlJX5vuaqkVTcADj0Nvw3wARiDIdb8hdnPN0SvBHKQF4IycwqH
efJDNn7S1AQFvp46SYIYBzkr8CyQ5BeSNKx8SuCJO0H1C1I4rMdnXuLt9Aa4Lhd0Z3taJXPqBdL/
yxAHhR3Hfd4Gh3jVJ2jiBf6UJZ7ly3IDml8w3AHEcBzUsK+i53gQ1mlemnyc4GNDE/V2QbX5qSI5
ZSFBO8PG+XUlolbSET9vXAPee+I2v7iP53xJ3iipVheoqmXyG0DaugwIYO/v/1OgLwltx/3+4626
SwYgQjZPvw71x8/4jzWQ/bUzvTdD65Bv8XgbOVoX++9lDei4/2LvLXSvsdvnHDM/1ntunYawyy2U
VhF+RXP6pzALH2eHN/f8aNXhX9fjW2PifxYYbzNdWb5aj5/R3YJDZ/zH6638cvBeaIK6ip7ipFbt
yz1vBnsOkJ35A5FlzuYXlNOJ3pW0doat8+tCRoCNcW/rfkO7BtQDd325y+Z3y3xmpUfKGCU16gJV
tfTUgnWgpLOCLMh9UTnWpxo9FBlOzpImMAWTE9Cfo9iNkIbgJO3fYDoIJ+BmmEwSJxJlDh6lIVIw
0RJJanuTrzoi3weTU5q7XW7RtArm9OWoGJ1gLYAXgoojnACT02STBu8EWENklq8MBHW3m6Fzku3p
+eWJ3yqJWskTfXJsiTUa8PbVJ2jSH+rzcXa/5JHgn8C6Ed48v+6brYZPn3tOK+mhp5+gRTjQ18vZ
/ZLnTwVhzQh/3KiLqqSuanIS0bfynTXwL8BnOFjlImRgEtG0AgbIzp0AwzmjUNKZQheEtf3wz2Fk
4E5glxnx6adx++keo4aGsEfuNxwcclla2QJpFcqpeJLP8CSn7Hro4hzhBjTxa/CXZGhlF98fYW5a
2z5AAmWt/M7F1lV1tJLXS2RkSMtnINYPLRJpXqI1NQ6/hhvv+My7B4ximufXdURGwlwH3VmMDjz2
x7Sk66PnDL+mReL3zOmxAAxG7HWBA+CyuZ40HyehK9wF1+T5PRGJZCBGxjF2xxMgy0CvNbKpJQVi
gSxiYE055ThzMOLHaBRTroOaAm75Oa0leaQ59bI7dCCrbFxlJKiLry0girmltQrQc282noMNA5Xt
wwZ93Z9kZ2Pml8P99HbvM3zviN1vBT7ySoHz6z4GAz1sEiO+8cJwHy1pUOgxSjpH/U7Ca6/YlUGW
8bZS2cgpMkldhTORF9jAJBKxvLzQPhMWyVUz02RXwRiMtzNlaX2JjNN4OOq8K+OFDhqLDUjbb2Za
yOKzeWF7qyU3Z/Ca75ab01n4CcnjmcgZ8GuzvPE6poXNraaMVjakHW8O+51xLTfeyL2Vcjc0V/Yc
L5z9O9qo+O6sleEP6BU9H/1tu9/dcH27dYZjuTl0EcrZpF7SVdbazM2NvM/pl7aVlK/qklabqoZb
Vl+Yk1dJz/omZHKauKnOxHVkfqHEPkYHcP7o2zXn6fMnE88v0LLcdk4hR8f88UV7rPPLrdrcbH4s
KZFa0ePTduDsiseS62C6gFtOTg+KHxkk/Wgd+bcqs6p/UIIo+Eav/FgLMS8k6E2N6eGTi2MLOeJN
t+nzn008b8/vm1EQ5ip8loUBeptoMb7UcvbLrM3iuptsfr2x36QF8sUOO86vG+EHWUnftRg4d4CV
VOhpsvktxFrXrGspry6qipo987p+GCIbXaDeqfSHz61U7KrwXZj4y7HEdkcV0NL/14OAIHtWVTlP
eoMQoeRaTe0iV6kMjLx3DTjf7HY7vPUT5xS8LpE9rKoIsqfB1/URBFUVQRBUVQRBVUUQpIpVVQ4I
/JA/Dk3OJ//h4q9axbNDvOBXywi5M4QZBb1G/DstfsRXxikolSPfllP2F0s5rILMh3kZ1PDteSH0
PWe6RKwKTYZw3U7JnmrhwpmOapYfysZB1sI28A0AAf1FzSZR4LNq5Wu9rNOnwsjWCxkP8PwplZxU
rZDcwwB+/aWmkdv5oUC8Ggppt1c9tLxw5eVbP73ac8RhuVfChPIfBr/9+eVbf/v5jUPuDMxUtHAa
ZVmvbsDUFE2ggMTiBduhHJWbctuV1PsvwLW/8Y2mlrMZI2pOWGe6bQB//y2+BTQ/FsSUqVneFsy+
GcYztPDQpb9JP9Iy9isacPrBVZW7oisxd+n2i/Nq5U1sy7guYDn5g60X8jtd/9yUXUhnrh+eJgHv
Gh1em/niI8xnpvO1y/cf+0w1FNLeq94HqyBGUpxhvEctLv1eiZpQNpMWh71wdUoQmHFlgGm4Cu8k
MR6xDGDqbxdVy27T57NsSQ1bUMGnbjPHSfZCnj8sneKFrKzblzLbSsv+cnuwPDMbxmY/z3tHNgo/
wl5k9IWThj1tUvSGWHzLTrI8mL0kK4vq5wUxP+U1eD/EyN8acLJRfsMOl/Zzt2vp2hn9AKyOluyS
mnkvyCKn6ja6cdFrmbwJMNcJGVin54Mk37IOdXrj3jDgDQ1GElAVCBnICCULqXI+kL1Cs27PrNsS
a2RAnIA0HATm9CiXhXfowg72+0JyZKUqyuix73bSi0O1TEegrtsn01cjVXiM2WXVj/vOMIO+2Uus
S4abnJdT9lzvVyy7zfnX8mwd7/X3bNeWRxztngG1+53r4wHfUCto9qXMttK0v9weWp6ZDePyXOZi
34mNIgy+s0eFmZ7Rg4aN6zWBvhUW37STLDNlZi/JylL/VGa597G8EHeRy4oj1ZGBl9uM8lt2uKml
9EoGct7aqrsLfr/0OZ/19j1ztNfH6Ta64d4fmQZwUEPfjr2LNOIJnlwKHtWjipOazyr8qnrmcSNr
sFa6SeV8PVJbn3dWt2fWbYk17tZeAV6FJE+nc+rdcvqC5uOFV6pxrro0Cr2n/Y4+QICJXwC8Qa6M
P2HNagomg8wYNMnmK8/lxpiehB9adpvJxjxbx+mJ7Zli0smECA9CIxxLwcQkNTDX7Esppv3l9rDl
OXkk+DGb/VqxHB0j+XkQHjJtXJ+xcqTbSZaHzV5yxRMMava2dmIvq+vRV6Nral+0xSy/ZYf7KmdZ
mVrX6MtNE5w9u87M080zoydXhCnDRrcbOqctRYcOkeYjFvX3HAHR720WjvIPUx/LuLAK4HrVvg0K
OTW6khqdMuyZdVtiQyE7Omg11ywHuv+cFPLYUaFNaKi2QtpUlbs8Pgrdjj5gAEJdpB+Lrc6sjtI3
5rL0mLZGWgG6Lj/vjBEKwYhlt6nZkjrKSgJsy5wqQpgc/bt4KnZHFu6808jLAPMMxHpvatn+21e2
PEs3rv9CF14qR3eMpuT/MfpBoDmiNq5dRo4Wo32PHSo/RyP0/Ogp/9X6hXzTdg7q+vkQ399IGk6z
/NQON2Sc8PzM/oSo4Fv27Dozz+rR2z8QoyJY/rNWLgBeG0uEYgCJdNck6XUWMhdSUx9KfII1G1BF
BmMvQwP5K1nIkNDfL9DrkxRynV7ZViEfjF9Jx2ogMcxNwNdIIT+YmksHWZMZraJC2h/WhBYu/1I3
iddtOqOaAR838GsDvD5SkME2IAwtXh4n5Y4aJprMsFG329TuWmlOpg1nfAdKHhIGbiHzJGZR6piZ
mvaX28Nmn7kMr5YzygvxA4eJCuXbvZp2kuVWhmkvmYBXCww/6khvQC15UuTPXn65xHy4azQT4/K6
GgdyUoilqCiW/1G71WYokU5mbePndj40wWW1vFxfParaElNjLaULqaZHY8m4Yc8csxeSW1YT2Vpj
xA/QUcf1zTJF4OGGalRVbzgU+iEd8YBs2HSmoYPOhn5M+gk2Zn8c2sdh1BYjGfonEuNuaGrV7qm1
k4Zft9sErajMAtC04TzRsQPfIpka6Y1OaVam5oMJ2sab9pfbQ7fPpBJr4YbxcqJMR3s6pnPsXvUc
rW5iGMFbKXsKpsyR3mCW/Bsge1b5dTtcW7oOPjfw+dyuJueCfrz/nG+gzsg/qb82M4zvHlUizbQo
zIjMkjP9CsTUu5lPNCUnw/4quY65AW6DQjb2+c4MhA17Zt2WWAsjCs2hAS8pa5N2eSZFGJ1hmuGN
fUoOVfijdFtQ1StjCf6B+LPwRPSIYdO5em75IZrhKIy2MCU5nzh53jLo+3n8/dyJ+AL0xpZ5rRNd
GY0YdpvaNXz+ZOL8AiiGDadneWx+u3NVCN0LpAsjeWkde9bwoLaVlv3lttDtM6kNoy+2+HRZOfLC
w6Ecu1ca37KTLDNlZi9Jy+IbXfxAgRtAURA44ASIvmIrv26Ha0vXwWl4IE9Q1H7Q9L/PKoow1Kzn
f/XsZz1mmJ+85k+OK7BU21p/fooEhRYQfcdYXoZXW+qHq8WOta7Ap4cc95nU42flE2e7mnR75nlh
pdYM4/csJj5CGtZvL900TGawI7Wz4G1lbe7cwicPJuLPVkURy7GskeFQ34vlWzsXt9vc2KQU2QKb
t8NtvpLakTBVzczR5I6EqRbKUVUh6/FtYo5Z3G6Thwwq1s6zeTtcfxlmtT7/rLtPS+CpwR0J4yZV
RRAEQZDd53ddmOc67FWRfYgLL3s0gkMQVFUEQSqgqk0+gf8Ee/0l6uP5gPEikN+wAgxzdN0068Fy
0zbXe3TGD3l547iYfSGCoKpSlteCiZfYGP62tYv1XZo9jOrrNvwjb/78pqTtc/c39m4vaWf85b7E
JawOBClDVVPp2Svag89kuuUV/RHo++wdnw+a2bKkzK6R0w0j+VPQEA5BkDdsLJtFntc+DWHYBtrd
zfVDtfjG2p38ALwv5FzfUrONFbJQH24g4bCuEFRVk3Zt/WG2p72+HH/N5v0K/D7daHaNhl1r3ZeJ
VmdArTNsLK/0ztR3M/3TbQMd7ub6oSy+ac/KzCwd61vqtrEeH6zSfzipRlBVrdljAvQ17UYSoL2j
vNxo71bhm6z7daw96lmT10a75XUPrPwus7Hsh3+/+gR7zU23DXS4O9cPddqzOta3TGu2sX+4JqtC
Rlb/EOsK2dfYvq0ETVcG7tc+KdP8yMC4sRpDm/XFGvm7r66Rbd213/0uPLeme3h77uuZbbmvZyYt
/ebrk9+/dmrhwqGW8Smqf5dowItrDvf5y2vp2teXdIk1193/ubbX1vSjS9f+ET0iu+R/7bV/9PW2
6fV/7fn4e+Lk7zs1WFnITtE25b4823rV+BV4QbNFlZc8ZwqZTNygfWHHaZfpgXT0QixNtrqNpTJz
5o6JhObFAjrdHeuH1jrW7sxZ35LZxtaBGJ2KitCI1xeCA2CNEzXTVFHCYXgcDoiQ/01N+VPwFOtH
NbvGDs0wcgb6vxD6fD/Z6jaW4p0L/1FTP9020Olurh9K4ztXtHQceTXb2B9AHxfi+7CmEBwAm/R/
v62tjY49h/uv0ffsA+C2P10//xV6ODMR/eLl574+NfEQvc976Br4TupcC6RXDkylvncIppLz/527
7KeT1Zn7js+8sVDrdF9641rhRSqRxp+571uZtxaNAfbMfRcmZhdBGwDP3Jf8h7eW4I+fgTfTvhb4
5texspD9PADedcsaXD8UufqEI6iqG4LrhyKoqluhbrcTTGvzXQRBqrtXRZCrylKeS9AdGceXgBAE
VRVBEFRVBEFVRRAEVRVBkC1gf1ijSNZvDnZHRfuIVMHNVaYiudiW0C1G1qsiL7LD3fI2HaQi9Veo
JnPSoJHzJObUvOTcpc/HJQXwIcKuqyo7/0o5VxH5K7i52ppaiVxsS+gWIytFIisFasDhoEgbaWrx
NApIdF4OSt6upOkqcvUGwIqiODZ65ShG9RQEG9edbB02474VyZuXlRdDcWGNF/pol0s+5OXoVSXa
KCsFOs4yGk4cB+0c0tYbww3UR9pkw6rY+kwpz1lxX/scKdOt2lW1eA0rmhoXvx50za6G2WqVCd29
8SGrpZ1pM6WytFByZ8+6F+aqFegIdrc3Uiowc9qW0IrkqGQl7EybaRtXFe+6UUurXlWrtyWVqk7o
Lp8qZYcbBqVwbSvYne4+npxOQCo6iDP9qreS9vPotzJNnyQVamx0Z7z1e/V7VX2mYm0kx3165pwX
pgrGQxXJxbaEViSy85wrkhVQ2984Qau1daRRQGJ+41wkLlJpNmEEh0OePU2J6i1d8y67LvaBERxq
6l7X1X05xt+TvSqC7AH0XjUAh/+fu3pVVFVkH3Lt5Vn49ZUlV+UZLWuQfYcc+L+zAP96kW9yqarK
AYEf8seNQ/3NyCafGWDEDzmeIRHiAZ4/pYIapkAD/zDAQyN6+Nv5oUCchvWGXFutevl2GbqoLa2P
bF7KgTDN0xA756d4PsDqS83yQkAGiW8gAZIbyM2Tw+ozbEsv7tfX11UF++uxPuMgTp31Gg+7bync
kRZ9zbQ3/y0ruyfbtk92H1peuPLyrZ9e1Q/1T3X3HDa/bnzR2tU85bFL6e90yRwspDPXD09PTcFd
seG1md/RFr6Z6Xz90v3HPqOSsP4P/exzLlVVvXy7mmazp5uc30PLc0JfTsozX6M+jwze/2R2IS3V
yD+48Em6jsFfiPPc8VOZbOKjz6v8RnLz5LD6jNjS+589//y2znmiqyEjPFXbQK9x8F3qnLk+/gqp
cf3D7i4i+PW3GvXmrFH5aoJzYa96H6yCGEmxHpM1lQ1eMc6zVVDZuqcC3dXXStVoT5+BDMiT5Oeg
9oTtUS4L79CXeTvYL4bkCFsSrnbiqFt7Vb18u8q7WXP5NFyYyE35w+v0V4TOCUgTv4lOYE3tl2By
EgYhyz0KjcJGcvPk6FjprYE4R/dUezvxPnNpIc35GuDcWJ+qsDwH83QFJPI33/hWyhd3n6p6oNNU
Qsb6T3vDtnVP02xXWytVIw3vhLvpyjVZouVJ3j9PzsTdcvqC5uuFVwxJE6C6VVX18u0qY5fp7xEI
hXJTvoOt7H4X9aG5Ipu7wNg7AnerIP/ehY3k5snRsdL7Aow0UVX9is8+E1g09up+qunzyj1+11Vr
6D1vkKsUbH+XeiXXqerSKPSe9tvamGkvdLMd27qnKx62VqrGGmmZvCB20AquWQ50Xwei/9hRoU2g
ixtDP9iuA9eqqlG+3SQR0to3yGsk7rX7sCVuH9VONeGbcMwvtj1+lG8oLTdPjtmeGke9o6dvrFmF
pqftM7lloxNtFv8d28aWe7v/3G3VuXaugJvrVJW7PD4K3bfYWqAu+Lk2D7daX+mv1i+YyyDTen0w
HkzHaiAxzNHR00Lmg6m5dJCpdRTMmg6Ba1dH1ct3FYjSn5oSPjFTt2Ka+8czFzJzqYupraVgHd3a
d+bFbB2k7i+s8AFtk+bugK+6rToXQy3a2Nf8e/vrS65TVQgtXP4laWJiRh8oy7q3bd1Tfa1UjRqi
jNyymsh6jGOAjjqub5a1UzzcYASUwbXYy7e7DIGsFlZVfVVaj1lDNXRviJ79Fa6vZb3cFJyr21rp
qXSuykPX6TC7U5FDz42Ws/ue9c2mrtPHvnSuCs1HV1rcN1f1hkOhH0Idqa0Z7XlT60tk1Bu1VkGN
gWyslapPWkibLgrNoQERfPc0ddAbT5BUYHSGSRX5T8mhMJvuHHDnLQhWCq18V4EYjL8NCt7P5aC9
g/jw0N4Of0tvAQrQMQ4/pmd/FWLNG+iP9XRFl+NMj3jXQrKJeEYiEXp7wvE0hhzoziI/1g6CC2t0
6dc+wLZUX7/1lnvei7RV65WxBP9A/FlQYh/TFKv2vWd/AQ9HD8P0+c8mnl8EX+ww+EYXP2DG+BL4
wO9ZTHxEBv+3l24aniZj5VoOhFZ2ac/+49MHE0QeYXX3l7HaKfTyXQWm4ycTw/OFfJ6JJ5Y752Gu
M5GIH6MOc8PLJ+PkohvxcCAulq0/upy89J6L1y9Zd5FgpGDkADe4cn7ajVU697nD2s413ntd9MB/
Wy8Wyof48sb5DckZ974EsR8Il/jA0MzR5FajVi39Y7Pw/n+edtVFub13gEOplbLCeb/6UVSHakbI
Fn92HHiq1MrVfNaTdl95wz8JriVcNinD1/WR/TiKcOFIAF/XRxBUVQRBUFURBFUVQRBUVQRBUFUR
ZK9ie4vIthAfOyx70bDq+ZZh9X2YFj+Vi+y8qrp/sSCl6oqg4ApMSAUHwGxZVfYRfX2BVYczWB4K
FA6JIEgFe1VnTyDlrkVuPzD2WRipalYtR5D91avah8R5TopdJaUNQl+VuWG1jcrxIkMq1KsWu8yU
Etdf1SwvJVWXZlRfjpA9qaqKY2U+qVQPWh0D4OobguOkANmNAXBe96nYl1mtvlEejn6RfdWrGoNZ
esPINnyzj3Fzxrss5F5dX3WP5QhxK2iviuxD0F4VQRBUVQRBVUUQBFUVQRBUVQRBVUUQpDpVVbH9
OvfKRCnwykS5EpV8X2WL2UAQ7FVLIxVSwO1ERxCkpKrmWqzaTVIVRTNatVms2oNZ4Zn2KXkSc+Ma
InRbWJs4MH3QHBbZ9xR8XT/fYtXapf8hx2LVMlclcZRCPaQlMS+usTHC5aeKH1NAEKeqKuWNTe1m
Xfn6Q7VVsh8VFSYVFCHlBUAQxKmqkjkM3Vh7lTLnpIV0dcPBrLKtOS+C7JcBMEgles2CHpvq/5xm
sGUFwP4V2e94Nu7YinZxRTrWnH604FcQFFsMpZB0Jc8HO1YEe9X8QavNYtWcUmq7ug2r0xDTdqTr
qZLjaUoE6ysmdGttjLBSXgA0+0SQrdmrbnAztsx7tflKjSC7gxvtVes2raYbzhxR9xCkClRV2oEQ
jnCo2AhSBvi6PoKgqiIIgqqKIKiqCIJUG8XXVzVc9Ucqm7r9Y38D34ieI8F6Q79gqtZzWv2BrH3h
V6VAjJw4IOkOeD8a2XOqWsp6ZZsXvFJCZaQC4i1LGqcFjuFSOo7xMrPdmgdB9uAAWLEZjerGqTmm
q1BktdV8w1JDSI7Fq2baWmZDIG2+YUCQPdyr5nRP9k4px3QVSqy26tQUh+Wr3b6VOuUPeguPa6Xi
elg4Ts5Lj6i5yN5U1Q36M8eCcE7b1LI7QKlQLyiVGDvnLpJjBJeKiUf9RPaBqupdVfmvyCsFd/OP
lS2MV6W8ieiGQ2LUUmSfqKq02b5Jcg54i6qNVIbCb07PFNRNZH8PgJUyn3JIipTbNSole01rppvn
vRWFkzbfTSPIXlFVyzDV8VCkqIUqOI1aHabkjkg2i1cmV9EemBZ4SqqHtCaplpyid4mKxUHFRfYE
7ltfdbOqh6qK5IHrq+4GkoKaiuxDXPgOsFTB0AiCqoogCKoqgqCqIgiCqoogCKoqgqCqIgiCqoog
CKoqgqCqIgiCqoogqKoIgqCqIgiCqoogqKoIgqCqIgiCqoogqKoIgqCqIghSlqo2+QT+Eyrdi/p4
PqA63UANh8PNAOEwO9I3Rky7SEkQjGMSyhHQicNXlzHih1JRID9xgxFfUdmwscyy0t18phCkAqq6
vBZMvMQ+RXTb2sX6rganG1xD/tYKC7mxx3603D/zernJRyI5Mk53b7Ukp3u2cx62ni6C7LaqptKz
VyBD95Lplle0PcuN/I5BWus1fayflYMCf0omOzzpUgCyAh+kztwg3BkC4ldvSg7yAvEif/VhiYRj
fbRPkLSuSD7FC1lZkwGCtkn6hSTx83uNuLTLIn+qX2hgvVeT6A05/XQBoIoCL4asUskkX/5mQ6ae
53BY8vENDYIwoufbnq4ZxueDuI/nfDQrkiDGRTKqUMNeKvQUScQ4puH9qpFWUCYDBE4/RQhSoblq
OwyZe7XmnhZmDZ6Gdbbj72Ef+m47/rPAeBtTYohAcOiM/zjVTpUe1R8/4z/WoEtoOO4XjwehdhVW
ia+fCa7r8elddNt4wDfUymQAbQvoxuvrv5dsnrqsxTWVvq7b/9dsZ3apL2nIBb0lYTEhKKcTvStW
kVqHfInuZUNm6/EzWp7XJwc616f7b9PzbU/XLNf8a3DLfGalh7Ypa2d6SWugwmNUq0me/Rd7b9GP
SfhEd72e1uLxNljueTPYcwCvLaRyqtqUgHP61C0BPtNNpNt4b81gTS/tRKcn2OVK1Mo7ASkj7s3Q
OWkdpSE4CUn9IAmTF4i/R42ro5n4KktSgMlpvTOHiUm94zZRZuFRsnlXSIt73HD3wkSvFoAjTYcu
10nySPCA1qQY+ZrkIklDZgaCWp6nWogqtpCAjnyzMGa5ko2QPH8qyIb900HofoNE/xM6hqB5bokk
9eM0vIuLrOhpJUn0dXj76hMpvLaQHcX+df2mK/33n2B7zYsD4wtOt9BvjSX83b9UwqT7CUczZENG
ugBRqmTUjR9g7voRN0iOYmmyS/4L/cwrOzQ89Pyx88eHa/RAmi8/QJsGNax1irq77kdUut9IDlhY
08eSaw9OuvDOMd+72ZHm4JTL8szyBXaRphCwysUiPvPfDGkQHlGF7MXrPClLqHZspcCKEs2EEv0Q
8yl4cVUvLv+6fvwKvKBpqrzkObNguJ3R3FahO9wN/4H6ylr4WngiEslYgoh7jXFU6ziiBx5oBO/I
VDRNtlRdTDE1VEyJmR2LG2MDaxLWiJXvp7MCr71iDzIK9hgsz2nnCXDkNKdcJw1pqkzcuYFfG6Cd
KnRoQrVjwUzBo8WUZ3453L+C+oBUSlVP1EzL2p2ex+GAqO3dXDMtar4qvBB5AL5CZ2Qd2u0lHsab
w366FyUXKzlqB68hy3Hkhfaj5IK+BP1CiO8nWzYAbm81fWfCPiZDU2FH/lhcnujSTBMbeHY8nuMn
GH56zLvhhna7AB7a1bBoy5ee55yc2tJ1hklr0hpfIuPtH0MXMM19HDpmiFDtOEbD+7SYR1Wy57uz
VoY/wGsLqZSqpvs+HNYeDv5Z/7v1Pa/hJq/Dm+SKXiUXdN2dwir1mx4+uTjGOt+Ho4dh+vxnE88v
GrKmz59MnF/QD6Y6E8fOL9JF52rpD7snNS+s6Petps4nWseeZTIIvthhR/5Y3CVQYh/jaNd+LuEh
Su2Uq/v5o2+njr2xGx3KPn0+4Y8vmUdmni1/lm9buvYwC7FW7e6X57ZzCnijMNqi5Xm5dWxJP2bh
FzVZx/zxRViML7Wc/TJeW0jF5qrVj+CdOvC+s8ndn9qw6agMh/penLMNv3OOEZyroqrqhFKrUPtc
166ny9ek2V0kj8/eY+ceI6iqqKoIgqqK9YbsA5byXIIuKwFa1iAIqiqCIKiqCIKqiiAIqiqCIFug
zravSNZvDnZHBUAqtrm6sDfkpQpIlXY7sl4VeZEd7pa36SAVqb8C+ckVQiM7fJkwRw5M0fa4CuBD
hF1XVVYVSjlXEfkruLnKSFBG/reiNVsu2hYjK0UiKwVqwOGgSBtoaoE4RhrOWpTyc6AUvAQkNCG6
CqpatOOUbLUmlVKUq9+x7oUmXily+SuVUQupvNNope6uc6zluraIu3sK41BViTbKSoGOUynnhEio
qZXTnXKvqs2fgMIVV2DgLrn6bC5VZ9ey7V41r1SKpsbFrwdds/cmylWLvLlrktZSuW2mZAyZClec
1kpLxabaOEGtVlXdekewB7o4pgBXI/LW5upltpnGhEYqVZ1Fp9p7uWHeS6pavbVUkZxJVy3yzs1y
EffjyekEpKKDONNvn7WnLhn97mahsTmoml5Vn6JYG3tbrWi3HPLC7NUx8LaKVpHIznNun1Jq+9KG
IhWpYMUV83U0zkXiIpVmE0ZwODvZ26MHaYs1747rYj8ZwaGm4kgfR8Pu6FURxL3oveo71qHmFXf2
qrUi1iKyDxAIiW8IU3Nz6/7m+RcvCwL2qghSlchtiVl9t7n7n0Kuy79trioHBH7IHzcO9fVCbWun
jljfutY9QyLEAzx/SmWrrxLHBv5hgIdG9PC380OBOA3rDbm2gvXy7TL+sFYf2byUA2GapyF2zk/x
fIDVl5rlhYAMEt9AAhT99qotvJ8X6OJ1kpe/fUSrz7AtvbhWmSopunU9APi0Sm/2CbyvyUgz7JJ1
ZeOBd04bmgqzP2o65bql+mwD4EPLC1devvXTq/phG0zRTc/hKSPARWtX85THLqW/0yVzsJDOXD88
PTUFd8WG12Z+5xEWZqbz9Uv3H/uMSsL6P/Szz7lUVfXy7WqazZ5ucn4PLc8JfTkpz3yN+jwyeP+T
2YW0VCP/4MIn6SIefyHOc8dPZbKJjz6v8kXFWuGD3Qs//rfZ1dBNcwuvf0dl9Rmxpfe9g3d8lVTm
ge6Ft279L8b1oAZ6tSuiZu2A/J7JVWmApTmlXyfVjVr/1TfmABr1ZqwxmYwcEFdq3dqr3gerIEZS
xlqmAA1eMW5bO5WtQUrbY1HvNaE9fQYyINOF3A5qT9ge5bLwDn0WcLBfDMnaEmm1E0fd2qvq5dtV
3s3U42m4MJGb8ofZGncidE5AmvhNdGrL9H0JJidhELLco9AolCiKET4Dc4OwDumowmUShreV3ho8
QDerMCdaq1+/z1jYJ5GeuwZqSEiWphtoFoXX5ulaSfN0vSR9O59a9o24VFU90Ck68r7+094wW7a0
3lqDtP6pzHLvY3qANLwT7qaLvWRJtSZ5/zxpvu6W0xc0Xy+Y6zxNgGtXBtbLt6uMXaa/RyAUyk35
Drbgz13Uh+aKbO4CY+8I3K2C/HsXioq1wgvQlAQOPlzjEx4yPzpupfdp+KDgk0n1jozAF8wRpLnK
CdzzW6OXNGnDLqjBpPiry+TKhPy/S+/yJl2pqkuj0HvaPjeZ9kI32zlurUG64gkG2dqnWuvbSBRS
7KAVXLMc6L4ORP+xo0KbwBZB7gfbDNW1qmqUbzdJhLT2DfIaiXvtPv1sHKOdasI34ZhfbHv8KN9Q
RKwV/tXRG0/GXoWJ/nn/k0es9tRI7z/HvuzrOQKKcPp0tNfwXuZMQX8z3ndEk+YKso3F/Q65UlW5
y+Oj0H2L5RDqgp9r94e0VpzNd/5q/YJZS7ReH4wH07EaSAxzdPS0kPlgai4dZGodtRZXCzmXRXQT
evmuAmwZrZoSPjFTt2Ka+8czFzJzqYvFVmG2wkt9L/51P9XR5ASs5qe3nOYmifu16RfPDNxaQFDo
AvGNuaUGxdRzh7Vxb85f46GXUoorVRVCC5d/SXpKc71StnqpFshc1jQBr1qToRqijNyymsh6jGOA
jjqub5ZNcHi4wQjo4pVd7OXbXYZAVgurqr56rcesIbbu7BA9+ytcX8t60bo2wvN0rrpq090C6WXp
jFYsPhwy06x+BhOBw41sfgr6PJVujzyXHHTTlWi7CL3hUOiHUGesVwrQ+hIZ9drWTqVrkHrghnEz
Rh2pT1FoDg2I4LunqYPeeIKkAqMzTKrIf0oOaQuPHgDOraqql+8qEIPxt0HB+7kctHcQHx7a2+Fv
6S1AATrG4cf07BP9ay7WsFjhORhJEoUX4Oi/QDonPeItCk0iiKR6yVy1FhxPY+iTN2Gmg1wNZpqu
aHATaXNaQPUUmr4VWB5015Voq9YrYwn+gfizxnqlpPF+79lf2NdOpWuQ+kYXP2DG+BL4wO9ZTHxE
Bv+3l24aniZj5VoOhFZ2ac/+49MHE0Qeu5dY51ZV1ct3FZiOn0wMzxfyeSaeWO6ch7nORCJ+jDrM
DS+fjJOx3IiHA3Gx2D1gK/xifKhhbBGWzh8b6lzNT++52qX6zilYfNfQ0NhzdP7j4EBt6/L5RTNN
tyhrzdx1v2kcNP166l7XdR7beltJPsQvlRWwITnj3pcg9gPaArKFmTma3GrUKkM+ukzfgmj2Td+5
71aCC6VWygrn/epHUR2qGSFb/Nlx4KlSI0U+60m7qKDSynpgMoSLNiKIS0YRLlRVXAgDQVBVEQRB
VUUQVFUEQVBVEQRBVUWQvYrtLaKclbFsi/Vt8ECnar5lWJn1VbebJXwchuywqkqu/4BoRdZX3Z6m
SvhVVqRyA2BFUfSP6LO9HGewPEiYgiGvsm4gyN7uVZ09gZS7Frn9QJFsi7BKVbNqOWoqsr96VceA
MtdJsauDtEFoBL8+j1SuVy12mSklrj9caahIY7er66si+1ZV2bC2YK8pFeiAq2DwWX3jX2y/kN0Y
AOd1n4p9mVUc5eHoF7mqvaoxmKU3jGzDN/sYN2e8y0JiBwLFzyWCbBe0V0X2IWiviiAIqiqCoKoi
CIKqiiAIqiqCoKoiCFKdqqrYfp17ZaIUeGWiXIlKvq+yxWwgCPaqpZEKKeB2oiMIUlJVcy1W7Sap
iqIZrdosVu3BrPBM+5Q8iblxDRG6LaxNHJg+VWMOiyBXi4Kv6+dbrFq79D/kWKxa5qokjlKoh7Qk
5sU1Nka4/FTxYwoI4lRVpbyxqd2sK19/qLZK9qOiwqSCIqS8AAiCOFVVMoehG2uvUuactJCubjiY
VbY150WQ/TIABqlEr1nQY1P9n9MMtqwA2L8i+x3Pxh1b0S6uSMea048W/AqCYouhFJKu5Plgx4pg
r5o/aLVZrJpTSm1Xt2F1GmLajnQ9VXI8TYlgfcWEbq2NEVbKC4BmnwiyNXvVDW7GlnmvNl+pEWR3
cKO9at2m1XTDmSPqHoJUgapKOxDCEQ4VG0HKAF/XRxBUVQRBUFURBFUVQZBqo/j6qoar/khlU7d/
7G/gG9FzJFhv6BdM1XAxl0y1L/daeB1V+7NXRTIc8H40sudUtZT1yjYveKWEykgFxFuWNMaSqYrD
r3Qc410nuzUPguzBAbBiMxrVjVNzTFehyGqr+YalhpAci1fNtLW8hgAt4BCkxPqqjk4px3QVSqy2
6lQrh+Wr3b6VOuUPeguOayWHa+7AulAcxWGmh2qO7FFVzRmclnLLsU0t+30GqdDoehMaZb4yVSoO
vjiM7HVVVTZ7pSsFd/OPlZ2aB5f1ZiMOnJG9rqrWG39lXunO4alSVKmkMhRe2pQiF4mDOorslwGw
UuZTDkmRcjVKKdlrWjPdPO+tKJdUxBE1FdkHqmoZpjoeihS1UAWnUavDlNwRyWbxyuTqDz8LPCXV
QxZSuKJ3ifLilBCCIK7Dfeurblb1UFWRPHB91d1AUlBTkX2IC98BlioYGkFQVREEQVVFEFRVBEFQ
VREEQVVFEFRVBEFQVREEQVVFEFRVBEFQVREEVRVBEFRVBEFQVREEVRVBEFRVBEFQVREEVRVBEFRV
BEFQVZFdQXGJzO+5JJ92oaiqCIK9KoIgqKoIsq+owY9vIlU+X9vXWPpZhycDqciVtXPqv49l4m0l
BMG5KoIgqKoIsm/B20oI4grwthKyo1gL6hp7W7/dYlucd4fv2ez4LSB9ie9t3ldzSMkVhqqK7PQl
a61Mz/52QNZOPwTa8WdKSm6Gty8lTxjOVZGK6261dYIV6lMrLAVVFakoUtUIqZi4nRK4gRRUVQRx
BaiqCIKqiiAIqiqC7CvwYQ2yk0ja00BFMvZ2RJa7Cr8zUvKE4dtKCIIDYARBUFURBFUVQRBUVQQp
hYynoDB4WwmpIGH6E2Gb6KJIfqWbXthAF8XkxlIjG/hYAche8dD27MUWaPZCv/WRj25f7IbZ3BL4
sAapJBFzMzJEdVWNX6kpHaM3Uq7QMn0iZWUv2eAnbcjpT4zthFgcACMuZnC4noxuM68Kstmfhetv
50eI+vq5gKo5hbV/9beDLAo+EjKc5P3EL+7nfXFyJHn5EAupivw3tPGy6G0IG5GZj58GAdnH4uvO
Wjzi5i/Wp4v+BAlwn7KqBVD9guQQS/IjgZlX3dmRf+obYLnV3QG8cVC9qKqI23R1gCgEH+I7bG7f
Hn4MoPFVdbbR6qxId1X7bXjMm/ZeS44feYMnfjcvZOZPkKO1y4FlFkz6p/o/ZjuPC5fXneNE/o15
6r6Ynrcmd1o84jZXdMIn95Ps1YU+r2Wv8cmZNYf34yJzIHnlG4vmv47LPFlnugMIS/CcgKqKuGKy
Gg7bD5vrgMtQV2DuU6HBCYB0I4hpR6yJEPxwEia66Xg4NJki3ROnBZkOyQMsRKZzNsV2nrgQmnfE
9U6GfkE2f0ZinDAdtXhOt0LZ4yGYYXvpYGjaEfKJCZbO7zWCbOU1N//eSQgKpjsAdwf88Ec4V0Vc
NFc1eq6DXQBROWTclAkx135608kRjrhnQxDiyW4XhAQtyIgZgTBg7I2EgIOcyF1E//r0GKZAyHUr
kL2WLnhMlVlgkq5Di/V0JohjLEeslf9+krZgy+bcPX/T8gD2qojLGIlCBx+JRLiOHI8YcdT6MttE
MiaDXMOcZD2I6ohjBPXIRizDxYqRKZpQAUIxED0kgOdJXUrcIdZjiU0XFRslgbJ2r/8lcSFUVcRd
JIeGYZ72k/x8TncmzIPkI9f5iNxqKeHnRej4PNm2Qjvpp1IqhES7NG68WbtfkzwKraSnjIVYZCpt
HOjeF3NjUJkF3ExNTSzAI9RT/FMmpQ1ORM080XTamVg9rw4st3QHjDsU+U3vDwBVFXHXlLV+cVAW
6Qxu0ptzF3b+Oj7lB1gMt9TSKdlB5tjbyKd6ybaWzxDVVuqFZMAeR3xwSfto2C8ygodcxP7EwVpd
2h3CQ2RzrIFfeS4nF70F3IzsJRZE+WmavQl2D3h+VaCqsTjUoosl6Xxfy2syV1X1/BNW0/wdq472
qT+4Y+cQX4FAqlrHy3h8GUqtVCLpZ+5IbFvGTPsKqiqyL+AzGwQIpmo8S9yOp5v1rvML2xdb/Dku
qiqC7FFwroogqKoIgqCqIgiqKoIgqKoIgqCqIgiqKoIgqKoIgpTm/wPWfqxkE3dXhQAAAABJRU5E
rkJggg==
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2016-01-28 12:07:32 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2015-12-21 11:28:06 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2015-12-17 12:50:05 +0100" MODIFIED_BY="[Empty name]">CENTRAL and DARE (<I>The Cochrane Library</I>) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2015-12-21 11:28:06 +0100" MODIFIED_BY="[Empty name]">
<P>1 MeSH descriptor Agranulocytosis explode all trees in MeSH products<BR/>2 MeSH descriptor Bacterial Translocation explode all trees in MeSH products<BR/>3 MeSH descriptor Immunocompromised Host explode all trees in MeSH products<BR/>4 (agranulocytosis or bacterial translocation or immunocompromised or cytopeni* or immunocompromized or neutropeni* or leukopeni* or leucopeni* or granulocytopeni*)<BR/>5 (1 OR 2 OR 3 OR 4)<BR/>6 MeSH descriptor Diet explode all trees in MeSH products<BR/>7 (low near bacteria* or low near microbia* or minimal near bacteria* or minimal near microbia* or germ near poor or neutropenic or cooked or reduced near bacteria* or sterile or clean )<BR/>8 (diet* or feeding or food* or water or nutrition)<BR/>9 (6 OR 8)<BR/>10 (dietary restriction*)<BR/>11 ((7 AND 9) OR 10)<BR/>12 (5 AND 11)<BR/>13 (dietary near restriction*)<BR/>16 (12)<BR/>17 MeSH descriptor Bone Marrow Transplantation explode all trees<BR/>18 MeSH descriptor Stem Cell Transplantation explode all trees<BR/>19 (bone marrow transplantation ):ti,ab,kw or (stem cell transplantation):ti,ab,kw<BR/>20 (5 OR 17 OR 18 OR 19)<BR/>21 (7 AND 8)<BR/>22 (21 OR 13)<BR/>23 (20 AND 22)</P>
<P>Adjusted search strategy used in June 2010, October 2011, and May 2015:</P>
<P>1 MeSH descriptor Agranulocytosis explode all trees<BR/>2 MeSH descriptor Bacterial Translocation explode all trees<BR/>3 MeSH descriptor Immunocompromised Host explode all trees<BR/>4 (agranulocytosis or bacterial translocation or immunocompromised or cytopeni* or immunocompromized or neutropeni* or leukopeni* or leucopeni* or granulocytopeni*)<BR/>5 (1 OR 2 OR 3 OR 4)<BR/>6 MeSH descriptor Diet explode all trees<BR/>7 (low near bacteria* or low near microbia* or minimal near bacteria* or minimal near microbia* or germ near poor or neutropenic or cooked or reduced near bacteria* or sterile or clean)<BR/>8 (diet* or feeding or food* or water or nutrition)<BR/>9 (dietary restriction*)<BR/>10 (dietary near restriction*)<BR/>11 (6 OR 7 OR 8 OR 9 OR 10)<BR/>12 MeSH descriptor Bone Marrow Transplantation explode all trees<BR/>13 MeSH descriptor Stem Cell Transplantation explode all trees<BR/>14 (bone marrow transplantation) or (stem cell transplantation):ti,ab,kw<BR/>15 (5 OR 12 OR 13 OR 14)<BR/>16 (11 AND 15)<BR/>
</P>
<P>[ti,ab,kw = title or abstract or keywords; * = zero or more characters]</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2015-12-21 11:28:19 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2015-12-17 12:50:31 +0100" MODIFIED_BY="[Empty name]">PubMed search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2015-12-21 11:28:19 +0100" MODIFIED_BY="[Empty name]">
<P>bone marrow transplantation[mesh] OR bone marrow transplantation[tw] OR cytopen*[tw] OR stem cell transplantation[mesh] OR stem cell transplantation[tw] OR agranulocytosis[mesh] OR agranulocytosis[tw] OR bacterial translocation[mesh] OR bacterial translocation[tw] OR immunocompromised host[mesh] OR immunocompromised host[tw] OR neutropeni*[tiab] OR leukopeni*[tiab] OR leucopeni*[tiab] OR granulocytopeni*[tiab] OR immunocompromized[tiab] OR immunocompromised[tiab] AND ((sterile[tiab] OR clean[tiab] OR low bacteria*[tiab] OR low microb*[tiab] OR minimal bacteria*[tiab] OR minimal microb*[tiab] OR germ poor[tiab] OR cooked[tiab] OR reduced bacteria*[tiab]) AND (diet[mesh] OR diet[tw] OR feeding[tiab] OR dietar*[tiab] OR food*[tiab] OR nutrition[tiab]) OR dietary restriction*[tiab])</P>
<P>[tw = text word; tiab = title or abstract; mesh = medical subject heading; * = zero or more characters]</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2015-12-21 11:29:31 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2015-12-21 11:29:17 +0100" MODIFIED_BY="[Empty name]">EMBASE (Ovid) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2015-12-21 11:29:31 +0100" MODIFIED_BY="[Empty name]">
<P>1 agranulocytosis.mp. or exp AGRANULOCYTOSIS/<BR/>2 stem cell transplantation.mp. or exp stem cell transplantation/<BR/>3 bone marrow transplantation.mp. or exp bone marrow transplantation/<BR/>4 bacterial translocation.mp. or exp Bacterial Translocation/<BR/>5 exp Immune Deficiency/<BR/>6 (neutropeni$ or leukopeni$ or cytopeni$ or granulocytopeni$ or leucopeni$ or immunocompromized or immunocompromised).tw.<BR/>7 or/1-6<BR/>8 (sterile or clean or low bacteria$ or low microbia$ or minimal bacteria$ or minimal microbia$ or germ poor or neutropenic or cooked or reduced bacteria$).tw.<BR/>9 exp Diet/<BR/>10 (diet$ or water or feeding or food$ or nutrition).tw.<BR/>11 8 and (9 or 10)<BR/>12 dietary restriction$.tw.<BR/>13 11 or 12<BR/>14 7 and 13</P>
<P>[tw = text word; / = Emtree term; $ = zero or more characters; mp = title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]</P>
<P>
<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2016-01-28 12:07:32 +0100" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2012-06-13 11:50:23 +0200" MODIFIED_BY="[Empty name]">CINAHL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-01-28 12:07:32 +0100" MODIFIED_BY="[Empty name]">
<P>S1 AB sterile or clean or low bacteria$ or low microbia$ or minimal bacteria$ or minimal microbia$ or germ poor or neutropenic or cooked or reduced bacteria$<BR/>S2 TI sterile or clean or low bacteria$ or low microbia$ or minimal bacteria$ or minimal microbia$ or germ poor or neutropenic or cooked or reduced bacteria$<BR/>S3 S2 or S1<BR/>S4 MH diet+<BR/>S5 AB diet$ or water or feeding or food$ or nutrition<BR/>S6 TI diet$ or water or feeding or food$ or nutrition<BR/>S7 S6 or S5<BR/>S8 S7 or S4<BR/>S9 S8 and S3<BR/>S10 MH agranulocytosis+ or bacterial translocation+ or bone marrow transplantation+ or immunocompromised host+<BR/>S11 AB neutropeni$ or leukopeni$ or granulocytopeni$ or leucopeni$ or immunocompromized or immunocompromised or agranulocytosis or bone marrow transplantation or stem cell transplantation or bacterial translocation or cytopen$<BR/>S12 TI neutropeni$ or leukopeni$ or granulocytopeni$ or leucopeni$ or immunocompromized or immunocompromised or agranulocytosis or bone marrow transplantation or stem cell transplantation or bacterial translocation or cytopen$<BR/>S13 S12 or S11 or S10<BR/>S14 AB dietary restriction$<BR/>S15 TI dietary restriction$<BR/>S16 S15 or S9<BR/>S17 (S15 or S9) and (S16 and S13)</P>
<P>Adjusted search strategy used in June 2010, October 2011, and May 2015:</P>
<P>S1 AB sterile or clean or low bacteria$ or low microbia$ or minimal bacteria$ or minimal microbia$ or germ poor or neutropenic or cooked or reduced bacteria$<BR/>S2 TI sterile or clean or low bacteria$ or low microbia$ or minimal bacteria$ or minimal microbia$ or germ poor or neutropenic or cooked or reduced bacteria$<BR/>S3 S2 or S1<BR/>S4 MH diet+<BR/>S5 AB diet$ or water or feeding or food$ or nutrition<BR/>S6 TI diet$ or water or feeding or food$ or nutrition<BR/>S7 S6 or S5<BR/>S8 S7 or S4<BR/>S9 S8 and S3<BR/>S10 MH agranulocytosis+ or bacterial translocation+ or bone marrow transplantation+ or immunocompromised host+<BR/>S11 AB neutropeni$ or leukopeni$ or granulocytopeni$ or leucopeni$ or immunocompromized or immunocompromised or agranulocytosis or bone marrow transplantation or stem cell transplantation or bacterial translocation or cytopen$<BR/>S12 TI neutropeni$ or leukopeni$ or granulocytopeni$ or leucopeni$ or immunocompromized or immunocompromised or agranulocytosis or bone marrow transplantation or stem cell transplantation or bacterial translocation or cytopen$<BR/>S13 S12 or S11 or S10<BR/>S14 AB dietary restriction$<BR/>S15 TI dietary restriction$<BR/>S16 S14 or S15 <BR/>S17 S16 or S9   <BR/>S18 S17 and S13   <BR/>
</P>
<P>[AB = abstract; TI = title; MH = exact subject heading; $ = zero or more characters; + = explosion]</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2016-01-25 13:23:32 +0100" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2012-06-13 11:50:45 +0200" MODIFIED_BY="[Empty name]">Ongoing trial registers and conference proceedings search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2016-01-25 13:23:32 +0100" MODIFIED_BY="[Empty name]">
<P>We have searched the register of the National Institutes of Health (www.clinicaltrials.gov) and ISRCTN register (www.controlled-trials.com) with the following key words: low bacterial AND diet; neutropenic AND diet; low bacterial AND cancer.</P>
<P>The conference proceedings (ASH, ASCO, ASPEN, EBMT, EHA, ESPEN, ICAAC, MASCC, ONS and SIOP) were searched electronically using the following search terms: "neutropenic diet", "low bacterial", "hospital diet", "normal diet", and LBD.</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;3 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;3 studies identified in initial review&lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 studies included in qualitative synthesis&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;6 articles full-text assessed for eligibility&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;495 records screened fot title and abstract&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;495 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;558 records identified through database searching&lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 additional records identified through other sources&lt;/p&gt;"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;489 records excluded&lt;/p&gt;"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;6 articles excluded, with reasons&lt;/p&gt;"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>